<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006468.pub5" GROUP_ID="GYNAECA" ID="815106050212325274" MERGED_FROM="" MODIFIED="2014-10-02 13:28:45 +0100" MODIFIED_BY="Gail Quinn" REVIEW_NO="K004" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2014-10-02 13:28:45 +0100" MODIFIED_BY="Gail Quinn">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Anticoagulation for people with cancer and central venous catheters</TITLE>
<CONTACT MODIFIED="2014-10-02 13:28:45 +0100" MODIFIED_BY="Gail Quinn"><PERSON ID="18055" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elie</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Akl</LAST_NAME><POSITION>Director of Clinical Epidemiology Unit</POSITION><EMAIL_1>ea32@aub.edu.lb</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><ADDRESS_1>Riad El Solh St</ADDRESS_1><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-10-02 13:28:45 +0100" MODIFIED_BY="Gail Quinn"><PERSON ID="18055" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elie</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Akl</LAST_NAME><POSITION>Director of Clinical Epidemiology Unit</POSITION><EMAIL_1>ea32@aub.edu.lb</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><ADDRESS_1>Riad El Solh St</ADDRESS_1><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON><PERSON ID="z1404291140152524269765581730208" ROLE="AUTHOR"><FIRST_NAME>Elie</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Ramly</LAST_NAME><EMAIL_1>elie.ramly@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON><PERSON ID="z1404081114197651019260336524884" ROLE="AUTHOR"><FIRST_NAME>Lara</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Kahale</LAST_NAME><POSITION>Clinical Epidemiology Unit</POSITION><EMAIL_1>lk45@aub.edu.lb</EMAIL_1><EMAIL_2>lara.kahale@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON><PERSON ID="05F9CC5082E26AA201A256C7CCA7DD21" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Victor</FIRST_NAME><MIDDLE_INITIALS>E D</MIDDLE_INITIALS><LAST_NAME>Yosuico</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><POSITION>Resident</POSITION><EMAIL_1>VYosuico@buffalomedicalgroup.com</EMAIL_1><ADDRESS><ORGANISATION>Buffalo Medical Group</ORGANISATION><ADDRESS_1>85 High Street</ADDRESS_1><CITY>Buffalo</CITY><ZIP>14203-1149</ZIP><REGION>New York</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 (716) 997 7061</PHONE_1></ADDRESS></PERSON><PERSON ID="02168E4582E26AA201A256C7D0473398" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maddalena</FIRST_NAME><LAST_NAME>Barba</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>maddalena.barba@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Division of Medical Oncology B - Scientific Direction</DEPARTMENT><ORGANISATION>Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 (06) 52665419</PHONE_1></ADDRESS></PERSON><PERSON ID="10402FB382E26AA2005EBC6E34E65A73" ROLE="AUTHOR"><FIRST_NAME>Francesca</FIRST_NAME><LAST_NAME>Sperati</LAST_NAME><POSITION>Biostatistician</POSITION><EMAIL_1>sperati@ifo.it</EMAIL_1><ADDRESS><DEPARTMENT>Biostatistics-Scientific Direction</DEPARTMENT><ORGANISATION>Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0652 66 6249</PHONE_1></ADDRESS></PERSON><PERSON ID="5235" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Deborah</FIRST_NAME><LAST_NAME>Cook</LAST_NAME><EMAIL_1>debcook@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1200 Main Street West</ADDRESS_1><ADDRESS_2>HSC-2C11</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8N 3Z5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 Ext: 22900</PHONE_1></ADDRESS></PERSON><PERSON ID="18105" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Holger</FIRST_NAME><LAST_NAME>Schünemann</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor and Chair</POSITION><EMAIL_1>schuneh@mcmaster.ca</EMAIL_1><URL>http://www.fhs.mcmaster.ca/ceb/inside_intro.htm</URL><MOBILE_PHONE>+19055375599</MOBILE_PHONE><ADDRESS><DEPARTMENT>Departments of Clinical Epidemiology and Biostatistics and of Medicine</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><CITY>Hamilton</CITY><ZIP>L8N 4K1</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 Ext: 24931 (assistant)</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-04-23 14:41:12 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="9" MONTH="2" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="2" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-10-02 13:25:42 +0100" MODIFIED_BY="Gail Quinn">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-10-02 13:25:42 +0100" MODIFIED_BY="Gail Quinn">
<DATE DAY="2" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>Exclusion of AbdelKefi 2004</P>
<P>Data abstraction verified and detailed statistical data included as appendix</P>
<P>Data reanalyzed by using a complete case analysis approach for the primary meta-analysis</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<DATE DAY="9" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Updated search (February 2013) and included 1 new study</P>
<P>Text revisions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-04-26 12:54:40 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-04-26 12:54:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Updated search (February 2010) and included two new studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-15 17:08:50 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-15 17:08:53 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Minor update. We added DeCicco 2006 as an excluded study.<BR/>We updated the interpretation of heterogeneity based on I<SUP>2</SUP> as follows: 0 to 30 = low; 30 to 60 = moderate and worthy of investigation; 60 to 90 = severe and worthy of understanding; 90 to100 = allowing aggregation only with major caution<BR/>
<BR/>We explained the implications for practice by providing two examples. We expanded on the limitations of the review particularly in relation to the small number of included studies and to the 3 abstracts for which we could not obtain.<BR/>We have updated the funding and conflict of interest sections.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="12" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-05-07 09:46:51 +0100" MODIFIED_BY="Gail Quinn">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-05-07 09:46:51 +0100" MODIFIED_BY="Gail Quinn">
<SOURCE MODIFIED="2014-05-07 09:46:51 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research Cochrane Review Incentive Scheme 2013</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-10-02 13:22:07 +0100" MODIFIED_BY="Gail Quinn">
<SUMMARY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Blood thinners to prevent blood clots in people with cancer and central venous catheters</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>
<B>Background</B>
</P>
<P>A central venous catheter (CVC) is a tube that is inserted into a large vein to give fluids or drugs. CVC placement increases the risk of blood clots in people with cancer. This systematic review evaluated the efficacy and safety of blood thinning agents (anticoagulants) in people with cancer.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched the scientific literature for studies of anticoagulants (e.g. heparin) in people with cancer. The evidence is current to February 2013.</P>
<P>
<B>Key results</B>
</P>
<P>We found clinically important effects of heparin on blood clots but not on death or major bleeding. The main limitation of this systematic review is the inclusion of different types and stages of cancer.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We judged the quality evidence for the effects of heparin to be low or moderate.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<ABS_BACKGROUND MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Central venous catheter (CVC) placement increases the risk of thrombosis in people with cancer. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis-related morbidity and mortality.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>To evaluate the relative efficacy and safety of anticoagulation for thromboprophylaxis in people with cancer with a CVC.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 12, 2012), MEDLINE Ovid (January 1966 to February 2013), and EMBASE Ovid (1980 to February 2013). We handsearched conference proceedings, checked references of included studies, used the 'related citations' feature within PubMed, and searched clinicaltrials.gov for ongoing studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized controlled trials (RCTs) comparing the effects of any dose of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), vitamin K antagonists (VKA), or fondaparinux with no intervention or placebo or comparing the effects of two different anticoagulants in people with cancer and a CVC.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Teams of two review authors independently used a standardized form to extract data in duplicate. They resolved any disagreements by discussion. They extracted data on risk of bias, participants, interventions, and outcomes. Outcomes of interest included mortality, symptomatic deep venous thrombosis (DVT), asymptomatic DVT, major bleeding, minor bleeding, infection, and thrombocytopenia. Where possible, we conducted meta-analyses using the random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Of 9559 identified citations, we included 12 RCTs (17 publications) reporting follow-up data on 2823 participants. Two of the RCTs included children. Of the 10 RCTs including 2564 adults, one compared prophylactic dose heparin with low-dose VKA. Three RCTs compared VKA with no VKA and four RCTs compared heparin with no heparin. Two additional trials had three separate arms comparing heparin, VKA, and no intervention. Prophylactic-dose heparin, compared with no heparin, was associated with a statistically significant reduction in symptomatic DVT (risk ratio (RR) 0.48; 95% confidence interval (CI) 0.27 to 0.86; moderate-quality evidence). However, results did not confirm or exclude a beneficial or detrimental effect of heparin on mortality (RR 0.82; 95% CI 0.53 to 1.26; moderate-quality evidence), major bleeding (RR 0.49; 95% CI 0.03 to 7.84; low-quality evidence), infection (RR 1.00; 95% CI 0.54 to 1.85; moderate-quality evidence); thrombocytopenia (RR 1.03; 95% CI 0.80 to 1.33; moderate-quality evidence), or minor bleeding (RR 1.35; 95% CI: 0.62 to 2.92). Low-dose VKAs, compared with no VKAs, were associated with a statistically significant reduction in asymptomatic DVT (RR 0.43; 95% CI 0.30 to 0.62). Results did not confirm or exclude a beneficial or detrimental effect of VKAs on mortality (RR 1.04; 95% CI 0.89 to 1.22; low-quality evidence), symptomatic DVT (RR 0.51; 95% CI 0.21 to 1.22; low-quality evidence), major bleeding (RR 7.60; 95% CI 0.94 to 61.49; very-low-quality evidence), or minor bleeding (RR 3.14; 95% CI 0.14 to 71.51). The use of heparin, compared with VKA was associated with a statistically significant increase in thrombocytopenia (RR 3.73; 95% CI 2.26 to 6.16; low-quality evidence) and asymptomatic DVT (RR 1.74; 95% CI 1.20 to 2.52). However, results did not show or exclude a beneficial or detrimental effect on any of the other outcomes of interest (very-low-quality evidence).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Compared with no anticoagulation, we found a statistically significant reduction of symptomatic DVT with heparin and asymptomatic DVT with VKA. Heparin was associated with a higher risk of thrombocytopenia and asymptomatic DVT when compared with VKA. However, the findings did not rule out other clinically important benefits and harms. People with cancer with CVCs considering anticoagulation should balance the possible benefit of reduced thromboembolic complications with the possible harms and burden of anticoagulants.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-10-02 13:22:07 +0100" MODIFIED_BY="Gail Quinn">
<BACKGROUND MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> shows definitions of technical terms used in the review.</P>
<CONDITION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>People with cancer often require long-term central venous access to receive chemotherapy, transfusions, parenteral nutrition, and antibiotics. However, central venous catheter (CVC) placement increases the risk of thrombosis in people with cancer (<LINK REF="REF-Heit-2000" TYPE="REFERENCE">Heit 2000</LINK>). Even in absence of a CVC, people with cancer have a four- to six-fold increased risk of thrombosis compared with the general population (<LINK REF="REF-Blom-2005" TYPE="REFERENCE">Blom 2005</LINK>; <LINK REF="REF-Heit-2000" TYPE="REFERENCE">Heit 2000</LINK>; <LINK REF="REF-Silverstein-1998" TYPE="REFERENCE">Silverstein 1998</LINK>; <LINK REF="REF-Sutherland-2003" TYPE="REFERENCE">Sutherland 2003</LINK>). Moreover, cancer treatments, including surgery, chemotherapy, and hormonal therapy, also increase the risk of thrombosis (<LINK REF="REF-Lee-1999" TYPE="REFERENCE">Lee 1999</LINK>). As a result, the incidence of clinically overt CVC-related deep venous thrombosis (DVT) in people with cancer ranges from 0.3% to 28.3% (<LINK REF="REF-Verso-2003" TYPE="REFERENCE">Verso 2003</LINK>). The incidence of clinically overt pulmonary embolism (PE) with CVC-related DVT varies between 15% and 25% (<LINK REF="REF-Verso-2003" TYPE="REFERENCE">Verso 2003</LINK>).</P>
<P>Both thrombosis and infection often necessitate the removal of the CVC, resulting in treatment delays as well as the clinical consequences of thrombosis and infections themselves (<LINK REF="REF-Bona-1999" TYPE="REFERENCE">Bona 1999</LINK>). More importantly, these complications can lead to significant morbidity and mortality (<LINK REF="REF-Monreal-1994" TYPE="REFERENCE">Monreal 1994</LINK>). Indeed, people with cancer with venous thromboembolism (VTE), compared with people with cancer without VTE, have a significantly reduced survival with an estimated mortality ratio of 2.2 (<LINK REF="REF-Sorensen-2000" TYPE="REFERENCE">Sorensen 2000</LINK>). In addition, people with cancer treated for VTE have higher thrombosis recurrence rates and more haemorrhagic complications compared with people without cancer treated for VTE (<LINK REF="REF-Hutten-2000" TYPE="REFERENCE">Hutten 2000</LINK>; <LINK REF="REF-Prandoni-2002" TYPE="REFERENCE">Prandoni 2002</LINK>). For example, among people with venous thrombosis on anticoagulation, bleeding was related to cancer status and to cancer severity but could not be explained by sub-therapeutic or supra-therapeutic levels of anticoagulation (<LINK REF="REF-Prandoni-2002" TYPE="REFERENCE">Prandoni 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Parenteral anticoagulants such as unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), and fondaparinux do not have intrinsic anticoagulant activity but potentiate the activity of antithrombin III in inhibiting activated coagulation factors. Heparin and its low-molecular-weight derivatives are not absorbed orally and must be administered parenterally by intravenous infusion or subcutaneous injections (<LINK REF="REF-Hirsh-1993" TYPE="REFERENCE">Hirsh 1993</LINK>).</P>
<P>Oral anticoagulants such as vitamin K antagonists (VKA) have been the mainstay of oral anticoagulant therapy since the 1950s. Well-designed clinical trials have shown their effectiveness for the primary and secondary prevention of a number of both venous and arterial thrombotic diseases (<LINK REF="REF-Ansell-2008" TYPE="REFERENCE">Ansell 2008</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Researchers have hypothesized that, because of the risk of thromboembolic events related to a CVC, anticoagulants may improve outcomes by reducing the incidence of these events. Moreover, researchers have hypothesized that anticoagulants may improve outcomes in people with cancer through an antitumour effect in addition to its antithrombotic effect (<LINK REF="REF-Smorenburg-2001" TYPE="REFERENCE">Smorenburg 2001</LINK>; <LINK REF="REF-Thodiyil-2002" TYPE="REFERENCE">Thodiyil 2002</LINK>). In addition, anticoagulation has the potential to reduce infections by preventing thrombus formation, a suspected risk factor for catheter-related infection (<LINK REF="REF-Lordick-2003" TYPE="REFERENCE">Lordick 2003</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Several studies have evaluated the efficacy of thromboprophylaxis with anticoagulants in people with cancer with CVC. One 2003 systematic review of thrombosis prophylaxis in people with CVC identified two randomized controlled trials (RCTs) conducted in people with cancer (<LINK REF="STD-Klerk-2003" TYPE="STUDY">Klerk 2003</LINK>). Our systematic review conducted in 2010 revealed no statistically significant effect of anticoagulation on any of the outcomes of interest. Since then, at least one eligible RCT has been published (<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>To evaluate the relative efficacy and safety of anticoagulation for thromboprophylaxis in people with cancer with a CVC.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<SELECTION_CRITERIA MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<CRIT_STUDIES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>RCTs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>People with cancer with a CVC of any age (including children), with either solid or haematological cancer, at any stage of their cancer and irrespective of the type of cancer therapy received. Participants had to have no clinical evidence of VTE at enrolment.</P>
<P>We included studies with subgroups of people with cancer that did not report subgroup-specific data, when people with cancer constituted 50% or more of the total population. Otherwise, we excluded them from the systematic review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Experimental intervention: parenteral anticoagulants (including UFH, LMWH, and fondaparinux) or oral anticoagulants (including VKA and newer oral anticoagulants) irrespective of the dose.<BR/>
</P>
<P>Comparison: another anticoagulant, placebo, or no intervention.</P>
<P>The protocol should have planned to provide all other co-interventions (e.g. chemotherapy) similarly.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>All-cause mortality.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Premature CVC removal.</LI>
<LI>Catheter-related bacteraemia. The diagnosis had to be based on pre-defined criteria.</LI>
<LI>Catheter exit site infection. The diagnosis had to be based on pre-defined criteria. We did not consider catheter colonization.</LI>
<LI>CVC-site DVT. The diagnosis of CVC thrombosis could have resulted either from screening with the described screening methods or from clinical suspicion with subsequent confirmation by one of the described tests.</LI>
<LI>Non-CVC-site DVT. DVT events had to be diagnosed using an objective diagnostic test such as: venography, <SUP>125</SUP>I-fibrinogen-uptake test, impedance plethysmography, or compression ultrasound.</LI>
<LI>PE. PE events had to be diagnosed using an objective diagnostic test such as: pulmonary perfusion/ventilation scan, computed tomography, pulmonary angiography, or autopsy.</LI>
<LI>Major bleeding: we accepted the authors' definitions of major bleeding.</LI>
<LI>Minor bleeding: we accepted the authors' definitions of minor bleeding.</LI>
<LI>Thrombocytopenia: we accepted the authors' definitions.</LI>
<LI>Heparin-induced thrombocytopenia (HIT).</LI>
<LI>Heparin-induced thrombocytopenia with thrombosis (HITT).</LI>
<LI>Quality of life.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<ELECTRONIC_SEARCHES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>The search was part of a comprehensive search for studies of anticoagulation in people with cancer. We conducted the original electronic search in January 2007 and updated it in February 2010 and in February 2013. We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 12, 2012), MEDLINE Ovid (January 1966 to February 2013), and EMBASE Ovid (January 1980 to February 2013). The search strategies combined terms for anticoagulants, terms for cancer, and a search filter for RCTs. We used no language restrictions. We list the full search strategies for each of the electronic databases in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We handsearched the conference proceedings of the American Society of Clinical Oncology (ASCO, 1982 up to June 2013) and the American Society of Hematology (ASH, 2003 to June 2013). We reviewed the reference lists of papers included in this review and other relevant systematic reviews. We used the 'related article' feature in PubMed to identify additional articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P> </P>
<STUDY_SELECTION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Two review authors independently screened the titles and abstracts of identified articles for eligibility. We retrieved the full text of articles judged as potentially eligible by at least one review author. Two review authors then independently screened the full-text articles for eligibility using a standardized form with explicit inclusion and exclusion criteria. The two review authors resolved any disagreements by discussion or by consulting a third review author.<BR/>
</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Two review authors independently extracted data from each included study and resolved any disagreements by discussion. We aimed to collect data on:</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<UL>
<LI>Number of participants randomized to each treatment arm.</LI>
<LI>Number of participants followed up in each treatment arm.</LI>
<LI>Number of withdrawals from treatment in each treatment arm.</LI>
<LI>Population characteristics (age, sex, co-morbidity).</LI>
<LI>Cancer characteristics (e.g. type, location, histology, stage, time since diagnosis, estimated life expectancy, previous and current cancer treatments, performance status).</LI>
<LI>CVC characteristics: type (e.g. port, external, tunnelled versus non-tunnelled, coated versus not coated), site (e.g. subclavian, internal jugular, external jugular, femoral), placement side, type of medication/fluids infused, speciality of physician placing the CVC (e.g. surgeon, radiologist, physician-in-training), aseptic insertion technique, antibiotic coverage during placement.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<UL>
<LI>Type of anticoagulant studied: LMWH, UFH, VKA, fondaparinux.</LI>
</UL>
<UL>
<LI>Type and dosage of LMWH (therapeutic versus prophylactic). We classified the dosage of LMWH as either prophylactic or therapeutic using a standardized chart (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</LI>
<LI>Dosage of UFH.</LI>
<LI>Intensity of VKA therapy (international normalized ratio (INR) target or dose).</LI>
<LI>Initiation of treatment relative to time of CVC insertion.</LI>
<LI>Duration of treatment.</LI>
<LI>Co-interventions.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>We extracted outcome data necessary to conduct intention-to-treat (ITT) analyses. We aimed to collect data at three and six months (time points defined a priori).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Author contact</HEADING>
<P>We attempted to contact trials' authors for incompletely reported data relating to trial characteristics, methodology, and outcomes. We included abstracts only if authors supplied us with the necessary information about their methods and results.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>First, we assessed risk of bias at the study level using the Cochrane 'Risk of bias' tool. Two review authors independently assessed the methodological quality of each included study and resolved any disagreements by discussion. Methodological criteria included:<BR/>
</P>
<UL>
<LI>adequate sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>participant blinding;</LI>
<LI>provider blinding;</LI>
<LI>data collector blinding;</LI>
<LI>outcome assessor blinding;</LI>
<LI>analyst blinding;</LI>
<LI>percentage of follow-up, and whether incomplete outcome data was addressed;</LI>
<LI>whether the study was free of selective reporting;</LI>
<LI>whether the study was stopped early for benefit;</LI>
<LI>whether the analysis followed the ITT principle.</LI>
</UL>
<P>Second, we assessed the quality of evidence at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We collected risk ratios (RRs) and 95% confidence intervals (CI) for categorical data. The reported data did not allow the meta-analysis of any of the outcomes of interest as time to event data or as continuous data.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-08-05 19:22:47 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<SUBSECTION>
<HEADING LEVEL="4">Determining participants with missing data</HEADING>
<P>It was not clear whether certain participant categories (e.g. those described as 'withdrew consent' or 'experienced adverse events') were actually followed up by the trialists (versus had missing participant data). To deal with this issue, we made the following considerations:</P>
<UL>
<LI>'ineligible participants' and 'did not receive the first dose' participant categories that were defined prior to the initiation of the study intervention, most likely had missing participant data;</LI>
<LI>'withdrew consent' and 'lost to follow-up' participant categories that were defined after the initiation of the study intervention, most likely had missing participant data;</LI>
<LI>'dead', 'experienced adverse events', 'non-compliant', and 'discontinued prematurely' (and similarly described) participant categories, less likely had missing participant data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with participants with missing data in the primary meta-analysis</HEADING>
<P>In the primary meta-analysis, we used a complete case analysis approach (i.e. we excluded participants considered to have missing data).</P>
<P>For categorical data, we used the following calculations for each study arm:</P>
<UL>
<LI>denominator: (number of participants randomized) - (number of participants most likely with missing data, both pre- and post-intervention initiation);</LI>
<LI>numerator: number of participants with observed events (i.e. participants who had at least one event for the outcome of interest during their available follow-up time).</LI>
</UL>
<P>For continuous data, for each study arm, we used the reported mean and standard deviation (SD) for participants actually followed up by the trialists.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessing the risk of bias associated with participants with missing data</HEADING>
<P>When the primary meta-analysis of a specific outcome found a statistically significant effect, we conducted sensitivity meta-analyses to assess the risk of bias associated with missing participant data. The sensitivity meta-analyses used a priori plausible assumptions about the outcomes of participants considered to have missing data. The assumptions we used in the sensitivity meta-analyses were increasingly stringent in order to challenge the statistical significance of the results of the primary analysis progressively (<LINK REF="REF-Akl-2013" TYPE="REFERENCE">Akl 2013</LINK>; <LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>).</P>
<P>For categorical data, and for RR showing a reduction in effect (RR less than 1), we used the following increasingly stringent but plausible assumptions (<LINK REF="REF-Akl-2013" TYPE="REFERENCE">Akl 2013</LINK>):</P>
<UL>
<LI>for the control arm, relative incidence (RI) among participants with missing data (lost to follow-up (LTFU)) compared with participants with available data (followed up (FU)) in the same arm (RI<SUB>LTFU/FU</SUB>) = 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 1.5;</LI>
</UL>
<UL>
<LI>For the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 2;</LI>
<LI>For the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 3;</LI>
<LI>For the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 5;</LI>
</UL>
<P>For RR showing an increase in effect (RR greater than 1), we switched the above assumptions between the control and interventions arms (i.e. used RI<SUB>LTFU/FU </SUB>= 1 for the intervention arm).</P>
<P>Specifically, we used the following calculations for each study arm:</P>
<UL>
<LI>denominator: (number of participants randomized) - (number of participants most likely with missing data, pre-intervention initiation);</LI>
<LI>numerator: (number of participants with observed events) + (number of participants most likely with missing data post-intervention initiation, with assumed events).</LI>
</UL>
<P>Assumed events were calculated by applying the a priori plausible assumptions to the participants considered most likely with missing data post-intervention initiation.</P>
<P>For continuous data, we used the four strategies suggested by Ebrahim et al. (<LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>). The strategies imputed the means for participants with missing data based on the means of participants actually followed up in individual trials included in the systematic review. To impute SD, we used the median SD from the control arms of all included trials (<LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>).</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We assessed heterogeneity among trials by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials that could not be ascribed to sampling variation (I<SUP>2</SUP> statistic) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), and by a formal statistical test of the significance of the heterogeneity (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>We assessed reporting bias by trying to identify whether the study was included in a trial registry, whether a protocol was available, and whether the methods section provided a list of outcomes. We compared the list of outcomes from those sources to the outcomes reported in the published paper. We did not create any inverted funnel plot due to the low number of included trials examining each outcome.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We calculated the agreement between the two independent review authors for the assessment of eligibility using kappa statistic.</P>
<P>For dichotomous data, we calculated the RR and 95% CI separately for each study for the incidence of outcomes by treatment arm. We then pooled the results of the different studies using a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We planned to explore heterogeneity by conducting subgroup analyses based on the type of anticoagulant and the characteristics of participants (type, severity and stage of cancer, and whether participants were receiving cancer treatment or not).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We planned for sensitivity analyses excluding lower-quality trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-10-02 13:22:07 +0100" MODIFIED_BY="Gail Quinn">
<STUDY_DESCRIPTION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<SEARCH_RESULTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>The February 2013 search strategy identified 9559 citations from which we removed the results of our February 2010 search. The title and abstract screening identified 44 potentially eligible citations. Of these, we included 12 eligible RCTs (17 reports) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We identified one ongoing study (<LINK REF="STD-Glaspy-2000" TYPE="STUDY">Glaspy 2000</LINK>).</P>
<P>Agreement between review authors for study eligibility was excellent (kappa = 0.94).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We included 12 studies in the systematic review (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Ruud-2006" TYPE="STUDY">Ruud 2006</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>; <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>). One of the studies was identified by the search update (<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>The 12 included RCTs reported follow-up data on 2823 participants. They examined either prophylactic-dose heparin (UFH or LMWH) or low-dose VKAs (either fixed low dose or target INR less than 2). Two of the RCTs conducted a three-way comparison (LWMH versus VKA versus no anticoagulation) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>). Most studies administered treatments for the specified fixed period or until CVC removal or thrombosis diagnosis. The studies varied in the thromboembolic outcomes they assessed (e.g. whether thrombosis was symptomatic or not, at the site of the catheter or not, CVC-related or not) and the definitions of CVC-related infection.</P>
<P>Seven RCTs compared heparin with no anticoagulation; five RCTs assessed LMWH and one assessed UFH.</P>
<UL>
<LI>Monreal et al. recruited participants with solid tumours (minimum life expectancy three months) and randomized them to dalteparin (prophylactic dose for 90 days starting two hours prior to catheter placement) versus no intervention. Surgeons placed subclavian ports with no antibiotic prophylaxis and flushed with heparin (<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>).</LI>
<LI>Karthaus et al. recruited participants with solid or haematological cancers (minimum age 18 years and minimum life expectancy 16 weeks) and randomized them to dalteparin (prophylactic dose for 16 weeks starting seven days prior to catheter placement) versus placebo. Participants had mostly ports that were placed either proximal or distal to the axilla and flushed with normal saline or heparin (<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>).</LI>
<LI>Verso et al. recruited participants with solid or haematological cancers (minimum age 18 years and minimum life expectancy three months) and randomized them to enoxaparin (prophylactic dose for six weeks starting two hours prior to catheter placement) versus placebo. Participants had either jugular or subclavian second-generation catheters (<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>).</LI>
<LI>Niers et al. recruited participants with haematological malignancies (minimum age 18 years) and randomized them to receive either once daily prophylactic-dose nadroparin or placebo injections. The study medication was started two hours before insertion of the CVC, and was continued for three weeks or until the day of CVC removal, whichever came first. The CVC was inserted according to a standard protocol under sterile conditions (<LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>).</LI>
<LI>Massicotte et al. recruited (newborns to 18 years of age, 51% of whom had cancer) and randomized participants with new CVC to twice daily reviparin sodium or standard care. Participants received either 30 international units (IU)/kg, if three or more than three months of age, or received 50 IU/kg twice daily if less than three months of age, or standard care (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>).</LI>
</UL>
<UL>
<LI>De Cicco et al. randomized participants (minimum age 18 years and minimum life expectancy three months) to receive acenocumarine (1 mg/day for three days before and eight days after CVC insertion) or dalteparin 5000 IU (two hours before and daily for eight days after CVC insertion) or no anticoagulation treatment (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>).</LI>
<LI>Lavau-Denes et al. recruited participants (median age 61 years and a life expectancy of more than three months) with solid invasive cancer, locally advanced or metastatic status and randomized them to LMWH (2500 U anti-XA/day; subcutaneous: dalteparin, nadroparin, or enoxaparin, once daily), or warfarin (oral 1 mg/day) or no anticoagulation. Participants had a subclavian CVC inserted for less than seven days.</LI>
</UL>
<P>Six RCTs compared VKAs with no anticoagulation.</P>
<UL>
<LI>Heaton et al. recruited participants with haematological cancer and randomized them to warfarin (1 mg/day for 90 days) versus no intervention. Radiologist placed external, tunnelled subclavian catheters with no antibiotic prophylaxis and flushed with heparin or saline (<LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>).</LI>
<LI>Bern et al. randomized participants with solid or haematological cancers (minimum life expectancy three months) to warfarin (1 mg/day for 90 days started three days prior to catheter placement) versus no intervention. Surgeons placed subclavian ports with no antibiotic prophylaxis and flushed with heparin (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>).</LI>
<LI>Young et al. randomized participants with solid and haematological cancers (minimum age 16 years) who were receiving chemotherapy through CVC to no warfarin, fixed-dose warfarin 1 mg/day, or dose-adjusted warfarin per day to maintain INR between 1.5 and 2.0 (<LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>).</LI>
<LI>Ruud et al. randomized children with solid or haematological cancers to warfarin (target INR 1.3 to 1.9) versus no intervention. Participants had jugular external tunnelled catheters or ports (<LINK REF="STD-Ruud-2006" TYPE="STUDY">Ruud 2006</LINK>).</LI>
<LI>De Cicco et al. randomized people with cancer (minimum age 18 years and minimum life expectancy three months) to receive either acenocumarine (1 mg/day for three days before and eight days after CVC insertion) or dalteparin 5000 IU (two hours before and daily for eight days after CVC insertion) or no anticoagulation treatment (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>).</LI>
<LI>Lavau-Denes et al. recruited participants (median age 61 years and a life expectancy of more than three months) with solid invasive cancer, locally advanced or metastatic status and randomized them to either LMWH (2500 U anti-XA/day; subcutaneous: dalteparin, nadroparin, or enoxaparin, once daily), or warfarin (oral 1 mg/day) or no anticoagulation. Participants had a subclavian CVC inserted for fewer than seven days.</LI>
</UL>
<P>Three RCTs compared LMWH with warfarin for thrombosis prophylaxis.</P>
<UL>
<LI>Mismetti et al. recruited participants with solid cancers (minimum age 18 years and minimum life expectancy three months) and randomized them to either nadroparin (prophylactic dose for 90 days started two hours prior to CVC placement) or warfarin (1 mg/day for 90 days started three days prior to CVC placement) (<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>).</LI>
<LI>De Cicco et al. randomized people with cancer (minimum age 18 years and minimum life expectancy three months) to receive either acenocumarine (1 mg/day for three days before and eight days after CVC insertion) or dalteparin 5000 IU (two hours before and daily for eight days after CVC insertion) or no anticoagulation treatment (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>).</LI>
<LI>Lavau-Denes et al. recruited participants (median age 61 years and a life expectancy of more than three months) with solid invasive cancer, locally advanced or metastatic status and randomized them to either LMWH (2500 U anti-XA/day; subcutaneous: dalteparin, nadroparin, or enoxaparin, once daily), or warfarin (oral 1 mg/day) or no anticoagulation. Participants had a subclavian CVC inserted for fewer than seven days.</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>We excluded 32 studies from the review (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). One study was an RCT that followed up participants for three months after catheter removal (which was different for the two study groups) resulting in a differential follow-up relative to randomization (63 days for the warfarin group and 84 days for the placebo group) (<LINK REF="STD-Couban-2005" TYPE="STUDY">Couban 2005</LINK>). The reasons for excluding the remaining 31 publications were: study not an RCT (13 studies), review (four studies), editorial or letter to the editor (two studies), intervention used was not relevant (four studies), intervention was compared with urokinase (two studies), not population of interest/not CVC (two studies), and required data not obtainable from authors (three studies). We excluded a previously included study after concerns were raised about the accuracy and validity of the data reported, and the practical aspects of the published protocol (<LINK REF="REF-Ruinemans_x002d_Koerts-2010" TYPE="REFERENCE">Ruinemans-Koerts 2010</LINK>). When asked by the editors, the authors were unable to provide evidence that the study had been conducted (<LINK REF="STD-Abdelkefi-2004" TYPE="STUDY">Abdelkefi 2004</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<ALLOCATION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Of the 12 included studies, allocation was adequately concealed in seven (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>; <LINK REF="STD-Ruud-2006" TYPE="STUDY">Ruud 2006</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>; <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>); it was unclear whether it was adequately concealed or not in three studies (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>). In two studies, allocation was not concealed (<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Of the 12 included studies, three blinded participants (<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>), three blinded providers (<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>), three blinded data collectors (<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>), 10 blinded outcome adjudicators (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Ruud-2006" TYPE="STUDY">Ruud 2006</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>; <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>), and two blinded data analysts (<LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>The percentage of follow-up varied across studies: 100% (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>; <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>), 98% (<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003;</LINK> <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>), 97% (<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>), 91% (<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>), 84% (<LINK REF="STD-Ruud-2006" TYPE="STUDY">Ruud 2006</LINK>), 81% (<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>), 77% (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>), and 68% (<LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Only two studies were registered (<LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>; <A HREF="http://clinicaltrials.gov/ct2/show/NCT00024297">NCT00024297</A>; <A HREF="http://www.controlled-trials.com/ISRCTN50312145/warp">ISRCTN50312145</A>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; NCT00199602) and all outcomes listed in the registry were reported on. None of the studies had a published protocol. All studies reported on the outcomes listed in their methods section.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Two studies were stopped early: one for insufficient accrual (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>), and one for benefit (<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>). Six studies used the ITT principle (<LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>; <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>), five did not use the ITT principle (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Ruud-2006" TYPE="STUDY">Ruud 2006</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>), and one was unclear about the use of the ITT principle (<LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-10-02 13:22:07 +0100" MODIFIED_BY="Gail Quinn">
<SUBSECTION>
<HEADING LEVEL="3">Prophylactic dose heparin versus no heparin</HEADING>
<P>We did not include the study by Massicotte et al. in the meta-analysis given its focus on children (<LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>). The trial did not confirm or exclude a beneficial or detrimental effect of LMWH on VTE (RR 1.15; 95% CI 0.42 to 3.23) or infection (RR 0.59; 95% CI 0.32 to 1.10) compared with no intervention. The paper reported non-statistically significant differences in incidences of minor bleeding (48/90 with heparin versus 41/94 with no heparin; P value = 0.24), major bleeding (0/90 with heparin versus 1/94 with no heparin; P value = 1.0), and mortality (0/92 with heparin versus 2/94 with no heparin; P value = 1.0) between the two groups.</P>
<P>We present below the meta-analysis of the remaining six studies that were conducted in adults.</P>
<P>
<B>Mortality: </B>Meta-analysis of the five RCTs including 1236 participants did not show or exclude a beneficial or detrimental effect on the risk of mortality with heparin compared with no heparin (RR 0.82; 95% CI 0.53 to 1.26; moderate-quality evidence) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> shows the associated risk of bias. The quality of evidence was moderate due to some risk of bias and serious imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<B>Symptomatic DVT: </B>Meta-analysis of the six RCTs including 1317 participants found a statistically significant decrease in the risk of symptomatic DVT with heparin compared with no heparin (RR 0.48; 95% CI 0.27 to 0.86; moderate-quality evidence) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> shows the associated risk of bias. Since the primary meta-analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta-analyses using the a priori plausible assumptions detailed in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section. The effect estimate remained statistically significant for the least three stringent plausible assumptions. However, it lost significance with the two more stringent plausible assumptions (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). The quality of evidence was moderate due to some risk of bias and serious imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<B>Major bleeding:</B> Meta-analysis of the four RCTs including 1012 participants did not show or exclude a beneficial or detrimental effect on the risk of major bleeding with heparin compared with no heparin (RR 0.49; 95% CI 0.03 to 7.84; low-quality evidence) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> shows the associated risk of bias. The quality of evidence was low due to some risk of bias and very serious imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<B>Minor bleeding: </B>Meta-analysis of the two RCTs including 544 participants did not show or exclude a beneficial or detrimental effect on the risk of minor bleeding with heparin compared with no heparin (RR=1.35; 95% CI 0.62 to 2.92; low quality evidence) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). The quality of evidence was low due to some risk of bias and serious imprecision.</P>
<P>
<B>Infection:</B> Meta-analysis of the two RCTs including 468 participants found no statistically significant difference in the risk of infection between heparin and no heparin (RR 1.00; 95% CI 0.54 to 1.85; moderate-quality evidence) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) (<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> shows the associated risk of bias. The quality of evidence was moderate due to some risk of bias and serious imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<B>Thrombocytopenia: </B>Meta-analysis of the four RCTs including 1002 participants did not show or exclude a beneficial or detrimental effect on the risk of thrombocytopenia with heparin compared with no heparin (RR 1.03; 95% CI 0.80 to 1.33; moderate-quality evidence) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) (<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> shows the associated risk of bias. The quality of evidence was moderate due to some risk of bias and serious imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<B>Asymptomatic DVT: </B>Meta-analysis of the six RCTs including 1319 participants found a trend towards reduced risk of asymptomatic DVT with heparin compared with no heparin (RR 0.82; 95% CI 0.65 to 1.03) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>; <LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>; <LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK> shows the associated risk of bias.</P>
<P>
<B>Quality of life:</B> None of the included studies assessed quality of life.</P>
<P>
<B>Subgroup analyses:</B> None of the subgroup analyses conducted for the above outcomes based on the type of heparin (LMWH versus UFH) was statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low-dose vitamin K antagonist versus no vitamin K antagonist</HEADING>
<P>We did not include the study by Ruud et al. in the meta-analysis given its focus on children (<LINK REF="STD-Ruud-2006" TYPE="STUDY">Ruud 2006</LINK>). The study was stopped early because of a higher incidence of ultrasound-detected VTE in the warfarin group (15/31 with warfarin versus 17/42 with no warfarin; P value = 0.36). There was only one symptomatic VTE event in each group. We present below the meta-analysis of the remaining five studies that were conducted in adults.</P>
<P>
<B>Mortality: </B>Meta-analysis of the five RCTs including 1451 participants found no statistically significant difference in the risk of mortality between VKA and compared with no VKA (RR 1.04; 95% CI 0.89 to 1.22; low-quality evidence) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK> shows the associated risk of bias. The quality of evidence was low due to serious risk of bias and serious imprecision (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<B>Symptomatic DVT: </B>Meta-analysis of the five RCTs including 1451 participants did not show or exclude a beneficial or detrimental effect on the risk of symptomatic DVT with VKA compared with no VKA (RR 0.51; 95% CI 0.21 to 1.22; low-quality evidence) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was moderate (I<SUP>2</SUP> = 66%). <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK> shows the associated risk of bias. The quality of evidence was low due to serious risk of bias, serious imprecision, and some heterogeneity (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<B>Major bleeding:</B> One of two studies assessing major bleeding reported no events (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>). The other study including 751 participants did not show or exclude a beneficial or detrimental effect on the risk of major bleeding with VKA compared with no VKA (RR 7.60; 95% CI 0.94 to 61.49; very-low-quality evidence) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) (<LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>). <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK> shows the associated risk of bias. The quality of evidence was very low due to serious risk of bias and very serious imprecision (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<B>Asymptomatic DVT: </B>Three studies including 618 participants found a statistically significant decrease in the risk of asymptomatic DVT with VKA compared with no VKA (RR 0.43; 95% CI 0.30 to 0.62) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK> shows the associated risk of bias.</P>
<P>Since the primary meta-analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta-analyses using the a priori plausible assumptions detailed in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section. The effect estimate remained statistically significant even when using the most stringent plausible assumption (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
<P>
<B>Minor bleeding:</B> Two studies assessing minor bleeding reported including 979 participants did not show or exclude a beneficial effect or detrimental of VKA on minor bleeding compared with placebo (RR 3.14; 95% CI 0.14 to 71.51) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was significant (I<SUP>2</SUP> = 84%). <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK> shows the associated risk of bias. The quality of evidence was low (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<B>Infection:</B> None of the included studies assessed infection.</P>
<P>
<B>Thrombocytopenia: </B>None of the included studies assessed thrombocytopenia.</P>
<P>
<B>Quality of life:</B> None of the included studies assessed quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prophylactic-dose heparin versus low-dose vitamin K antagonist</HEADING>
<P>
<B>Mortality: </B>Meta-analysis of the three RCTs including 551 participants did not show or exclude a beneficial or detrimental effect on the risk of mortality between with LMWH compared with VKA (RR 1.14; 95% CI 0.59 to 2.21; very-low-quality evidence) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was moderate (I<SUP>2</SUP> = 42%). <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK> shows the associated risk of bias. The quality of evidence was very low due to serious risk of bias, serious imprecision, and some heterogeneity (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<B>Symptomatic DVT: </B>Meta-analysis of the three RCTs including 551 participants did not show or exclude a beneficial or detrimental effect on the risk of symptomatic DVT with LMWH compared with VKA (RR 2.15; 95% CI 0.65 to 7.14; very-low-quality evidence) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<SUP>2</SUP> = 0%). <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK> show the associated risk of bias. The quality of evidence was very low due to serious risk of bias and very serious imprecision (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<B>Major bleeding:</B> One of two studies assessing major bleeding reported no events (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>). The other study including 45 participants did not show or exclude a beneficial or detrimental effect on the risk of major bleeding with LMWH compared with VKA (RR 3.41, 95% CI 0.15 to 79.47; very-low-quality evidence) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>) (<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>). <LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK> shows the associated risk of bias. The quality of evidence was very low due to serious risk of bias and very serious imprecision (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<B>Thrombocytopenia:</B> Meta-analysis of the two RCTs including 317 participants found a statistically significant increase in the risk of thrombocytopenia with LMWH compared with VKA (RR 3.73; 95% CI 2.26 to 6.16; low-quality evidence) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) (<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>). <LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK> shows the associated risk of bias.</P>
<P>Since the primary meta-analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta-analyses using the a priori plausible assumptions detailed in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section. The effect estimate remained statistically significant for the least two stringent plausible assumptions. However, it lost significance with the three more stringent plausible assumptions (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). The quality of evidence was low due to serious risk of bias and serious imprecision (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<B>Asymptomatic DVT: </B>Meta-analysis of the three RCTs including 551 participants found a statistically significant increase in the risk of asymptomatic DVT with LMWH compared with VKA (RR 1.74; 95% CI 1.20 to 2.52) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>; <LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>). <LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK> shows the associated risk of bias.</P>
<P>Since the primary meta-analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta-analyses used the priori plausible assumptions detailed in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section. The effect estimate remained statistically significant for the least stringent plausible assumption only. However, it lost significance with the remaining four more stringent assumptions (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
<P>
<B>Minor bleeding:</B> One study including 234 participants did not show or exclude a beneficial or detrimental effect on in the risk of minor bleeding with LMWH compared with VKA (RR 0.95; 95% CI 0.20 to 4.61) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>) (<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>). <LINK REF="FIG-18" TYPE="FIGURE">Figure 18</LINK> show the associated risk of bias.</P>
<P>
<B>Pulmonary embolism:</B> Two studies including 452 participants did not show or exclude a beneficial or detrimental effect on in the risk of PE with LMWH compared with VKA (RR 1.70; 95% CI 0.74 to 3.92) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) (<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>; <LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>). <LINK REF="FIG-19" TYPE="FIGURE">Figure 19</LINK> show the associated risk of bias.</P>
<P>
<B>Infection:</B> None of the included studies assessed infection.</P>
<P>
<B>Quality of life:</B> None of the included studies assessed quality of life.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<SUMMARY_OF_RESULTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>In people with cancer with CVC, the use of a prophylactic-dose heparin compared with no anticoagulation was associated with a statistically significant reduction in symptomatic DVT. The use of a low-dose VKA compared with no anticoagulation was associated with a statistically significant reduction in asymptomatic DVT, but a non-statistically significant trend towards a reduction in symptomatic DVT. The use of heparin compared with VKA was associated with a statistically significant reduction in asymptomatic DVT, but not symptomatic DVT, and increase in the risk of thrombocytopenia. The available data did not show or exclude a beneficial or detrimental effect of either LMWH or VKA on mortality, infection, and bleeding outcomes. We did not identify any RCTs evaluating fondaparinux as the anticoagulant or specifically evaluating HIT or HITT as outcomes.</P>
<P>We noted an interesting decrease in the baseline risk of symptomatic DVT by year of publication. This decline could reflect technological advances in CVC materials and designs, better CVC management strategies (e.g. shorter insertion times), and advances in clinical care in general (e.g. early mobilisation of participants). There was also a progressive decrease in the effect size of anticoagulation on thrombosis in people with cancer with CVC by year of publication), particularly in studies testing heparin therapy. A similar decrease in effect size of specific interventions has been shown in studies of mental health as more data have become available (<LINK REF="REF-Trikalinos-2004" TYPE="REFERENCE">Trikalinos 2004</LINK>). The smaller size of earlier studies (<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>; <LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>) provides a possible explanation for this phenomenon in our review, as small trials have been shown to exaggerate intervention effects compared with larger trials (<LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>). Another potentially contributing explanation is the early stopping of the study by Monreal et al. for benefit (<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>); Montori et al. have shown that RCTs stopped early for benefit show implausibly large treatment effects (<LINK REF="REF-Montori-2005" TYPE="REFERENCE">Montori 2005</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>The included studies recruited participants with a variety of cancer types and stages, which should increase the applicability of the results. The results apply best to LMWH given that only one study evaluated UFH. Unfortunately, no data were available to evaluate the impact of the intervention on quality of life. This outcome is important given the potential burden of both oral and subcutaneous anticoagulants.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>The quality of the evidence according to GRADE varied from very low to moderate. While the results showed consistency in most cases, and the likelihood of publication bias was low, the quality was affected mainly by imprecision and risk of bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Our systematic approach to searching, study selection, and data extraction followed that of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Additional strengths of the review include the high agreement between authors and the low likelihood of publication bias. One limitation of this review is that the 'no difference' findings may be related to the relatively small number of RCTs, small number of participants and of events, as well as the absence of a true effect. Another limitation related to the small number of RCTs was our inability to conduct subgroup analyses exploring the impact on the treatment effect of the characteristics of participants (adult versus children, solid versus haematological cancer, type of catheter), outcomes (symptomatic versus screening detected DVT, early versus late DVTs), and methodological quality criteria (allocation concealment and blinding). Another limitation was that we could not include three eligible studies published as abstracts for which we unable to obtain the necessary data from the authors.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Chaukiyal et al. conducted a systematic review to assess primary thromboprophylaxis in people with cancer with CVCs, and included eight RCTs with 1428 participants (<LINK REF="REF-Chaukiyal-2008" TYPE="REFERENCE">Chaukiyal 2008</LINK>). While we included six of these trials, we excluded Couban et al. because of unequal follow-up of the two study groups (<LINK REF="STD-Couban-2005" TYPE="STUDY">Couban 2005</LINK>). We also excluded Abdelkefi et al. because the publishing journal published an "Expression of Concern": reportedly, concerns about the accuracy and validity of the trial findings were raised by readers, and when asked by the editors "to provide evidence that the study was conducted, the authors were unable to provide this evidence" (<LINK REF="STD-Abdelkefi-2004" TYPE="STUDY">Abdelkefi 2004</LINK>). Chaukiyal et al. found no statistically significant difference in catheter-related thrombosis for the use of warfarin versus placebo; heparin versus placebo; or warfarin, UFH, or LMWH versus placebo. Moreover, the results did not confirm a detrimental effect of thromboprophylaxis on the risk of overall bleeding and thrombocytopenia.</P>
<P>A more recently published systematic review focused on children with cancer with CVC (<LINK REF="REF-Schoot-2013" TYPE="REFERENCE">Schoot 2013</LINK>). The authors could not confirm or exclude any effect of preventive systemic treatments (including LMWH, antithrombin supplementation, low-dose warfarin, and cryoprecipitate/fresh frozen plasma) compared with no intervention on VTE (symptomatic and asymptomatic), major bleeding, or minor bleeding.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>People with cancer with central venous catheters (CVC) considering anticoagulation should balance the possible benefit of reduced incidence of thromboembolic complications with the harms and burden of taking anticoagulants. People may opt against prophylactic anticoagulation because they are bleeding averse, because anticoagulants (e.g. daily subcutaneous injections) would be a burden for them, or they are uncomfortable with the uncertainty of benefit. Other people may opt for prophylactic anticoagulation because they have low aversion to bleeding, because they do not consider anticoagulation as a burden, and they have a high preference for avoidance of thrombosis (and the associated increased risk of a pulmonary embolism, premature CVC removal, and the need to start a relatively long therapeutic anticoagulation).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>More data from randomized controlled trials (RCT) are needed to answer the question about the role of anticoagulants for thromboprophylaxis in people with cancer and CVC confidently. There is at least one RCT addressing this question that has not been published yet (<LINK REF="STD-Glaspy-2000" TYPE="STUDY">Glaspy 2000</LINK>). Studies should adhere to high methodological quality and be adequately powered to assess participant-important outcomes such as mortality, premature CVC removal, symptomatic thrombosis, and bleeding. Studies should also aim to use standardized definitions for major and minor bleeding and for catheter-related infections. Research should demonstrate a definite benefit of anticoagulation before conducting additional studies comparing the effects of different anticoagulants.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-10-02 13:21:28 +0100" MODIFIED_BY="Gail Quinn">
<P>We would like to thank Ms. Annie Young, Dr. Abderrahman Abdelkefi, Dr. Murray Bern, Dr. Alison Inder, Dr. Patrick Mismetti, and Dr. Manuel Monreal for supplying us with the requested information to complete this review.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological Cancer Group.</P>
<P>The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>EAA is executive committee members of the American College of Chest Physicians Antithrombotic Therapy Guidelines.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>EAA: protocol development, search for trials, screening, data extraction, data analysis, manuscript drafting, review coordination.</P>
<P>GK: screening, search for trials, full-text retrieval, data extraction, manuscript review.</P>
<P>VY: full-text retrieval, data extraction, manuscript review.</P>
<P>SYK: search for trials, screening, manuscript review.</P>
<P>MB: screening, manuscript review.</P>
<P>FS: data analysis, manuscript review.</P>
<P>DJC: protocol development, methodological advice, manuscript review.</P>
<P>HJS: protocol development, data analysis, methodological advice, manuscript review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<STUDIES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<INCLUDED_STUDIES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Bern-1990" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Bern 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bern MM, Lokich JJ, Wallach SR, Bothe A, Jr., Benotti PN, Arkin CF, et al</AU>
<TI>Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1990</YR>
<VL>112</VL>
<NO>6</NO>
<PG>423-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-24 14:24:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bern MM, Lokich JJ, Wallach SR, Huberman M, Tangen O</AU>
<TI>Very low-dose warfarin prevents thrombosis in central vein catheters</TI>
<SO>ASCO Annual Meeting Proceedings</SO>
<YR>1986</YR>
<VL>5</VL>
<PG>254</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Cicco-2009" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="De Cicco 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M, et al</AU>
<TI>Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies</TI>
<SO>Annals of Oncology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1936-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Cicco M, Matovic M, Pacenzia R, Fantin D, Caserta M, Bortolussi R, et al</AU>
<TI>Short-term acenocumarine (A) or dalteparine (D) for the prevention of central venous catheter-related thrombosis (CVCrT) in cancer patients. A randomized controlled study based on serial venographies</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24 Suppl</VL>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heaton-2002" NAME="Heaton 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heaton DC, Hyan DY, Inder A</AU>
<TI>Minidose (1mg) warfarin as prophylaxis for central vein catheter thrombosis</TI>
<SO>Internal Medicine Journal</SO>
<YR>2002</YR>
<VL>32</VL>
<PG>84-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karthaus-2006" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Karthaus 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al</AU>
<TI>Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>2</NO>
<PG>289-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichardt P, Kretzschmar A, Biakhov M, Irwin D, Slabber C, Miller L, et al</AU>
<TI>A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1474</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavau_x002d_Denes-2013" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Lavau-Denes 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Vénat-Bouvet L, et al</AU>
<TI>Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study</TI>
<SO>Cancer Chemotherapy Pharmacology</SO>
<YR>2013</YR>
<VL>72</VL>
<PG>65-73</PG>
<IDENTIFIERS MODIFIED="2014-09-23 09:48:17 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-25 14:12:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-25 14:12:30 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00199602"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massicotte-2003" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Massicotte 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al</AU>
<TI>An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial</TI>
<SO>Thrombosis Research</SO>
<YR>2003</YR>
<VL>109</VL>
<NO>2-3</NO>
<PG>101-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mismetti-2003" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Mismetti 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, et al</AU>
<TI>Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial</TI>
<SO>Haematologica</SO>
<YR>2003</YR>
<VL>88</VL>
<NO>1</NO>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monreal-1996" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Monreal 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al</AU>
<TI>Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin)</TI>
<SO>Thrombosis &amp; Haemostasis</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>2</NO>
<PG>251-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niers-2007" MODIFIED="2014-09-20 19:29:25 +0100" MODIFIED_BY="Anne Lawson" NAME="Niers 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-09-20 19:29:25 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niers TMH, Di Nisio M, Klerk CPW, Baarslag HJ, Buller HR, Biemond BJ</AU>
<TI>Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>9</NO>
<PG>1878-82</PG>
<IDENTIFIERS MODIFIED="2010-07-29 19:36:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruud-2006" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Ruud 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruud E, Holmstrom H, Hopp E, Wesenberg F</AU>
<TI>Low-dose warfarin for the prevention of central line-associated thrombosis in children with malignancies - a randomized, controlled study</TI>
<SO>Acta Paediatrica</SO>
<YR>2006</YR>
<VL>95</VL>
<NO>9</NO>
<PG>1053-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verso-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Verso 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Agnelli G, Verso M, Bertoglio S, Ageno W, Bazzan M, Parise P, et al</AU>
<TI>A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>734S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al</AU>
<TI>Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4057-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-2009" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Young 2009" YEAR="2005">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young AM, Begum G, Billingham LJ, Hughes AI, Kerr DJ, Rea D, et al</AU>
<TI>WARP - a multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16S</NO>
<PG>8004</PG>
<IDENTIFIERS MODIFIED="2010-08-18 16:17:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, et al</AU>
<TI>Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>373</VL>
<NO>9663</NO>
<PG>567-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdelkefi-2004" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Abdelkefi 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abdelkefi A, Ben Othman T, Kammoun L, Chelli M, Ben Romdhane N, Kriaa A, et al</AU>
<TI>Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-ontological disease - a randomized controlled trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>92</VL>
<NO>3</NO>
<PG>654-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1987" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Anderson 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Anderson AJ, Krasnow SH, Boyer MW, Raucheisen ML, Grant CE, Gasper OR, et al. Hickman catheter clots: a common occurrence despite daily heparin flushing. Cancer Treatment Reports. 1987 Jun;71(6):651-3.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson AJ, Krasnow SH, Boyer MW, Raucheisen ML, Grant CE, Gasper OR, et al</AU>
<TI>Hickman catheter clots: a common occurrence despite daily heparin flushing</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1987</YR>
<VL>71</VL>
<NO>6</NO>
<PG>651-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1989" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Anderson 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest. 1989 Jan;95(1):71-5.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, et al</AU>
<TI>Thrombosis: the major Hickman catheter complication in patients with solid tumor</TI>
<SO>Chest</SO>
<YR>1989</YR>
<VL>95</VL>
<NO>1</NO>
<PG>71-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Attal-1992" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Attal 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al</AU>
<TI>Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial</TI>
<SO>Blood</SO>
<YR>1992</YR>
<VL>79</VL>
<NO>11</NO>
<PG>2834-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barman-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Barman 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Barman B, Ghosh R, Mondal A, Saha K, Mukhopadhyay S, Mukhopadhyay A. Central venous catheters in bone marrow transplantation and leukemia patients. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005 23(16S):Abstract No: 8269&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Barman B, Ghosh R, Mondal A, Saha K, Mukhopadhyay S, Mukhopadhyay A</AU>
<TI>Central venous catheters in bone marrow transplantation and leukemia patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<PG>8269</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boraks-1998" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Boraks 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. British Journal of Haematology. 1998 Jun;101(3):483-6.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, et al</AU>
<TI>Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>101</VL>
<NO>3</NO>
<PG>483-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conte-2003" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Conte 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conte GF, Aravena PC, Fardella PD, Araos DM, Alfaro JI, Flores CA, et al</AU>
<TI>Prophylaxis of venous thrombosis (VT) associated with central venous catheter (CVC) with low molecular weight heparin (LMWH) in hematologic malignancies</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>11</NO>
<PG>4195</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Couban-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Couban 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al</AU>
<TI>Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4063-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curigliano-2004" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Curigliano 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Curigliano G, Mandal&amp;#195;&amp;#160; M, Bucciarelli P, Peruzzotti G, Colleoni M, Biffi R, et al. Factor V Leiden mutation in patients with breast cancer and a central venous catheter: Relationship with deep vein thrombosis. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings 2004;22(14S):8020.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curigliano G, MandalÃ  M, Bucciarelli P, Peruzzotti G, Colleoni M, Biffi R, et al</AU>
<TI>Factor V Leiden mutation in patients with breast cancer and a central venous catheter: relationship with deep vein thrombosis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>8020</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dillon-2004" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Dillon 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM. Prophylactic urokinase in the management of long-term venous access devices in children: A Children's Oncology Group study. Journal of Clinical Oncology. 2004;22(13):2718-23.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM</AU>
<TI>Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>13</NO>
<PG>2718-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freytes-2003" NAME="Freytes 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Freytes C. Thromboembolic complications related to indwelling central venous catheters in children. Current Opinion in Oncology. 2003 Jul;15(4):289-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freytes C</AU>
<TI>Thromboembolic complications related to indwelling central venous catheters in children</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>4</NO>
<PG>289-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gould-1996" MODIFIED="2014-09-20 19:35:52 +0100" MODIFIED_BY="Anne Lawson" NAME="Gould 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-09-20 19:35:52 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gould JR, Riggs B</AU>
<TI>Warfarin (WP) dose and incidence of port-related thrombotic complications (CMPs) in cancer patients (pts)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Handrup-2012" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Handrup 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Handrup MM, Fuursted K, Funch P, Møller JK, Schrøder H</AU>
<TI>Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin</TI>
<SO>APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica</SO>
<YR>2012</YR>
<VL>120</VL>
<NO>10</NO>
<PG>794-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henrickson-2000" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Henrickson 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. Journal Of Clinical Oncology. 2000 Mar;18(6):1269-78.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, et al</AU>
<TI>Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1269-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffman-2001" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Hoffman 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Hoffman KR. Subcutaneous Ports Used for Vascular Access Need Only Be Flushed Every Eight Weeks to Maintain Patency. Journal of Clinical Oncology, 2001 ASCO Annual Meeting Proceedings 2001;20:1634.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffman KR</AU>
<TI>Subcutaneous ports used for vascular access need only be flushed every eight weeks to maintain patency</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>1634</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horne-2006" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Horne 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horne MK, McCloskey DJ, Calis K, Wesley R, Childs R, Kasten-Sportes C</AU>
<TI>Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices</TI>
<SO>Pharmacotherapy</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>9</NO>
<PG>1262-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huisman-2006" NAME="Huisman 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Huisman MV. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups. Journal Of Thrombosis And Haemostasis. 2006 Jan;4(1):10-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huisman MV</AU>
<TI>Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>1</NO>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iniesta-2003" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Iniesta 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iniesta P, Garcia T, Ayala F, Macias J, Flores B, Cava C, et al</AU>
<TI>Dalteparin is effective as prophylaxis of central venous catheter related thrombosis in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>3151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansson-2005" NAME="Jansson 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Jansson JH. Central venous catheter and malignant disease. The value of thrombosis prophylaxis is questioned now. Lakartidningen. 2005 Jun 27-Jul 10;102(26-27):1984-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansson JH</AU>
<TI>Central venous catheter and malignant disease. The value of thrombosis prophylaxis is questioned now</TI>
<SO>Lakartidningen</SO>
<YR>2005</YR>
<VL>102</VL>
<NO>26-27</NO>
<PG>1984-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klerk-2003" NAME="Klerk 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klerk CPW, Smorenburg SM, Buller HR</AU>
<TI>Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>16</NO>
<PG>1913-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klerk-2004" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Klerk 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Klerk CPW, Buller HR. Thrombosis prophylaxis in cancer patients with a central venous catheter - In reply. Archives Of Internal Medicine. 2004 Feb 23;164(4):459-60.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klerk CPW, Buller HR</AU>
<TI>Thrombosis prophylaxis in cancer patients with a central venous catheter - in reply</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<NO>4</NO>
<PG>459-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lersch-2002" NAME="Lersch 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Lersch C, Kotowa W, Janssen D. Thromboembolic prophylaxis with dalteparin-Na (Fragmin) in oncological patients following port implantations. [German]. Tumor Diagnostik und Therapie. 2002;23(3):104-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lersch C, Kotowa W, Janssen D</AU>
<TI>Thromboembolic prophylaxis with dalteparin-Na (Fragmin) in oncological patients following port implantations</TI>
<SO>Tumor Diagnostik und Therapie</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>3</NO>
<PG>104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Levine 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Levine M, Kakkar AK. Catheter-associated thrombosis: Thromboprophylaxis or not? Journal Of Clinical Oncology. 2005 Jun 20;23(18):4006-8.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine M, Kakkar AK</AU>
<TI>Catheter-associated thrombosis: thromboprophylaxis or not?</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4006-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magagnoli-2004" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Magagnoli 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Magagnoli M, Masci G, Castagna L, Zucali PA, Pedicini V, Bramanti S, et al. Retrospective analysis of central venous catheter-related thrombosis in 427 cancer patients prophylaxed with low-dose warfarin. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings. 2004;22(14S ):8102.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magagnoli M, Masci G, Castagna L, Zucali PA, Pedicini V, Bramanti S, et al</AU>
<TI>Retrospective analysis of central venous catheter-related thrombosis in 427 cancer patients prophylaxed with low-dose warfarin</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>14S</NO>
<PG>8102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magagnoli-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Magagnoli 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Magagnoli M, Masci G, Castagna L, Zucali PA, Morenghi E, Pedicini V, et al. Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients. Anticancer Research. 2005 Jul-Aug;25(4):3143-7.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magagnoli M, Masci G, Castagna L, Zucali PA, Morenghi E, Pedicini V, et al</AU>
<TI>Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients</TI>
<SO>Anticancer Research</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>3143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-1999" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Park 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Park K, Oh SY, Kim WS, Jeong HS, Lee JT, Kong K, et al</AU>
<TI>Randomized phase III trial of very low dose warfarin to prevent catheter-associated thrombosis</TI>
<SO>American Society of Clinical Oncology</SO>
<YR>1999</YR>
<PG>2330</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratcliffe-1999" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Ratcliffe 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Ratcliffe M, Broadfoot C, Davidson M, Kelly KF, Greaves M, Ratcliffe M, et al. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clinical &amp;amp; Laboratory Haematology. 1999 Oct;21(5):353-7.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratcliffe M, Broadfoot C, Davidson M, Kelly KF, Greaves M, Ratcliffe M, et al</AU>
<TI>Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease</TI>
<SO>Clinical and Laboratory Haematology</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>5</NO>
<PG>353-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romano-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Romano 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Romano G, Tartarone A, Ardito R, Bochicchio A, Capobianco A, Coccaro M, et al. The influence of externalised groshong catheters or subcutaneously implanted ports on normal daily activities of cancer patients. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005;23(16S):8155.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romano G, Tartarone A, Ardito R, Bochicchio A, Capobianco A, Coccaro M, et al</AU>
<TI>The influence of externalised Groshong catheters or subcutaneously implanted ports on normal daily activities of cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16S</NO>
<PG>8155</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomon-2001" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Solomon 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Solomon B, Moore J, Arthur C, Prince HM, Solomon B, Moore J, et al. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin. European Journal of Cancer. 2001 Dec;37(18):2379-84.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomon B, Moore J, Arthur C, Prince HM, Solomon B, Moore J, et al</AU>
<TI>Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin</TI>
<SO>European Journal of Cancer</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>18</NO>
<PG>2379-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tesselaar-2001" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Tesselaar 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Tesselaar MET, Ouwerkerk J, Rosendaal FR, Osanto S. Prophylaxis with Low Molecular Weight Heparin Reduces the Risk for Catheter-Related Venous Thrombosis in Cancer Patients in Centrally, but not in Peripherally, Inserted Central Venous Catheters. Journal of Clinical Oncology, 2001 ASCO Annual Meeting Proceedings. 2001;20:1584.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tesselaar MET, Ouwerkerk J, Rosendaal FR, Osanto S</AU>
<TI>Prophylaxis with low molecular weight heparin reduces the risk for catheter-related venous thrombosis in cancer patients in centrally, but not in peripherally, inserted central venous catheters</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>1584</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Th_x00fc_rlmann-1992" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Thürlmann 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thürlimann B, Bachmann I</AU>
<TI>Effective prevention of chemotherapy-induced phlebitis by low-dose heparin: a prospective randomised trial</TI>
<SO>Annals of Oncology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>4</NO>
<PG>311-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Rooden-2003" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="van Rooden 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;van Rooden CJ, Rosendaal FR, Barge RMY, van Oostayen JA, van der Meer FJM, Meinders AE, et al. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. British Journal Of Haematology. 2003 Nov;123(3):507-12.&lt;/p&gt;" NOTES_MODIFIED="2014-09-29 11:58:06 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Rooden CJ, Rosendaal FR, Barge RMY, van Oostayen JA, van der Meer FJM, Meinders AE, et al</AU>
<TI>Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound</TI>
<SO>British Journal of Haematology</SO>
<YR>2003</YR>
<VL>123</VL>
<NO>3</NO>
<PG>507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-11-05 10:25:48 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Glaspy-2000" MODIFIED="2013-11-05 10:25:48 +0000" MODIFIED_BY="[Empty name]" NAME="Glaspy 2000" YEAR="2000">
<IDENTIFIERS MODIFIED="2013-11-05 10:25:42 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-05 10:25:42 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00006083"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<REFERENCE ID="REF-Akl-2013" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Akl 2013" TYPE="JOURNAL_ARTICLE">
<AU>Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al</AU>
<TI>Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers</TI>
<SO>PLoS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>2</NO>
<PG>e57132</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ansell-2008" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Ansell 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G</AU>
<TI>Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)</TI>
<SO>Chest</SO>
<YR>2008</YR>
<VL>133</VL>
<NO>6 Suppl</NO>
<PG>160S-198S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blom-2005" NAME="Blom 2005" TYPE="JOURNAL_ARTICLE">
<AU>Blom JW, Doggen CJ, Osanto S, Rosendaal FR</AU>
<TI>Malignancies, prothrombotic mutations, and the risk of venous thrombosis</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>6</NO>
<PG>715-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bona-1999" NAME="Bona 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bona RD</AU>
<TI>Thrombotic complications of central venous catheters in cancer patients</TI>
<SO>Seminars in Thrombosis &amp; Hemostasis</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>2</NO>
<PG>147-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaukiyal-2008" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Chaukiyal 2008" TYPE="JOURNAL_ARTICLE">
<AU>Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD</AU>
<TI>Thromboprophylaxis in cancer patients with central venous catheters: a systematic review and meta-analysis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2008</YR>
<VL>99</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publication Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebrahim-2013" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Ebrahim 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, et al</AU>
<TI>Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers.</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>9</NO>
<PG>1014-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heit-2000" NAME="Heit 2000" TYPE="JOURNAL_ARTICLE">
<AU>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd</AU>
<TI>Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>6</NO>
<PG>809-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Higgins 2005" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2005</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-1993" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Hirsh 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J</AU>
<TI>Low molecular weight heparin</TI>
<SO>Thrombosis &amp; Haemostasis</SO>
<YR>1993</YR>
<VL>70</VL>
<NO>1</NO>
<PG>204-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutten-2000" NAME="Hutten 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR</AU>
<TI>Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>17</NO>
<PG>3078-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2010-12-10 00:45:35 +0000" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1999" NAME="Lee 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Levine MN</AU>
<TI>The thrombophilic state induced by therapeutic agents in the cancer patient</TI>
<SO>Seminars in Thrombosis &amp; Hemostasis</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>2</NO>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lordick-2003" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Lordick 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lordick F, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, et al</AU>
<TI>Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study</TI>
<SO>British Journal of Haematology</SO>
<YR>2003</YR>
<VL>120</VL>
<NO>6</NO>
<PG>1073-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monreal-1994" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Monreal 1994" TYPE="JOURNAL_ARTICLE">
<AU>Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, et al</AU>
<TI>Pulmonary embolism in patients with upper extremity DVT associated to venous central lines - a prospective study</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>4</NO>
<PG>548-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montori-2005" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Montori 2005" TYPE="JOURNAL_ARTICLE">
<AU>Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA, Eggert CH, Briel M, et al</AU>
<TI>Randomized trials stopped early for benefit: a systematic review</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>17</NO>
<PG>2203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prandoni-2002" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Prandoni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al</AU>
<TI>Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>10</NO>
<PG>3484-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruinemans_x002d_Koerts-2010" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Ruinemans-Koerts 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ruinemans-Koerts J, Peterse-Stienissen I, Verbruggen B</AU>
<TI>Expression of concern: non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2010</YR>
<VL>104</VL>
<NO>5</NO>
<PG>1080-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schoot-2013" MODIFIED="2014-07-26 09:21:17 +0100" MODIFIED_BY="[Empty name]" NAME="Schoot 2013" TYPE="COCHRANE_REVIEW">
<AU>Schoot RA, Kremer LCM, van de Wetering MD, van Ommen CH</AU>
<TI>Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2014-07-26 09:18:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-26 09:18:25 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009160.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Silverstein-1998" NAME="Silverstein 1998" TYPE="JOURNAL_ARTICLE">
<AU>Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd</AU>
<TI>Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>6</NO>
<PG>585-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smorenburg-2001" MODIFIED="2013-10-24 14:30:03 +0100" MODIFIED_BY="[Empty name]" NAME="Smorenburg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Smorenburg SM, Van Noorden CJ</AU>
<TI>The complex effects of heparins on cancer progression and metastasis in experimental studies</TI>
<SO>Pharmacological Review</SO>
<YR>2001</YR>
<VL>53</VL>
<NO>1</NO>
<PG>93-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorensen-2000" NAME="Sorensen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA</AU>
<TI>Prognosis of cancers associated with venous thromboembolism</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>25</NO>
<PG>1846-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutherland-2003" NAME="Sutherland 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland DE, Weitz IC, Liebman HA</AU>
<TI>Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment</TI>
<SO>American Journal of Hematology</SO>
<YR>2003</YR>
<VL>72</VL>
<NO>1</NO>
<PG>43-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thodiyil-2002" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Thodiyil 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thodiyil P, Kakkar AK</AU>
<TI>Can low-molecular-weight heparins improve outcomes in patients with cancer?</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2002</YR>
<VL>28</VL>
<PG>151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trikalinos-2004" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NAME="Trikalinos 2004" TYPE="JOURNAL_ARTICLE">
<AU>Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al</AU>
<TI>Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2004</YR>
<VL>57</VL>
<NO>11</NO>
<PG>1124-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verso-2003" MODIFIED="2008-08-19 14:26:25 +0100" MODIFIED_BY="Gail Quinn" NAME="Verso 2003" TYPE="JOURNAL_ARTICLE">
<AU>Verso M, Agnelli G</AU>
<TI>Venous thromboembolism associated with long-term use of central venous catheters in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>19</NO>
<PG>3665-75</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-10-02 13:20:30 +0100" MODIFIED_BY="Gail Quinn">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-10-02 13:20:30 +0100" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Bern-1990">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>121 participants with solid and haematological cancers</P>
<P>Mean age: 56 years for warfarin; 60.6 years for no warfarin</P>
<P>Minimum life expectancy: 3 months<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: warfarin 1 mg/day; 3 days prior to CVC placement and continuing for 90 days<BR/>Control: no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Mortality</LI>
<LI>DVT asymptomatic</LI>
<LI>DVT symptomatic</LI>
<LI>DVT total</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up: 90 days</P>
<P>CVC characteristics: port; subclavian; placed by surgeons; flushed with heparin; no antibiotic prophylaxis</P>
<P>DVT assessment: screening (90 days) by venography or diagnosis by venography when signs or symptoms developed</P>
<P>Funding: Pharmacia-NuTech, Inc. and E.I. DuPont<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-De-Cicco-2009">
<CHAR_METHODS MODIFIED="2010-07-29 18:36:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>450 participants aged &gt; 18 years with solid and haematological cancers included in the study</P>
<P>Mean age: 55.5 for acenocumarine; 55.3 for dalteparin; 55.1 for no anticoagulant treatment</P>
<P>Expected life expectancy at least 3 months</P>
<P>Discontinued treatment: "The primary efficacy population was 77.3% (348 of 450 patients): 76% in group A, 80% in group D and<BR/>76% in group NT"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: acenocumarine 1 mg/day for 3 days before and 8 days after CVC insertion, dalteparin prophylactic dose; started 2 hours before and daily for 8 days after CVC insertion</P>
<P>Control: no anticoagulant treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>CRT</LI>
<LI>Clinically overt PE</LI>
<LI>Compulsory catheter removal</LI>
<LI>Major bleeding (retroperitoneal and intracranial bleeding and any other haemorrhage requiring surgical intervention were also considered as major. Any other bleeding was considered as minor)</LI>
<LI>Mortality</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up started after the second venography or on study withdrawal when this occurred</P>
<P>Follow-up: 2 months for 3 visits after initial 30 days, therefore, 7 months total</P>
<P>DVT assessment: venography on days 8 and 30 after insertion then every 2 months 3 visits or earlier if there was a clinical suspicion</P>
<P>Diagnostic test for PE: high probability ventilation-perfusion lung scanning or by multislice CT</P>
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Heaton-2002">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>88 participants with haematological cancers</P>
<P>Mean age: 43 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: warfarin 1 mg/day; with CVC placement; 90 days<BR/>Control: no intervention<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Venous thrombosis related to the catheter confirmed by venography</LI>
<LI>Premature removal of the catheter for any reason before day 90</LI>
<LI>Infection of catheter or subcutaneous tunnel</LI>
<LI>CVC occlusion</LI>
<LI>DVT symptomatic</LI>
</UL>
<P>DVT assessment: no screening; diagnosis by venography<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>CVC characteristics: external, tunnelled; subclavian; place by radiologists; flushed with heparin or saline; no antibiotic prophylaxis</P>
<P>Follow-up: 90 days</P>
<P>Catheter thrombosis confirmed by venography</P>
<P>Not funded<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-02 13:20:30 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Karthaus-2006">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Multinational double-blind randomized controlled trial (phase III)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>439 participants with solid and haematological cancers</P>
<P>Mean age 56.3 years; </P>
<P>Minimum age 18 years</P>
<P>Minimum life expectancy: 16 weeks</P>
<P>Setting: 48 different centres in: Austria, Canada, France, Germany, Greece, Portugal, the Russian Federation, the Slovak Republic, South Africa, Sweden, the UK and the USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: dalteparin prophylactic dose; started 5-7 days prior to CVC placement; once daily for 16 weeks<BR/>Control: placebo</P>
<P>Co-intervention: chemotherapy for &#8805; 12 weeks, administered to both groups </P>
<P>DVT assessment: screening by venography or Doppler or CT scan (16 weeks); diagnosis by venography or Doppler or CT scan</P>
<P>VQ scan or spiral CT were used to verify PE occurrence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-02 13:20:30 +0100" MODIFIED_BY="Gail Quinn">
<P/>
<P>Primary outcomes:</P>
<UL>
<LI>CRT that was symptomatic or that required anticoagulation treatment or infusion of fibrinolytic agent with or without catheter removal</LI>
<LI>Catheter-related clinically relevant PE with or without catheter removal</LI>
<LI>Catheter obstruction requiring catheter removal</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>CRT asymptomatic</LI>
<LI>Incidence of CRC per day of exposure to the study drug</LI>
<LI>Time to the first clinically relevant CRC</LI>
<LI>Time to catheter removal</LI>
<LI>Catheter-related infection or positive catheter tip culture, or both</LI>
<LI>Use of bolus injections of fibrinolytic agents for CRT or catheter obstruction</LI>
<LI>Clinically relevant and objectively verified non-catheter-related venous or arterial TEE</LI>
<LI>Clinical and laboratory adverse events (major bleeding, thrombocytopenia)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>CVC characteristics: mostly ports; proximal or distal to axilla; flushed with heparin and saline<BR/>
</P>
<P>Duration of follow-up: 16 weeks</P>
<P>Funding: Pfizer, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Open-label randomized controlled trial (phase III)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>420 participants with histological evidence of solid invasive cancer, locally advanced or metastatic status</P>
<P>Subclavian CVC inserted for &lt; 7 days</P>
<P>Receiving first-line chemotherapy</P>
<P>Median age: 61 years, 75% males, 46% had a metastatic extension</P>
<P>Life expectancy: &gt; 3 months</P>
<P>Setting: Centre Hospitalier Universitaire de Limoges</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of treatment: first 6 days after central venous access device implantation and was prescribed for 90 days</P>
<P>Intervention 1: LMWH 2500 U anti-XA/day (subcutaneous: dalteparin, nadroparin, or enoxaparin, once daily)</P>
<P>Intervention 2: warfarin oral 1 mg/day</P>
<P>Control: no anticoagulant</P>
<P>Co-intervention: chemotherapy, administered to all groups </P>
<P>Diagnostic test for DVT: Doppler ultrasound and venographies</P>
<P>Quote: "Asymptomatic DVT were blindly assessed by both Doppler US [ultrasound] and venographies"</P>
<P>Quote: "Two patients were diagnosed by chance during surgery performed for the cancer resection (head and neck cancers), and 2 others thanks to a computed tomography scan planned for tumor evaluation"</P>
<P>Consent withdrawn or no data: 1/142 participants in LMWH group (intervention 1); 3/138 participants in warfarin group (intervention 2); 3/140 participants in control group</P>
<P>Lost to follow-up: 3/142 in LMWH group (intervention 1); 1/138 participants in warfarin group (intervention 2); 2/140 participants in control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Symptomatic and asymptomatic catheter-related DVT of the ipsilateral upper limbs and cervical veins</LI>
<LI>Superior vena cava, subclavian vein, jugular and humeral vein thrombosis</LI>
<LI>PE</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 3 months</P>
<P>Funding: not reported in the manuscript; however, in clinicaltrial.gov "Sponsors and collaborators: University Hospital, Limoges" (<A HREF="http://clinicaltrials.gov/show/NCT00199602">clinicaltrials.gov/show/NCT00199602</A>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Massicotte-2003">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Open-label, multicentre international randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>186 participants</P>
<P>Age: newborns to 18 years</P>
<P>51% of whom had cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: reviparin prophylactic dose, started within 12 hours of randomization (randomization could occur up to 5 days after insertion of the CVC)<BR/>Control: no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>CVC-related VTE asymptomatic (venogram on day 30 or at time of CVC removal)</LI>
<LI>CVC-related VTE symptomatic</LI>
<LI>Mortality; catheter-related</LI>
<LI>Major bleeding</LI>
<LI>Minor bleeding</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up: 30 days but varied depending on the time of CVC removal</P>
<P>CVC characteristics: different types (subcutaneous, exteriorized, percutaneous inserted central catheter); flushed with heparin</P>
<P>Funding: Medical Research Council of Canada (MRC), Pharmaceutical Manufacturers Association of Canada (PMAC) Health Program and Knoll AG</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Mismetti-2003">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Multicentre open, parallel-group randomized controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>60 participants with solid (non-haematological) cancers</P>
<P>Minimum age: 18 years; mean age: 58.7 years</P>
<P>Minimum life expectancy: 3 months.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: prophylactic dose; nadroparin 2850 IU subcutaneously, once daily started 2 hours prior to CVC placement; for 90 days<BR/>Control: warfarin 1 mg/day; starting 3 days prior to CVC placement; 90 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Mortality (90 days, 6 months)</LI>
<LI>CVC premature removal</LI>
<LI>CVC-site DVT asymptomatic</LI>
<LI>CVC-site DVT symptomatic</LI>
<LI>Non-CVC-site DVT</LI>
<LI>CVC-related infection</LI>
<LI>Major bleed</LI>
<LI>HIT</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up: 6 months</P>
<P>CVC characteristics: port; subclavian; placed by surgeons; flushed with heparin and saline; no antibiotic prophylaxis</P>
<P>DVT assessment: ."by day 90 confirmed by bilateral venography performed routinely 90±5 days after insertion of the catheter, or earlier if symptoms of thrombosis had appeared.&#8221;</P>
<P>For TEEs: venography of the extremities, Doppler or venography of lower limbs (or both), VQ scan, pulmonary angiogram, helical CT, autopsy</P>
<P>CRC: infection, catheter removal, obstruction</P>
<P>Funding: Sanofi-Synthélabo, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Monreal-1996">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Open randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>32 participants with solid tumours</P>
<P>Mean age: 54 years</P>
<P>Minimum life expectancy: 3 months</P>
<P>29 participants completed the study (study was stopped prematurely)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: fragmin (LMWH) 2500 IU subcutaneously; 2 hours prior to CVC placement; 90 days<BR/>Control: no intervention<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Mortality</LI>
<LI>DVT asymptomatic</LI>
<LI>DVT symptomatic</LI>
<LI>DVT total</LI>
<LI>Infection</LI>
<LI>Major bleeding</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up: 90 days</P>
<P>CVC characteristics: port; subclavian; placed by surgeons; flushed with heparin; no antibiotic prophylaxis</P>
<P>DVT assessment: screening (90 days) by venography; diagnosis by venography</P>
<P>Not funded<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Niers-2007">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Single centre randomized placebo-controlled double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>113 participants with haematological malignancies</P>
<P>Age: &gt; 18 years; mean age: 56.5 years (58 years for nadroparin, 55 years for placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: once-daily nadroparin (LMWH) 2850 IU subcutaneously prophylactic dose; started 2 hour before CVC insertion; for 3 weeks or until the day of CVC removal</P>
<P>Control: placebo injections subcutaneously</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Catheter-related CVT</LI>
<LI>Major, clinically relevant non-major, or minor bleeding</LI>
<LI>Catheter colonization</LI>
<LI>Catheter-related sepsis</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up: 3 weeks.</P>
<P>Funding: "The study drug was obtained commercially, and there was financial support for the study"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Ruud-2006">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized controlled study</P>
<P>Setting: 2 university hospitals in Oslo, Norway<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>73 children with solid and haematological cancers</P>
<P>Mean age: 6.8 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: warfarin 0.1 mg/kg starting the day of insertion of CVC (target INR 1.3-1.9), duration not reported<BR/>Control: no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>VTE symptomatic</LI>
<LI>VTE asymptomatic</LI>
<LI>Major bleeding</LI>
<LI>Presence of infections (positive blood cultures)</LI>
<LI>Removal of CVC due to CVC-related infection</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up: 6 months</P>
<P>CVC characteristics: external tunnelled catheters and ports; jugular<BR/>DVT assessment: screening (1, 3, and 6 months): ultrasound</P>
<P>Funding: Norwegian Cancer Society<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Verso-2005">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Multicentre (11 Italian centres), double-blind randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>385 participants with solid and haematological cancers</P>
<P>Minimum age: 18 years; mean age: 59.3 years</P>
<P>Minimum life expectancy: 3 months<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: enoxaparin 40 mg/day subcutaneously prophylactic dose; started 2 hours prior to CVC placement; for 6 weeks<BR/>Control: placebo (preloaded syringes)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Mortality (6 weeks; 4.5 months)</LI>
<LI>DVT symptomatic</LI>
<LI>DVT asymptomatic</LI>
<LI>DVT total</LI>
<LI>VTE (4.5 months)</LI>
<LI>Major bleed</LI>
<LI>Minor bleed</LI>
<LI>Thrombocytopenia</LI>
<LI>Mortality from TEE</LI>
<LI>Mortality from any cause during study period or within 3 months of its completion</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Follow-up: 3 months</P>
<P>CVC characteristics: second-generation CVC; jugular or subclavian</P>
<P>DVT assessment: screening by venography (6 weeks); diagnosis by venography</P>
<P>PE: by VQ scan, CT, pulmonary angiogram, autopsy</P>
<P>Funding: grant-in-aid from Aventis, Inc.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Young-2009">
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Open-label multicentre randomized controlled trial</P>
<P>Setting: 68 clinical centres in the UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>590 participants with solid and haematological cancers</P>
<P>Minimum age: 16 years; 1participantmedian age: 60.5 years (60 years for warfarin, 61 years for control)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: warfarin: fixed dose 1 mg/day or dose adjusted to maintain INR 1.5-2)<BR/>Control: no intervention<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Mortality</LI>
<LI>VTE symptomatic (CVC-related local thrombosis or PE in participants who had catheter complications)</LI>
<LI>Non-catheter related thrombotic events</LI>
<LI>Catheter patency</LI>
<LI>Major bleed</LI>
<LI>Minor bleed</LI>
<LI>Catheter-related infection</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>All types of CVC allowed</P>
<P>Follow-up: median 45 months (range 26 to 88 months)</P>
<P>Funding: Medical Research Council and Cancer Research UK</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CT: computed tomography; CRC: catheter-related complication; CRT: catheter-related thrombosis; CVC: central venous catheter; HIT: heparin-induced thrombocytopenia; INR: international normalized ratio; IU: international unit; LMWH: low-molecular-weight heparin; PE: pulmonary embolism; TEE: thromboembolic event; U: unit; VQ: ventilation/perfusion.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Abdelkefi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Concerns about the accuracy and validity of the data reported, and the practical aspects of the published protocol. When asked by the review editors, the authors were unable to provide evidence that the study had been conducted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Anderson-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; no control group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Anderson-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 16:47:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Attal-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 16:47:57 +0100" MODIFIED_BY="[Empty name]">
<P>Not population of interest (participants did not previously have CVC, it was rather inserted for intervention)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Barman-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Boraks-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; historic control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Conte-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>No obtainable needed data from study authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-10 00:13:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Couban-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-10 00:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>Unequal follow-up of study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Curigliano-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Dillon-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Inadequate control groups; intervention compared with urokinase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-10 00:13:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freytes-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-10 00:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Gould-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>No obtainable needed data from study authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Handrup-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Not intervention of interest (locking solution)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henrickson-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Different drug/agent studied</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoffman-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Different drug/agent studied</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 16:50:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horne-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 16:50:59 +0100" MODIFIED_BY="[Empty name]">
<P>Not intervention of interest (flushing solution)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huisman-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Iniesta-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jansson-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klerk-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klerk-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lersch-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Magagnoli-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Magagnoli-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-19 13:29:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-19 13:29:24 +0000" MODIFIED_BY="[Empty name]">
<P>No obtainable needed data from the authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Ratcliffe-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Romano-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Solomon-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Inadequate control groups; intervention compared with urokinase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Tesselaar-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Th_x00fc_rlmann-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Not population of interest (peripheral venous catheter and not CVC)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-van-Rooden-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT; observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CVC: central venous catheter; RCT: randomized controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Glaspy-2000">
<CHAR_STUDY_NAME MODIFIED="2010-09-07 19:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Study type: interventional</P>
<P>Study design: randomized</P>
<P>Control: placebo</P>
<P>Intervention model: parallel assignment</P>
<P>Masking: double-blind</P>
<P>Primary purpose: supportive care</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>People with cancer who are receiving chemotherapy through a catheter</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: fragmin at 5000 international units injected subcutaneously daily</P>
<P>Control: placebo injected subcutaneously daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn"/>
<CHAR_STARTING_DATE MODIFIED="2010-09-07 19:16:58 +0100" MODIFIED_BY="[Empty name]">
<P>April 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-07 19:17:57 +0100" MODIFIED_BY="[Empty name]">
<P>John A. Glaspy, MD, MPH</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>Projected accrual: 345 participants (230 in intervention and 115 in control)</P>
<P>ClinicalTrials.gov Identifier: NCT00006083 (<A HREF="http://clinicaltrials.gov/show/NCT00006083">clinicaltrials.gov/show/NCT00006083</A>)</P>
<P>Other study ID numbers: CDR0000068075, P30CA016042, UCLA-9910055, P-UPJOHN-98-FRAG-076, NCI-G00-1822</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Quote: "Assignment to receive or not receive the drug was made according to a previously established yes or no code"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Quote: "Eligible patients were randomly assigned to receive either Acenocumarine or Dalteparin or No anticoagulant treatment"</P>
<P>Comment: permuted blocks of 4 were used for allocation of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Communication with the author: "Randomisation was from computer generated sequentially numbered sealed opaque envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "Eligible patients with documented cancer were randomly assigned to receive dalteparin or placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Quote: "The randomization list was generated by an independent statistician who used a standard method of permuted block of variable size without stratification"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "...randomly assigned by a computer derived protocol"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Quote: "Computer derived treatment schedules were used to assign treatment regimens. To obtain a continuing balance of treatments, the randomized list was divided into consecutive blocks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Quote: "...prescribed randomized arrangement to receive or not 2500 IU (subcutaneous) of a low molecular weight heparin"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Quote: "...prospective, randomized, placebo controlled double blinded study"</P>
<P>Comment: specifics of the randomization process not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Quote: "Children were randomized to receive low dose warfarin or to a control group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to receive drug or placebo"</P>
<P>Comment: permuted blocks of 4 were used for treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Quote: "Randomly assigned patients using computerised block algorithm"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Communication with author: "yes or no code held in sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Comment: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Communication with the author: "Randomisation was from computer generated sequentially numbered sealed opaque envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "...centralized interactive voice processing system"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Open label</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "...randomly assigned by a computer derived protocol"</P>
<P>Comment: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Quote: "...concealment of randomization was achieved through centralized distant randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Inadequate "communication with the authors". Administration of a placebo was not specifically reported. The control group was listed as "no prophylaxis" and referred to as not receiving the intervention (subcutaneous injection)</P>
<P>Therefore, there was obviously no allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-24 09:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Quote: "Randomization was practically organized by the primary investigator by drawing closed envelopes from boxes." "We did not use block randomization, but (...) we used stratified randomization (according to whether patient is also receiving asparaginaze, a hypothesized significant prothrombotic factor)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Quote: "Eligible patients were randomly assigned to receive subcutaneously either enoxaparin or placebo by using preloaded syringes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Personal communication with the author: "Randomisation was executed via a computerised block algorithm and performed by randomisation officers at the central randomisation office in the departmental trials unit, accessed by telephone and fax"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="GROUP" NO="16">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="GROUP" NO="17">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="7">
<NAME>Blinding of participants?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions by the participants adequately prevented during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Communication with the author: "The radiologists who interpreted the venograms were blinded to the patients' randomization status"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Communication with the author: "No there was no placebo 'warfarin tablet'; so it was known who was on the warfarin arm"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "...trial described as double blinded placebo controlled study"</P>
<P>Comment: yes participants in both groups received an injection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Open label</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:59:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "...open-label study, with blinded central outcome adjudication"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Open randomized trial. The participants received either syringes or tablets</P>
<P>Comment: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Quote: "...open prospective study"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Quote: "...prospective, randomized, placebo controlled double blinded study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Quote: "The children in the standard arm did not receive placebo"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Quote: "...as the trial is placebo controlled"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Quote: "Patients were aware of the group to which they were assigned. All preference were those of the clinicians"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="8">
<NAME>Blinding of providers?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions by the providers adequately prevented during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Communication with the author: "The radiologists who interpreted the venograms were blinded to the patients' randomization status"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 17:51:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Communication with the author: "No there was no placebo 'warfarin tablet'; so it was known who was on the warfarin arm"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "...trial described as double blinded placebo controlled study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Open label</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:59:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "...open-label study, with blinded central outcome adjudication"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Quote: "...open prospective study"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Quote: "...prospective, randomized, placebo controlled double blinded study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Quote: "The children in the standard arm did not receive placebo"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Quote: "...as the trial is placebo controlled"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Quote: "...an open-label randomised trial"</P>
<P>Comment: probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="9">
<NAME>Blinding of data collectors?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions by the data collectors adequately prevented during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Communication with the author: "The radiologists who interpreted the venograms were blinded to the patients' randomization status"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 17:51:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Communication with the author: "No there was no placebo 'warfarin tablet'; so it was known who was on the warfarin arm"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "...trial described as double blinded placebo controlled study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Not reported</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "open-label study, with blinded central outcome adjudication"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Quote: "...open prospective study"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Quote: "...prospective, randomized, placebo controlled double blinded study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Quote: "The children in the standard arm did not receive placebo"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Quote: "...as the trial is placebo controlled"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Quote: "...an open-label randomised trial"</P>
<P>Comment: probably not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="10">
<NAME>Blinding of outcome adjudicators?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions by the outcome adjudicators adequately prevented during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Communication with the author: "The radiologists who interpreted the venograms were blinded to the patients' randomization status." "The laboratory personnel were unaware of the status of patients in the study"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Quote: "All bleeding episodes and deaths with their causative pathology were adjudicated by two physicians blinded to the treatment assignments"</P>
<P>Quote: "Venograms were evaluated independently by two radiologists who were unaware of the patients' clinical status and the assigned treatment, immediately after venography had been carried out"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Communication with the author: "No there was no placebo 'warfarin tablet'; so it was known who was on the warfarin arm"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "...trial described as double blinded placebo controlled study" "a central adjudication committee reviewed all tests (venograms, CTs, US, etc) obtained for a suspected CRC and made final judgement, blinded to patient treatment assignment"<BR/>
</P>
<P>Comment: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Not reported</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 14:00:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "An independent and blinded Central Adjudication Committee assessed all efficacy and safety outcomes"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Quote: "All outcome events were reviewed by a central adjudication committee, the members of which were unaware of the patients treatment allocation"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Quote: "...interpretation of venograms was done independently by two expert radiologists who were unaware of patients' status and therapy"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Quote: "All venograms were independently adjudicated by an expert radiologist using prior criteria without knowledge of treatment allocation"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Quote: "The radiologists who performed the ultrasonography were blinded to the treatment assignment"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Quote: "Venographies were evaluated by a central adjudication committee consisting of three radiologists who were unaware of the patients' clinical status"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Quote: "All thromboses were radiologically confirmed by two investigators, unaware of treatment allocation, using central protocol"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="11">
<NAME>Blinding of data analysts?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions by the data analysts adequately prevented during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Communication with the author: "The radiologists who interpreted the venograms were blinded to the patients' randomization status"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Communication with the author: "Those conducting the analysis were blinded, to the point of analysis for thrombotic and bleeding complications"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "...trial described as double blinded placebo controlled study"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Not reported</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 14:00:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "...open-label study, with blinded central outcome adjudication"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Communication with the authors: "The statistical analysts were blinded too"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 18:44:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 10:44:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-01 11:34:52 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Probably not </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Quote: "...an open-label randomised trial"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="12">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Quote: "121 entered the study and 82 patients completed the study"</P>
<P>Quote: "39 withdrawal from study after randomization. No patient withdrew because of catheter failure or because of symptoms or signs suggestive of thrombosis. None of the 26 patients who died from progressive disease before completing the study had complications from their catheters or warfarin therapy. None had clinical evidence of catheter-related thrombosis. An analysis for bias introduced by withdrawal or death of patients was conducted. Deaths while participating in the study were equally distributed between the two groups. On average, there were no laboratory differences between those who completed the study and those who did not, except for one laboratory value"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>77% follow-up rate for asymptomatic and symptomatic DVT. Drop-outs excluded from denominator (primary efficacy populations)</P>
<P>Overall drop-out rate: 22.7%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>100% follow-up rate. Not mentioned but assumed in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>97% follow-up rate; 439 participants randomized; 425 participants followed-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Several participants were described as discontinued treatment but it was not reported whether they were followed up for outcome assessments:</P>
<UL>
<LI>45/142 participants in LMWH arm (intervention 1); 36/138 participants in warfarin arm (intervention 2), 34/140 participants in control arm (115 total discontinued = 28%) for several reasons including toxicity concomitant event, non-compliance, protocol deviation, and thrombosis event</LI>
</UL>
<P>Quote: "Seven patients withdrew their consent or had no data, 6 were lost to follow-up, so 407 patients were evaluable for the main objective, well balanced"</P>
<P>Comment: 97% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 14:00:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>100% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>98% follow-up: 60 participants randomized; 59 participants followed up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>91% follow-up rate; 32 participants randomized; 29 participants followed up (29 participants completed the study, which was stopped prematurely). Participants who did not complete the study were excluded from analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>68% follow-up rate; 113 participants randomized, 87 followed up. Unclear how participants lost to follow-up were considered in the analyses.</P>
<P>Quote: "approximately one quarter of the randomized patients were not analyzed by venography for various reasons. Although this is a considerable proportion, the number of missed venographies was similar in both groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>84% follow-up rate; 73 randomized, 62 followed up. Excluded from most analyses. Follow-up of excluded cases unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>81% follow-up rate; 385 participants randomized and 310 participants followed up. Participants with no follow-up not included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>98% follow-up rate</P>
<P>Quote: "...small number of unknown-outcome patients combined with those who did not have an event"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="13">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Study not registered. No published protocol. No complete list of outcomes provided in the methods section. Deaths mentioned to be equal between the 2 groups but not reported numerically</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Study not registered. No published protocol</P>
<P>PE outcome listed in the methods section not reported on in the results section</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section were reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Study registered in Clinicaltrials.gov (<A HREF="http://clinicaltrials.gov/show/NCT00199602">clinicaltrials.gov/show/NCT00199602</A>)</P>
<P>Some outcomes of interest were poorly reported (e.g. survival)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section were reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section were reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section were reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-07 19:58:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section were reported on.</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section were reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Study not registered. No published protocol. All outcomes listed in the methods section were reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Study registered as ISRCTN50312145 (<A HREF="http://www.controlled-trials.com/ISRCTN50312145">www.controlled-trials.com/ISRCTN50312145</A>). All outcomes listed in the registry were reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="14">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 19:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Quote: "Day 90 Doppler US and venographies were not always performed to detect asymptomatic thrombosis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 14:09:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Study stopped early for insufficient accrual but not for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Quote: "Patient recruitment was terminated earlier than planned, after inclusion of 32 patients, because of an excess of thrombotic events in patients without prophylaxis"</P>
<P>Study stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-29 20:08:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Study stopped early for harm but not for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-10 00:13:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Study not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="STUDY" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="15">
<NAME>Intention-to-treat analysis?</NAME>
<DESCRIPTION>
<P>Was analysis conducted according to the intention to treat anlaysis?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Bern-1990">
<DESCRIPTION>
<P>Only participants who received the intervention and completed follow-up were included in the analysis</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-De-Cicco-2009">
<DESCRIPTION>
<P>Quote: "Data analysis was carried out on an intent-to-treat basis. The intent-to-treat population was defined as all randomized patients who underwent CVC insertion and the first venography"</P>
<P>Quote: "Patients who developed any medical condition requiring therapeutic anticoagulation after enrollment stopped the study medication and were analyzed according to their initial anticoagulant treatment assignment"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Heaton-2002">
<DESCRIPTION>
<P>Quote: "All patients randomized were included in the analysis"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Karthaus-2006">
<DESCRIPTION>
<P>Quote: "Intention-to-treat and as treated study populations were evaluated"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lavau_x002d_Denes-2013">
<DESCRIPTION>
<P>Quote: "The intention to treat population was evaluated and was defined as all randomized patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 14:09:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-2003">
<DESCRIPTION>
<P>Quote: "The analysis included all patients randomized who had evaluable outcome assessments and was based on the intention-to-treat principle"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Mismetti-2003">
<DESCRIPTION>
<P>Quote: "Efficacy and safety analyses were by ITT [intention to treat]"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Monreal-1996">
<DESCRIPTION>
<P>Only participants who completed the study were included in the analysis</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-30 16:37:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niers-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Ruud-2006">
<DESCRIPTION>
<P>Yes only for primary outcome.</P>
<P>Quote: "Only children who completed the study satisfactorily (n=62) from the basis of our descriptive statistics and analyses, but ITT [intention-to-treat] analyses have also been performed for the primary outcome"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Verso-2005">
<DESCRIPTION>
<P>Quote: "The intent-to-treat population was defined as all randomized patients who received at least one dose of study medication and underwent venography of the CVC limb or had a confirmed symptomatic PE"</P>
<P>Comment: the definition excludes those who did not undergo venography of the CVC limb or have a confirmed symptomatic PE</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Young-2009">
<DESCRIPTION>
<P>Quote: "Analysis was by Intention-to-treat basis, with small number of unknown-outcome patients combined with those who did not have an event"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Heparin compared with no heparin for thrombosis prophylaxis in people with cancer with central venous catheters</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Heparin compared with no heparin for thrombosis prophylaxis in people with cancer with central venous catheters</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with cancer with thrombosis prophylaxis and central venous catheters<BR/>
<B>Settings:</B> outpatient or inpatient<BR/>
<B>Intervention:</B> heparin<BR/>
<B>Comparison: </B>no heparin</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>N</B>
<B>o heparin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Heparin</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>63 per 1000</B>
</P>
<P>(41 to 97)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.53 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1236<BR/>(5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Moderate due to some risk of bias and serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Symptomatic deep venous thrombosis</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
</P>
<P>(16 to 51)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.48 </B>
<BR/>(0.27 to 0.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1317<BR/>(6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Moderate due to some risk of bias and serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Major bleeding</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1 per 1000</B>
<BR/>(0 to 18)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.49 </B>
<BR/>(0.03 to 7.84)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1012<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Low due to some risk of bias and very serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Infection</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>93 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>93 per 1000</B>
<BR/>(50 to 172)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1 </B>
<BR/>(0.54 to 1.85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>468<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Moderate due to some risk of bias and serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Thrombocytopenia</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>176 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>181 per 1000</B>
<BR/>(140 to 233)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
<BR/>(0.8 to 1.33)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1002<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Moderate due to some risk of bias and serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Refer to Figures 2-8 for the risk of bias by outcome (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>; <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). Although the newly included trial has a higher risk of bias profile compared with the previously included trials, its inclusion in the meta-analyses did not introduce any heterogeneity (<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>). For this reason, we did not consider the overall risk of bias to be serious enough to rate down the quality of evidence to low. However, the risk of bias contributed to the decision (along imprecision) to rate down the quality of evidence by one level to moderate.<BR/>
<SUP>2</SUP> Relatively small number of events. Imprecision was the main reason for rating down the quality of evidence to moderate.<BR/>
<SUP>3</SUP> CI includes both values suggesting no effect and values suggesting either benefit or harm. Imprecision was the main reason for rating down the quality of evidence to moderate.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Vitamin K antagonists (VKA) compared with no VKA for thrombosis prophylaxis in people with cancer with central venous catheters</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>Vitamin K antagonists (<B>VKA) compared with no VKA for thrombosis prophylaxis in people with cancer with central venous catheters</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with cancer with thrombosis prophylaxis and central venous catheters<BR/>
<B>Settings:</B> outpatient or inpatient<BR/>
<B>Intervention:</B> VKA<BR/>
<B>Comparison: </B>no VKA</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>N</B>
<B>o VKA</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>VKA</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>258 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>269 per 1000</B>
<BR/>(230 to 315)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.89 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1451<BR/>(5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Low due to serious risk of bias and serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Symptomatic deep venous thrombosis</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>51 per 1000</B>
<BR/>(21 to 122)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.51 </B>
<BR/>(0.21 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1451<BR/>(5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Low due to serious risk of bias, serious imprecision, and some heterogeneity</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Major bleeding</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
<BR/>(2 to 122)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 7.6 </B>
<BR/>(0.94 to 61.49)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>979<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very</B> <B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Very low due to serious risk of bias and very serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Refer to Figure 9-13 for the risk of bias by outcome (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>; <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>; <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>; <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>; <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>). We considered the overall risk of bias to be serious enough to rate down the quality of evidence by one or two levels.<BR/>
<SUP>2</SUP> Relatively small number of events. We considered the imprecision to be serious enough to rate down the quality of evidence by one level.<BR/>
<SUP>3</SUP> CI includes both values suggesting no effect and values suggesting either benefit or harm. As noted above, we considered the imprecision to be serious enough to rate down the quality of evidence by one level.</P>
<P>
<SUP>4</SUP> I<SUP>2</SUP> = 66%</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="3" READONLY="YES">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Low-molecular-weight heparin (LMWH) compared with vitamin K antagonist (VKA) for thrombosis prophylaxis in people with cancer with central venous catheters</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Low-molecular-weight heparin </B>
<B>(LMWH) compared with vitamin K antagonist (VKA) for thrombosis prophylaxis in people with cancer with central venous catheters</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with cancer with thrombosis prophylaxis and central venous catheters<BR/>
<B>Settings:</B> outpatient or inpatient<BR/>
<B>Intervention:</B> LMWH<BR/>
<B>Comparison: </B>VKA</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>VKA</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>99 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>113 per 1000</B>
<BR/>(59 to 219)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.14</B>
</P>
<P>(0.59 to 2.21)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>113 per 1000</B>
<BR/>(59 to 219)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Very low due to serious risk of bias, serious imprecision, and some heterogeneity</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Symptomatic deep venous thrombosis</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
<BR/>(10 to 105)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.15 </B>
<BR/>(0.65 to 7.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>551<BR/>(3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Very low due to serious risk of bias and very serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Major bleeding</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 3.41 </B>
<BR/>(0.15 to 79.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>279<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very</B> <B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Very low due to serious risk of bias and very serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Thrombocytopenia</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>101 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>378 per 1000</B>
<BR/>(229 to 624)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 3.73 </B>
<BR/>(2.26 to 6.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>317<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Low due to serious risk of bias and serious imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Refer to Figure 14-19 for the risk of bias by outcome (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>; <LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>; <LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK>; <LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>; <LINK REF="FIG-18" TYPE="FIGURE">Figure 18</LINK>; <LINK REF="FIG-19" TYPE="FIGURE">Figure 19</LINK>). We considered the overall risk of bias to be serious enough to rate down the quality of evidence by one level.<BR/>
<SUP>2</SUP> Relatively small number of events. We considered the imprecision to be serious enough to rate down the quality of evidence by one level.<BR/>
<SUP>3</SUP> CI includes both values suggesting no effect and values suggesting either benefit or harm. As noted above, we considered the imprecision to be serious enough to rate down the quality of evidence by one level.</P>
<P>
<SUP>4</SUP> I<SUP>2</SUP> = 42%.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<TITLE>Glossary</TITLE>
<TABLE COLS="2" ROWS="26">
<TR>
<TH>
<P>Term</P>
</TH>
<TH>
<P>Definition</P>
</TH>
</TR>
<TR>
<TD>
<P>Adjuvant therapy</P>
</TD>
<TD>
<P>Assisting in the amelioration, or cure of disease</P>
</TD>
</TR>
<TR>
<TD>
<P>Anticoagulation</P>
</TD>
<TD>
<P>The process of hindering the clotting of blood especially by treatment with an anticoagulant</P>
</TD>
</TR>
<TR>
<TD>
<P>Antithrombotic</P>
</TD>
<TD>
<P>Used against or tending to prevent thrombosis (clotting)</P>
</TD>
</TR>
<TR>
<TD>
<P>Bacteraemia</P>
</TD>
<TD>
<P>The presence of bacteria in the blood</P>
</TD>
</TR>
<TR>
<TD>
<P>Central venous line</P>
</TD>
<TD>
<P>Synthetic tube that is inserted into a central (large) vein to provide temporary intravenous access for the administration of fluid, medication, or nutrients</P>
</TD>
</TR>
<TR>
<TD>
<P>Coagulation</P>
</TD>
<TD>
<P>Clotting</P>
</TD>
</TR>
<TR>
<TD>
<P>Deep venous (vein) thrombosis (DVT)</P>
</TD>
<TD>
<P>A condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (as swelling and pain) and that is potentially life threatening if dislodgment of the thrombus results in pulmonary embolism</P>
</TD>
</TR>
<TR>
<TD>
<P>Fibrin</P>
</TD>
<TD>
<P>A white insoluble fibrous protein formed from fibrinogen by the action of thrombin especially in the clotting of blood</P>
</TD>
</TR>
<TR>
<TD>
<P>Fondaparinux</P>
</TD>
<TD>
<P>An anticoagulant medication</P>
</TD>
</TR>
<TR>
<TD>
<P>Haemostatic system</P>
</TD>
<TD>
<P>The system that shortens the clotting time of blood and stops bleeding</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Heparin</P>
</TD>
<TD>
<P>An enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. 2 forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH)</P>
</TD>
</TR>
<TR>
<TD>
<P>Impedance plethysmography</P>
</TD>
<TD>
<P>A technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment</P>
</TD>
</TR>
<TR>
<TD>
<P>Kappa statistics</P>
</TD>
<TD>
<P>A measure of degree of non-random agreement between observers or measurements of a specific categorical variable or both</P>
</TD>
</TR>
<TR>
<TD>
<P>Metastasis</P>
</TD>
<TD>
<P>The spread of cancer cells from the initial or primary site of disease to another part of the body</P>
</TD>
</TR>
<TR>
<TD>
<P>Oncogene</P>
</TD>
<TD>
<P>A gene having the potential to cause a normal cell to become cancerous</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Osteoporosis</P>
</TD>
<TD>
<P>A condition that affects especially older women and is characterized by decrease in bone mass with decreased density and enlargement of bone spaces producing porosity and brittleness</P>
</TD>
</TR>
<TR>
<TD>
<P>Parenteral nutrition</P>
</TD>
<TD>
<P>The practice of feeding a person intravenously, circumventing the gastrointestinal tract</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pulmonary embolism (PE)</P>
</TD>
<TD>
<P>Embolism of a pulmonary artery or 1 of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by laboured breathing, chest pain, fainting, rapid heart rate, cyanosis, shock, and sometimes death</P>
</TD>
</TR>
<TR>
<TD>
<P>Stroma</P>
</TD>
<TD>
<P>The supporting framework of an organ typically consisting of connective tissue</P>
</TD>
</TR>
<TR>
<TD>
<P>Thrombin</P>
</TD>
<TD>
<P>A proteolytic enzyme formed from prothrombin that facilitates the clotting of blood by catalysing conversion of fibrinogen to fibrin</P>
</TD>
</TR>
<TR>
<TD>
<P>Thrombocytopenia</P>
</TD>
<TD>
<P>A persistent decrease in the number of blood platelets that is often associated with haemorrhagic conditions</P>
</TD>
</TR>
<TR>
<TD>
<P>Thrombosis</P>
</TD>
<TD>
<P>The formation or presence of a blood clot within a blood vessel</P>
</TD>
</TR>
<TR>
<TD>
<P>Vitamin K antagonists (VKA)</P>
</TD>
<TD>
<P>Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Warfarin</P>
</TD>
<TD>
<P>An anticoagulant medication that is a vitamin K antagonist that is used for anticoagulation</P>
</TD>
</TR>
<TR>
<TD>
<P>Ximelagatran</P>
</TD>
<TD>
<P>An anticoagulant medication</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Low-molecular-weight heparin definitions of prophylactic and therapeutic dosages</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH>
<P>LMWH</P>
</TH>
<TH>
<P>Generic name</P>
</TH>
<TH>
<P>Prophylactic dose</P>
</TH>
<TH>
<P>Therapeutic dose</P>
</TH>
</TR>
<TR>
<TD>
<P>Lovenox</P>
</TD>
<TD>
<P>Enoxaparin</P>
</TD>
<TD>
<P>40 mg once daily</P>
</TD>
<TD>
<P>1 mg/kg twice daily</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fragmin</P>
</TD>
<TD VALIGN="TOP">
<P>Dalteparin</P>
</TD>
<TD VALIGN="TOP">
<P>2500-5000 U once daily</P>
</TD>
<TD>
<P>200 U/kg once daily or<BR/>100 U/kg twice daily<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Innohep</P>
</TD>
<TD>
<P>Tinzaparin, logiparin</P>
</TD>
<TD>
<P>4500 U once daily</P>
</TD>
<TD>
<P>90 U/kg twice daily</P>
</TD>
</TR>
<TR>
<TD>
<P>Fraxiparine</P>
</TD>
<TD>
<P>Nadroparin</P>
</TD>
<TD>
<P>35-75 anti-Xa IU/kg/day</P>
</TD>
<TD>
<P>175 anti-Xa IU/kg/day</P>
</TD>
</TR>
<TR>
<TD>
<P>Certoparin</P>
</TD>
<TD>
<P>Sandoparin</P>
</TD>
<TD>
<P>3000 anti-Xa IU once daily</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Reviparin</P>
</TD>
<TD>
<P>Reviparin</P>
</TD>
<TD>
<P>1750-4200 anti-Xa IU</P>
</TD>
<TD>
<P>7000-12,600 anti-Xa IU</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>IU: international units; U: units; Xa: factor Xa.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<COMPARISON ID="CMP-001" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<NAME>Heparin versus no heparin</NAME>
<DICH_OUTCOME CHI2="1.735079997309768" CI_END="1.2553964250252765" CI_START="0.5295014404379569" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8153123422171072" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.09878088758217161" LOG_CI_START="-0.2761328541147487" LOG_EFFECT_SIZE="-0.08867598326628856" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="0.7843359020404416" P_Q="1.0" P_Z="0.35384563545544756" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="689" TOTAL_2="547" WEIGHT="100.00000000000001" Z="0.9271558450162285">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2538913064645714" CI_START="0.47653122566127715" EFFECT_SIZE="1.0363636363636364" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.35293296843552535" LOG_CI_START="-0.32190863607903025" LOG_EFFECT_SIZE="0.015512166178247558" MODIFIED="2014-03-11 10:57:47 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.3964052990116675" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.15713716108452952" WEIGHT="30.86448388495187"/>
<DICH_DATA CI_END="17.506055058920246" CI_START="0.22322976586172527" EFFECT_SIZE="1.9768339768339769" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2431882900487365" LOG_CI_START="-0.6512478962595785" LOG_EFFECT_SIZE="0.29597019689457893" MODIFIED="2014-03-11 10:58:35 +0000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="1.1128011934478665" STUDY_ID="STD-Karthaus-2006" TOTAL_1="259" TOTAL_2="128" VAR="1.2383264961389961" WEIGHT="3.916541712660054"/>
<DICH_DATA CI_END="2.294993878374696" CI_START="0.31925958059643245" EFFECT_SIZE="0.8559782608695652" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.36078153144555214" LOG_CI_START="-0.4958560612133865" LOG_EFFECT_SIZE="-0.06753726488391716" MODIFIED="2014-03-11 10:59:19 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.5031931623523329" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="135" VAR="0.25320335863814125" WEIGHT="19.154395905749947"/>
<DICH_DATA CI_END="4.390931793153384" CI_START="0.04432696461014987" EFFECT_SIZE="0.4411764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6425566910130239" LOG_CI_START="-1.3533320069861718" LOG_EFFECT_SIZE="-0.3553876579865739" MODIFIED="2014-03-11 11:00:08 +0000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="1.1723949010131223" STUDY_ID="STD-Monreal-1996" TOTAL_1="17" TOTAL_2="15" VAR="1.3745098039215686" WEIGHT="3.5284996601576024"/>
<DICH_DATA CI_END="1.2599029628782383" CI_START="0.33534328630738525" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.10033709725297246" LOG_CI_START="-0.47451038396726125" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2014-03-11 11:00:55 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.33766825600968964" STUDY_ID="STD-Verso-2005" TOTAL_1="155" TOTAL_2="155" VAR="0.1140198511166253" WEIGHT="42.53607883648055"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.947470912198585" CI_END="0.8609880579292496" CI_START="0.26633099469586197" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4788609462981456" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.06500287225296225" LOG_CI_START="-0.574578288904325" LOG_EFFECT_SIZE="-0.3197905805786437" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="0.4223246818027283" P_Q="1.0" P_Z="0.013893662368868083" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="726" TOTAL_2="591" WEIGHT="99.99999999999999" Z="2.4600010127965795">
<NAME>Symptomatic deep venous thrombosis (DVT)</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.610549170180048" CI_START="0.19574674657786073" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.663752658008758" LOG_CI_START="-0.7083054474310626" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2010-08-19 15:49:44 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.8059537229325092" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.6495614035087719" WEIGHT="13.793419003743695"/>
<DICH_DATA CI_END="2.831403353792801" CI_START="0.34504732138662375" EFFECT_SIZE="0.9884169884169884" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.4520017421480256" LOG_CI_START="-0.4621213396868301" LOG_EFFECT_SIZE="-0.005059798769402255" MODIFIED="2014-03-11 11:02:26 +0000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.5369604232520272" STUDY_ID="STD-Karthaus-2006" TOTAL_1="259" TOTAL_2="128" VAR="0.2883264961389962" WEIGHT="31.074745912137917"/>
<DICH_DATA CI_END="0.7659619042295674" CI_START="0.0888463638738808" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.11579282983777511" LOG_CI_START="-1.0513603414301234" LOG_EFFECT_SIZE="-0.5835765856339492" MODIFIED="2014-03-11 11:02:44 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.5495569874432178" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="135" VAR="0.30201288244766505" WEIGHT="29.666524602005733"/>
<DICH_DATA CI_END="1.345908809888182" CI_START="0.02313817123665161" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.12901563588797973" LOG_CI_START="-1.6356709692052027" LOG_EFFECT_SIZE="-0.7533276666586115" MODIFIED="2014-03-11 11:03:20 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="1.0365856471713124" STUDY_ID="STD-Monreal-1996" TOTAL_1="17" TOTAL_2="15" VAR="1.0745098039215686" WEIGHT="8.338381441059715"/>
<DICH_DATA CI_END="9.410345981208485" CI_START="0.01655807074749288" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9736055910114718" LOG_CI_START="-1.7809902661337298" LOG_EFFECT_SIZE="-0.40369233756112893" MODIFIED="2014-03-11 11:03:36 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="1.6180632419564942" STUDY_ID="STD-Niers-2007" TOTAL_1="37" TOTAL_2="44" VAR="2.6181286549707603" WEIGHT="3.422166664822048"/>
<DICH_DATA CI_END="1.6260099352108868" CI_START="0.06833359914046311" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21112319488294637" LOG_CI_START="-1.1653657043222712" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-03-11 11:04:10 +0000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.8085563931230864" STUDY_ID="STD-Verso-2005" TOTAL_1="155" TOTAL_2="155" VAR="0.653763440860215" WEIGHT="13.704762376230887"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.837413238845138" CI_START="0.031163603130848434" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4942084942084942" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.894172746170593" LOG_CI_START="-1.5063523350373598" LOG_EFFECT_SIZE="-0.30608979443338347" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6171961081751958" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="571" TOTAL_2="441" WEIGHT="100.0" Z="0.4998281232894396">
<NAME>Major bleeding</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-11 11:05:56 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.837413238845138" CI_START="0.031163603130848434" EFFECT_SIZE="0.4942084942084942" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.894172746170593" LOG_CI_START="-1.5063523350373598" LOG_EFFECT_SIZE="-0.30608979443338347" MODIFIED="2014-03-11 11:07:10 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="1.4100803154923467" STUDY_ID="STD-Karthaus-2006" TOTAL_1="259" TOTAL_2="128" VAR="1.9883264961389961" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-11 11:07:37 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Niers-2007" TOTAL_1="37" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-11 11:08:31 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.0" STUDY_ID="STD-Verso-2005" TOTAL_1="155" TOTAL_2="155" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06887040095878409" CI_END="1.8472236855824677" CI_START="0.5434298653171552" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.001916422994822" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2665194885816069" LOG_CI_START="-0.2648564977068137" LOG_EFFECT_SIZE="8.314954373965445E-4" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="0.7929886350542468" P_Q="1.0" P_Z="0.9951058940010535" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="172" WEIGHT="100.0" Z="0.006133890701346473">
<NAME>Infection</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.394693815858155" CI_START="0.34280984680216225" EFFECT_SIZE="0.9060489060489061" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.37924999266336645" LOG_CI_START="-0.46494671198097054" LOG_EFFECT_SIZE="-0.042848359658802036" MODIFIED="2014-03-11 11:12:36 +0000" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.49588532314916695" STUDY_ID="STD-Karthaus-2006" TOTAL_1="259" TOTAL_2="128" VAR="0.24590225371475372" WEIGHT="39.62018901370732"/>
<DICH_DATA CI_END="2.3518774137856377" CI_START="0.48704853608020654" EFFECT_SIZE="1.0702702702702702" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.37141468139053857" LOG_CI_START="-0.31242775767350406" LOG_EFFECT_SIZE="0.029493461858517287" MODIFIED="2014-03-11 11:13:24 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.4016924337808858" STUDY_ID="STD-Niers-2007" TOTAL_1="37" TOTAL_2="44" VAR="0.16135681135681135" WEIGHT="60.37981098629269"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8186242774347913" CI_END="1.327842212220537" CI_START="0.8012591129530282" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0314774224894185" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.12314647079007662" LOG_CI_START="-0.09622701808753135" LOG_EFFECT_SIZE="0.013459726351272683" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="5" P_CHI2="0.8450074225481594" P_Q="1.0" P_Z="0.8099361842133688" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="569" TOTAL_2="433" WEIGHT="100.0" Z="0.24050835882887625">
<NAME>Thrombocytopenia</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0358324220349737" CI_START="0.42804675446075574" EFFECT_SIZE="0.9335049335049335" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.3087420265228954" LOG_CI_START="-0.36850879151176436" LOG_EFFECT_SIZE="-0.029883382494434424" MODIFIED="2014-03-11 11:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.39782048295917594" STUDY_ID="STD-Karthaus-2006" TOTAL_1="259" TOTAL_2="128" VAR="0.15826113666187197" WEIGHT="10.492263961885653"/>
<DICH_DATA CI_END="1.4483058894196899" CI_START="0.8188443402128671" EFFECT_SIZE="1.0890073831009024" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="53" LOG_CI_END="0.16086029670724578" LOG_CI_START="-0.08679864843699625" LOG_EFFECT_SIZE="0.037030824135124756" MODIFIED="2014-03-11 11:15:18 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.14547609030927783" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="135" VAR="0.021163292851673156" WEIGHT="78.46215768039802"/>
<DICH_DATA CI_END="5.5162686574153295" CI_START="0.14113647488075015" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7416454093514776" LOG_CI_START="-0.8503607339966631" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2014-03-11 11:15:47 +0000" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.9351522891602034" STUDY_ID="STD-Monreal-1996" TOTAL_1="17" TOTAL_2="15" VAR="0.8745098039215686" WEIGHT="1.8987981762104347"/>
<DICH_DATA CI_END="1.728774199588685" CI_START="0.32537505484165125" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.23773827246618637" LOG_CI_START="-0.4876157456827862" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-11 11:15:53 +0000" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.42607654082100416" STUDY_ID="STD-Verso-2005" TOTAL_1="155" TOTAL_2="155" VAR="0.18154121863799283" WEIGHT="9.146780181505884"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.91653736789924" CI_END="1.0348095050790114" CI_START="0.6472769462157255" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8184181916126674" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.014860409206088795" LOG_CI_START="-0.18890986078616998" LOG_EFFECT_SIZE="-0.0870247257900406" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="6" P_CHI2="0.4261509982426168" P_Q="1.0" P_Z="0.09411205903642193" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="726" TOTAL_2="593" WEIGHT="100.00000000000001" Z="1.6740943447680905">
<NAME>Asymptomatic DVT</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0073884785641485" CI_START="0.5583744622548621" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="57" LOG_CI_END="0.00319697955263615" LOG_CI_START="-0.253074452769236" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-08-20 15:05:11 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.1505351079099168" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.022660818713450298" WEIGHT="63.223895244950725"/>
<DICH_DATA CI_END="2.2160976954674734" CI_START="0.3061462952139413" EFFECT_SIZE="0.8236808236808236" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.34558890211559606" LOG_CI_START="-0.5140709917496503" LOG_EFFECT_SIZE="-0.08424104481702713" MODIFIED="2014-03-11 11:23:46 +0000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.5049684770415503" STUDY_ID="STD-Karthaus-2006" TOTAL_1="259" TOTAL_2="128" VAR="0.2549931628056628" WEIGHT="5.618602525417139"/>
<DICH_DATA CI_END="1.9620441198623062" CI_START="0.4098486165078508" EFFECT_SIZE="0.8967391304347826" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.29270876899566595" LOG_CI_START="-0.38737652658692634" LOG_EFFECT_SIZE="-0.04733387879563019" MODIFIED="2014-03-11 11:24:19 +0000" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.39948546910172167" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="135" VAR="0.15958864002342263" WEIGHT="8.97748880054197"/>
<DICH_DATA CI_END="2.2749454911448357" CI_START="0.007088068074020624" EFFECT_SIZE="0.12698412698412698" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3569709952003322" LOG_CI_START="-2.1494721201236087" LOG_EFFECT_SIZE="-0.8962505624616381" MODIFIED="2014-03-11 11:24:43 +0000" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.4722970930348027" STUDY_ID="STD-Monreal-1996" TOTAL_1="17" TOTAL_2="15" VAR="2.1676587301587302" WEIGHT="0.6609459360787334"/>
<DICH_DATA CI_END="6.869146207798808" CI_START="0.689105239942718" EFFECT_SIZE="2.175675675675676" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8369027603077874" LOG_CI_START="-0.1617144477060403" LOG_EFFECT_SIZE="0.3375941563008736" MODIFIED="2014-03-11 11:24:56 +0000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.5865926912222256" STUDY_ID="STD-Niers-2007" TOTAL_1="37" TOTAL_2="46" VAR="0.3440909853953332" WEIGHT="4.1637395029629625"/>
<DICH_DATA CI_END="1.5965126921150772" CI_START="0.5176571943796141" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.20317237548657002" LOG_CI_START="-0.28595774580302014" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2014-03-11 11:26:55 +0000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.28731745447865475" STUDY_ID="STD-Verso-2005" TOTAL_1="155" TOTAL_2="155" VAR="0.08255131964809384" WEIGHT="17.355327990048462"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9889234972660068" CI_END="2.9160528033665116" CI_START="0.6233227481162088" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3481995575753571" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.46479538384452224" LOG_CI_START="-0.20528702327474718" LOG_EFFECT_SIZE="0.12975418028488753" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="7" P_CHI2="0.32000585793791403" P_Q="1.0" P_Z="0.4478217705023779" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="269" WEIGHT="100.0" Z="0.7590514763555967">
<NAME>Minor bleeding</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1138528950835997" CI_START="0.16303154551762172" EFFECT_SIZE="0.7125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4932980917380411" LOG_CI_START="-0.7877283543769454" LOG_EFFECT_SIZE="-0.14721513131945219" MODIFIED="2014-03-06 16:19:13 +0000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.7524812756311207" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.5662280701754385" WEIGHT="27.361521288760166"/>
<DICH_DATA CI_END="4.238321454326634" CI_START="0.6933819300572568" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6271938925696611" LOG_CI_START="-0.15902748050292517" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2014-03-11 11:11:41 +0000" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.461830326401401" STUDY_ID="STD-Verso-2005" TOTAL_1="155" TOTAL_2="155" VAR="0.21328725038402457" WEIGHT="72.63847871123983"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<NAME>Vitamin K antagonist (VKA) versus no VKA</NAME>
<DICH_OUTCOME CHI2="0.7912974551839838" CI_END="1.2181123753471275" CI_START="0.8859284276315849" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0388264442965705" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="191" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.08568735540844624" LOG_CI_START="-0.05260136246984722" LOG_EFFECT_SIZE="0.016542996469299524" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="0.8515474631564368" P_Q="1.0" P_Z="0.6391216062108358" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="712" TOTAL_2="739" WEIGHT="100.0" Z="0.46892729607538997">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>VKA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours VKA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.603982206697526" CI_START="0.41264720250919307" EFFECT_SIZE="0.8135593220338984" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2051995462574086" LOG_CI_START="-0.38442109479052244" LOG_EFFECT_SIZE="-0.08961077426655695" MODIFIED="2014-03-11 16:24:52 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.34634608322079957" STUDY_ID="STD-Bern-1990" TOTAL_1="59" TOTAL_2="56" VAR="0.11995560936238903" WEIGHT="5.500828981003107"/>
<DICH_DATA CI_END="2.6830742819612823" CI_START="0.603723393584068" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4286326964510359" LOG_CI_START="-0.21916199541100986" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2014-04-24 15:04:25 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.38051780863520634" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="114" TOTAL_2="114" VAR="0.14479380268853953" WEIGHT="4.557206732348254"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-11 16:25:52 +0000" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.0" STUDY_ID="STD-Heaton-2002" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.60602310944451" CI_START="0.3894750822226889" EFFECT_SIZE="1.007462686567164" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.41597826258904896" LOG_CI_START="-0.4095203223286521" LOG_EFFECT_SIZE="0.0032289701301984487" MODIFIED="2014-03-11 16:26:12 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.4849019550645557" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="134" TOTAL_2="135" VAR="0.2351299060254284" WEIGHT="2.8063435382105597"/>
<DICH_DATA CI_END="1.2391776718708165" CI_START="0.8810243987317872" EFFECT_SIZE="1.0448663853727145" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="158" LOG_CI_END="0.09313357948431804" LOG_CI_START="-0.055012064246459075" LOG_EFFECT_SIZE="0.019060757618929464" MODIFIED="2014-03-11 16:26:39 +0000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.087021484460222" STUDY_ID="STD-Young-2009" TOTAL_1="360" TOTAL_2="391" VAR="0.007572738757660657" WEIGHT="87.13562074843809"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.81544834983569" CI_END="1.2174204900544714" CI_START="0.2136586847473591" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5100122162159685" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="74" I2="66.14601594821727" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.085440606964143" LOG_CI_START="-0.6702794493892729" LOG_EFFECT_SIZE="-0.2924194212125649" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="0.018777743829745397" P_Q="1.0" P_Z="0.12932156951945917" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5718668552271051" TOTALS="YES" TOTAL_1="712" TOTAL_2="739" WEIGHT="99.99999999999997" Z="1.5167826475909953">
<NAME>Symptomatic deep venous thrombosis (DVT)</NAME>
<GROUP_LABEL_1>VKA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours VKA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8423810889069641" CI_START="0.1012503889476829" EFFECT_SIZE="0.2920469361147327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.0744913914374091" LOG_CI_START="-0.9946032997922273" LOG_EFFECT_SIZE="-0.5345473456148182" MODIFIED="2014-03-11 16:19:07 +0000" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.5404782895950226" STUDY_ID="STD-Bern-1990" TOTAL_1="59" TOTAL_2="56" VAR="0.2921167815235612" WEIGHT="22.80822997339299"/>
<DICH_DATA CI_END="3.156994889205249" CI_START="0.03519521412309999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4992738788222918" LOG_CI_START="-1.4535163882616169" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-07-30 21:38:35 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="1.1470786693528088" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="114" TOTAL_2="114" VAR="1.3157894736842104" WEIGHT="10.439367155155201"/>
<DICH_DATA CI_END="4.309280764500631" CI_START="0.5424341931544524" EFFECT_SIZE="1.528888888888889" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6344047907931778" LOG_CI_START="-0.26565294187284244" LOG_EFFECT_SIZE="0.18437592446016765" MODIFIED="2014-03-11 16:16:40 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.528698367525652" STUDY_ID="STD-Heaton-2002" TOTAL_1="45" TOTAL_2="43" VAR="0.27952196382428945" WEIGHT="23.145638090730053"/>
<DICH_DATA CI_END="0.5013091344559742" CI_START="0.00899849343394422" EFFECT_SIZE="0.06716417910447761" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.29989438194652646" LOG_CI_START="-2.0458301959044394" LOG_EFFECT_SIZE="-1.1728622889254827" MODIFIED="2014-03-11 12:34:03 +0000" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="1.0255713396405417" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="134" TOTAL_2="135" VAR="1.0517965726920953" WEIGHT="12.136713275307123"/>
<DICH_DATA CI_END="1.3539018124416224" CI_START="0.5430460509536579" EFFECT_SIZE="0.8574561403508771" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.13158716962164485" LOG_CI_START="-0.2651633401587813" LOG_EFFECT_SIZE="-0.0667880852685682" MODIFIED="2014-03-11 16:17:25 +0000" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.23305321339171986" STUDY_ID="STD-Young-2009" TOTAL_1="360" TOTAL_2="391" VAR="0.05431380027220652" WEIGHT="31.470051505414627"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="61.4919798858672" CI_START="0.9399962409009438" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.602777777777779" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.7888184764511246" LOG_CI_START="-0.026873883165451737" LOG_EFFECT_SIZE="0.8809722966428364" METHOD="MH" MODIFIED="2014-09-20 19:58:12 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.057178277586235365" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="474" TOTAL_2="505" WEIGHT="100.0" Z="1.901945518085588">
<NAME>Major bleeding</NAME>
<GROUP_LABEL_1>VKA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours VKA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-11 16:19:58 +0000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="114" TOTAL_2="114" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="61.4919798858672" CI_START="0.9399962409009438" EFFECT_SIZE="7.602777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7888184764511246" LOG_CI_START="-0.026873883165451737" LOG_EFFECT_SIZE="0.8809722966428364" MODIFIED="2014-03-11 16:20:25 +0000" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.0665466798609107" STUDY_ID="STD-Young-2009" TOTAL_1="360" TOTAL_2="391" VAR="1.1375218203223318" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4340643404614257" CI_END="0.622578836855654" CI_START="0.3019338528180946" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4335638671462782" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.20580564625071132" LOG_CI_START="-0.5200881911575402" LOG_EFFECT_SIZE="-0.36294691870412576" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="0.48819907214932434" P_Q="1.0" P_Z="5.985513333937519E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="305" WEIGHT="100.0" Z="4.526900398943642">
<NAME>Asymptomatic DVT</NAME>
<GROUP_LABEL_1>VKA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours VKA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8725512288160107" CI_START="0.009322019998438385" EFFECT_SIZE="0.19" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5879971716203847" LOG_CI_START="-2.030489969714727" LOG_EFFECT_SIZE="-0.721246399047171" MODIFIED="2014-03-11 16:24:17 +0000" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="1.5381123085406379" STUDY_ID="STD-Bern-1990" TOTAL_1="59" TOTAL_2="56" VAR="2.3657894736842104" WEIGHT="1.440587464246396"/>
<DICH_DATA CI_END="0.598029851086084" CI_START="0.2675451730535248" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="57" LOG_CI_END="-0.223277137352054" LOG_CI_START="-0.5726028799920212" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-03-11 16:23:00 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.20519567041703082" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.042105263157894736" WEIGHT="80.94300814734439"/>
<DICH_DATA CI_END="1.590501494926118" CI_START="0.28362293082836076" EFFECT_SIZE="0.6716417910447762" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.20153408164071557" LOG_CI_START="-0.5472586594916811" LOG_EFFECT_SIZE="-0.17286228892548272" MODIFIED="2014-03-11 16:23:23 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.4398445627250174" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="134" TOTAL_2="135" VAR="0.19346323935876172" WEIGHT="17.61640438840922"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.252664216489249" CI_END="71.50827387732751" CI_START="0.13760217878189426" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.136828698933475" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="84.0068174880902" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.8543562948273409" LOG_CI_START="-0.861374689461971" LOG_EFFECT_SIZE="0.49649080268268486" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="5" P_CHI2="0.012400757042606014" P_Q="1.0" P_Z="0.4735947320223185" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="4.285865991196179" TOTALS="YES" TOTAL_1="474" TOTAL_2="505" WEIGHT="100.0" Z="0.7166424786128803">
<NAME>Minor bleeding</NAME>
<GROUP_LABEL_1>VKA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours VKA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.275867819450336" CI_START="0.1717102248937452" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5153263697546007" LOG_CI_START="-0.7652038429712007" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-06 16:20:25 +0000" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.7521897856819184" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="114" TOTAL_2="114" VAR="0.5657894736842104" WEIGHT="52.45160068110884"/>
<DICH_DATA CI_END="115.04907642266593" CI_START="2.0096547225088006" EFFECT_SIZE="15.205555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="2.0608831366409093" LOG_CI_START="0.3031214479727259" LOG_EFFECT_SIZE="1.1820022923068176" MODIFIED="2014-03-11 16:22:21 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="1.0325179169843788" STUDY_ID="STD-Young-2009" TOTAL_1="360" TOTAL_2="391" VAR="1.0660932488937604" WEIGHT="47.54839931889116"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="3">
<NAME>Low-molecular-weight heparin (LMWH) versus vitamin K antagonist (VKA)</NAME>
<DICH_OUTCOME CHI2="3.4765020411487506" CI_END="2.2061663385752226" CI_START="0.5925620646477818" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.14336804247039" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" I2="42.47090965782565" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.3436382538892749" LOG_CI_START="-0.22726615515345" LOG_EFFECT_SIZE="0.05818604936791251" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="0.1758279727017238" P_Q="1.0" P_Z="0.6895134552479216" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1438355376914747" TOTALS="YES" TOTAL_1="279" TOTAL_2="272" WEIGHT="100.0" Z="0.39951543325791133">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6849636309427372" CI_START="0.3935166387649644" EFFECT_SIZE="0.8142857142857143" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.22659053128964696" LOG_CI_START="-0.4050368999731778" LOG_EFFECT_SIZE="-0.08922318434176543" MODIFIED="2014-03-11 16:29:01 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.37102107972999326" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.13765664160401003" WEIGHT="39.95173687878204"/>
<DICH_DATA CI_END="2.277748680118293" CI_START="0.3169288146436182" EFFECT_SIZE="0.8496376811594203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3575058036504292" LOG_CI_START="-0.4990382736786606" LOG_EFFECT_SIZE="-0.07076623501411564" MODIFIED="2014-03-11 16:29:44 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.5031382309846714" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="134" VAR="0.25314807947838447" WEIGHT="28.328880574021838"/>
<DICH_DATA CI_END="5.620232906664408" CI_START="0.9295859945098052" EFFECT_SIZE="2.2857142857142856" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7497543134308501" LOG_CI_START="-0.03171042814751428" LOG_EFFECT_SIZE="0.3590219426416679" MODIFIED="2014-03-11 16:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.4590362575159894" STUDY_ID="STD-Mismetti-2003" TOTAL_1="21" TOTAL_2="24" VAR="0.21071428571428577" WEIGHT="31.719382547196126"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7947271039601345" CI_END="7.136188475353604" CI_START="0.647273281275803" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1492008119867942" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.853466311761159" LOG_CI_START="-0.188912319807305" LOG_EFFECT_SIZE="0.33227699597692695" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="0.6720898611290481" P_Q="1.0" P_Z="0.21146481866923394" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="279" TOTAL_2="272" WEIGHT="100.0" Z="1.2495477656252452">
<NAME>Symptomatic deep venous thrombosis (DVT)</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.002421519922272" CI_START="0.3008063552377054" EFFECT_SIZE="2.85" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4314027125139377" LOG_CI_START="-0.5217129924969173" LOG_EFFECT_SIZE="0.4548448600085102" MODIFIED="2010-08-19 16:40:54 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="1.1472698332020408" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="1.3162280701754385" WEIGHT="28.483611617202918"/>
<DICH_DATA CI_END="34.30379017048542" CI_START="0.43977374649349843" EFFECT_SIZE="3.8840579710144927" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5353421071911446" LOG_CI_START="-0.3567707006080775" LOG_EFFECT_SIZE="0.5892857032915335" MODIFIED="2014-03-11 16:31:28 +0000" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="1.1114364294107162" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="134" VAR="1.2352909366212417" WEIGHT="30.349877942990982"/>
<DICH_DATA CI_END="7.418311812845265" CI_START="0.17606734280405414" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8703050840144342" LOG_CI_START="-0.7543211900590607" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-11 16:31:32 +0000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.9543135154205277" STUDY_ID="STD-Mismetti-2003" TOTAL_1="21" TOTAL_2="24" VAR="0.9107142857142857" WEIGHT="41.1665104398061"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="79.46792003171949" CI_START="0.14624644538082063" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4090909090909087" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.9001918460788256" LOG_CI_START="-0.8349146809398379" LOG_EFFECT_SIZE="0.5326385825694938" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4452413320451426" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="138" WEIGHT="100.0" Z="0.7633724158821754">
<NAME>Major bleeding</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-11 16:33:00 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="79.46792003171949" CI_START="0.14624644538082063" EFFECT_SIZE="3.409090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9001918460788256" LOG_CI_START="-0.8349146809398379" LOG_EFFECT_SIZE="0.5326385825694938" MODIFIED="2014-03-11 16:33:12 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="1.6066151129664257" STUDY_ID="STD-Mismetti-2003" TOTAL_1="21" TOTAL_2="24" VAR="2.581212121212121" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17813918155209743" CI_END="6.162815879095266" CI_START="2.256454487926791" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7290901770607543" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.7897791928990343" LOG_CI_START="0.35342657834294194" LOG_EFFECT_SIZE="0.5716028856209882" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="0.6729773049252802" P_Q="1.0" P_Z="2.822421535229757E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="158" WEIGHT="100.0" Z="5.1349346006143355">
<NAME>Thrombocytopenia</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.388923526131645" CI_START="2.2832067480535403" EFFECT_SIZE="3.8193236714975844" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="15" LOG_CI_END="0.8054276897634114" LOG_CI_START="0.3585452393366568" LOG_EFFECT_SIZE="0.5819864645500341" MODIFIED="2014-04-25 15:05:25 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.26250096348448165" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="134" VAR="0.06890675583028116" WEIGHT="95.34294566679385"/>
<DICH_DATA CI_END="23.44357047502594" CI_START="0.2228538439349045" EFFECT_SIZE="2.2857142857142856" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3700237557894768" LOG_CI_START="-0.651979870506141" LOG_EFFECT_SIZE="0.3590219426416679" MODIFIED="2014-03-11 16:35:27 +0000" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="1.1877349391654206" STUDY_ID="STD-Mismetti-2003" TOTAL_1="21" TOTAL_2="24" VAR="1.4107142857142856" WEIGHT="4.657054333206147"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7633344910958991" CI_END="2.520041707506797" CI_START="1.2011128260793924" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7397857388602271" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.4014077285554188" LOG_CI_START="0.07958380460709975" LOG_EFFECT_SIZE="0.24049576658125926" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="5" P_CHI2="0.6827223620336945" P_Q="1.0" P_Z="0.0033970169839217996" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="279" TOTAL_2="272" WEIGHT="100.0" Z="2.929322563410884">
<NAME>Asymptomatic DVT</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7216715235671005" CI_START="1.1657731416249564" EFFECT_SIZE="1.78125" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="24" LOG_CI_END="0.4348357093646016" LOG_CI_START="0.06661404534056932" LOG_EFFECT_SIZE="0.2507248773525854" MODIFIED="2010-08-20 15:04:13 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.21629522817435004" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.04678362573099415" WEIGHT="76.38674057596559"/>
<DICH_DATA CI_END="3.2161599368740346" CI_START="0.5542672045278787" EFFECT_SIZE="1.335144927536232" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5073376377053725" LOG_CI_START="-0.2562808174456674" LOG_EFFECT_SIZE="0.12552841012985258" MODIFIED="2014-03-11 16:39:16 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.44855326052803646" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="134" VAR="0.20120002753033253" WEIGHT="17.76167093902491"/>
<DICH_DATA CI_END="13.216934334214915" CI_START="0.6176368210432928" EFFECT_SIZE="2.857142857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1211307322955297" LOG_CI_START="-0.20926682099608088" LOG_EFFECT_SIZE="0.4559319556497244" MODIFIED="2010-08-19 17:15:14 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.7814821083775915" STUDY_ID="STD-Mismetti-2003" TOTAL_1="21" TOTAL_2="24" VAR="0.6107142857142857" WEIGHT="5.851588485009505"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.142190680208706E-32" CI_END="4.610549170180048" CI_START="0.19574674657786073" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.663752658008758" LOG_CI_START="-0.7083054474310626" LOG_EFFECT_SIZE="-0.022276394711152253" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.9492545102527656" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="114" WEIGHT="100.0" Z="0.06364297716861082">
<NAME>Minor bleeding</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.610549170180048" CI_START="0.19574674657786073" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.663752658008758" LOG_CI_START="-0.7083054474310626" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2014-03-06 16:21:57 +0000" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.8059537229325092" STUDY_ID="STD-De-Cicco-2009" TOTAL_1="120" TOTAL_2="114" VAR="0.6495614035087719" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9184906637532975" CI_START="0.7369002518479962" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6992753623188406" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.5931188163495055" LOG_CI_START="-0.1325912950497744" LOG_EFFECT_SIZE="0.23026376064986556" METHOD="MH" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.21358379687966422" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="158" WEIGHT="100.0" Z="1.2437712269112409">
<NAME>Pulmonary embolism</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9184906637532975" CI_START="0.7369002518479962" EFFECT_SIZE="1.6992753623188406" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.5931188163495055" LOG_CI_START="-0.1325912950497744" LOG_EFFECT_SIZE="0.23026376064986556" MODIFIED="2014-03-11 16:40:36 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.4262857117589247" STUDY_ID="STD-Lavau_x002d_Denes-2013" TOTAL_1="138" TOTAL_2="134" VAR="0.18171950804981304" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-11 16:40:52 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.0" STUDY_ID="STD-Mismetti-2003" TOTAL_1="21" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAVTCAYAAADnea74AAB/MElEQVR42uy9f2RX/////2KSSSZm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</FILE>
</FIGURE>
<FIGURE FILENAME="H, death.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - heparin versus no heparin: review authors' judgements about each methodological quality item for each included study that evaluated mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAGvCAIAAABZ2XIlAAAbjElEQVR42u3dv24kxRbHcUtIiMDB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</FILE>
</FIGURE>
<FIGURE FILENAME="H, Symp DVT.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - heparin versus no heparin: review authors' judgements about each methodological quality item for each included study that evaluated symptomatic deep venous thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAHNCAIAAAAc5dx0AAAedUlEQVR42u3dvW4jRxaGYQIGDAcK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</FILE>
</FIGURE>
<FIGURE FILENAME="H, maj bleed.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - heparin versus no heparin: review authors' judgements about each methodological quality item for each included study that evaluated major bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbQAAAGRCAIAAACCN9GUAAAZQklEQVR42u3dv44Ty7rGYUtIiGAC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</FILE>
</FIGURE>
<FIGURE FILENAME="H, infection.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - heparin versus no heparin: review authors' judgements about each methodological quality item for each included study that evaluated infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbQAAAFVCAIAAAAITo02AAATZ0lEQVR42u3dsW5cRRfA8ZWQEIWL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</FILE>
</FIGURE>
<FIGURE FILENAME="H, thrombocy.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - heparin versus no heparin: review authors' judgements about each methodological quality item for each included study that evaluated thrombocytopenia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAGRCAIAAABnqRT4AAAYYUlEQVR42u3dv24kSxXHcUtIiMDB
BvsE9xkmQiMiiHgnNnRgiRv6LRCPgDCExhEZ4mKjvRs48IWMvaya2bW0jDzdMz0zfarrdH1+Gl1Z
fb2/aVed/tap6vpzcUFERKHqiIgoQCBLRASyREQgS0REIEtEBLJERCBLREQgS0QEskREIEtERCC7
iCqxGI8IZCmiMsZcJCKQpaNr4uT/S0QgS0QEslRTSqtqiECWAglroIAIZAlkiQhkQZaIQJa2qwRh
iUCWiIhAlogIZOl1lVhZSwSyFFEf2z+oGiKQpUDI4iwRyBLIEhHI5uSsqiECWSIiAlkiIpA1SnDR
J4VDBLJERASyREQgq0qMFRCBLEXVx8ErRASyBLJEBLLVc1bVEIEsTVoTpnARgSwREYEsERHIEhGB
LBERgSwREcjSyCoxu4AIZCmiPhQCEcgSyBIRyOIsEYEs9dSHMVkikCUiIpAlIgJZGh4xUCBEIEtT
1sfBK0QEsgSyRASyjUHWQAQRyFIICnutVD0RyFJIdhyUKRMRyBIRgWzD+Wboiq+vViqdCGQpatBg
9wciAtnmULjnCsjS9AgQDCDbTqwHDReALO1v1MUDyDaayU5e2Z4oGoq3rxEiPECWiGpv1Alk9eCI
TDUB2eYzi7hlteqdCGRBNmp2gUonAtm2qyRyJcLkOTItI9j0ckCWQJbCu1ACA2RpAs6qdNpDVeEB
sk304MQ6gSzIkk49LappBwSQBdkTPb3cIAJZkskSgSzpuNFyo067DrIE36T/BLJU8YO05wqBrNgA
2VbSzLj9ZEGWQBZkKTyZVem0p41XICBLFeXIRASyKZko3yQCWYrq0Rsdo7kCT8iBLMhSgl6IqCOQ
Fe4UUnfpak3UgWyj2ZCqyQvZLtXJryALshSCb/UeCtmMsYGwIEuNIiAjqohANkHfLeKMLyICWYQN
GR1T0VS4aSeQbQiyVnwB1ixNO3nYhDu1XoOiDmRbrBKxDrLuGWQpZ2UbKwAsTTvItvxwnvB/T/NX
74BFINvuw7n/IsgSgSzV1akH2Rp6JPVHncAAWaoO35Sds158gSxR1pYsxfMFsiBLRCALslT3I2TF
F41PwBUIyBIBFoEsTfGITrh3wcEr1GY5iwSQbfoRjaC2JAtkcRZkPaKeIpCdrfMkWkAWZykNsxSI
eBAHreQUeY9TJQJZ0o2lfOVsvB5kCWRz90LSHY4gMEC2uWc1hTOlJpQGGGTlm0SiDmRJuNPAuEHL
/SdSpg1B1p6hJWtQORPItpVT2GlpFsgqZwJZDz+1W86mcIEsgWzuos5SyKZwgWwrT2b0ii+pCu0n
LM6CLBGBLMiScFeJqapPLwdkm6mJgOECLzc0kwSy5IEEWQJZIlpo11svB2SbHjeY3Lnx9ApHhnLt
aWNDOYNsQ+HemSfb13kX+XGxoZxBtqFwB9mhh7/bWi8wFVYyvmCMhuy05QyyBLKZIEu7UTFJESln
kG0o3F9XdvMjZWJeOYMsUdpnyXzkRVQiyOrMUo5KVKEqDmQb4mzG3aEKlHPcuesTVmjSpDhXah/0
sg5kEwTl5EyRZBV4wTghZFOnxr03X+dfEXRXIAsrSiOmezhdG1lgOlR00/7qSs3J7OT3BrKwojRq
L43oeyuwBCYLZGWybY0YTB6L23Wt0nOVRuhzWj6vB1mSYdFk/e42V3wt5jGcbK9Rz8aCw32/g3Vf
y/iiqrDiGQTZ5nKK3lq27ivdFyU9orHxvB5kaw/KFM469QUgm2vaWd5+EsgSNZq4BQ0lha4XSMqW
ad/RgSxRoxlWGRTCC8g2lArRnnJuMMOaJZjtJ0u1ZCtUuJxDN+3OMg+38aY9aNt1kG0Fsk5Rnbc0
IqbiBb1SAwSZLM5O0GUzfytRk1Ps9dTks7NFHcjmeJwMRBQo6kQojGtyrPjaLQezC4iqTpMbX/GV
cZDKPFmaMtXCwckf/lCsJFrxlXeQCmQbQmEXvOmclqbkDqptduqt+ALZ5VcwyJYvDSu+skedFV8g
i7NiIzA2Jt8xQ8WBbCuZrDHZMljJkmGVGeJIui4DZBto97ybiiyB6NdTSV/1SD8jwg9kqcU0M+Pq
qej9GDXtQbRVpo2GS/0TgHr5UvOZsr2Q7WIOakv0zCbF9+4Nn3zzIFt1REYcK+181jJ3Hl3OKbCV
dDGCMdkWe8oTbi+SZZZl3sgMXTIwYYYFskUzJ2irPCgbhKzBkwW0OjbiAdmGINt5uaHJqYBc7ZaA
UKg8KKuto2KnEOZ6PZUiw0qd14MsNZd3h060iltkLJNVGmNaNZClGUKni59oFb2Q1OCJcj5YGvYu
oBOBWK3nAjKsuK53opMRhnxsdUgge0oARQMrF2HLDHGE4jsu6kCWcLa5MZN0WWHSVqdr9ZwIkNXZ
1CqkzGS7PKunGt8BDmSbe0Trb/kXwNkgmoSWszeBIAuyldIq1x64cqtltGSFE3CQBdk5nyWzLEF2
DLAiWt8UpQGyrXQ2M77qkQeVdM7SAJffaxhkqRasRMRosdeA9WeFJQ9/rLkBLrPXMMiSwZOJn6JE
Y98ZneMgW6C9MSa7WLJ0MZtvFTj2ufGVSOlomO6A9JSHLEBbhYQt026nwHc6yMaRJd0oB4EsyDaX
B4U6L2Bib2gvJ2mBgOwS2714rKj3dE2OAhnq6MTtNWxZLc0WOvA9C1bSLYy2R4RHolHIdnW/Ty9z
FkDEn1AMKykGT1LHM8i2MlyQ8SVSUFZoC75iNdhyaXR24dLTrCR0Ctx2ydmsIJurNLo8ew2DbEOQ
LZZ6Z5xolaLrHf2qJ3UcgiwtmbPFCJ6x+nIdmQMIINsWUxz7vIA20lyLxjehB9nmHv7QE0kxBWTL
RF3cXIvJaxBkhXuNzl+fnIwzcDN2vaNncWSJuoiJgyDbSvfK2VNUPvvOGHX2k5VvVpdhRR8/Uybf
zJgjm8VRIE5AFmSX30GOfj67gBcyBbreja/4StSYKVOQTRb66TqbjgRP/Qxa8bX8VrT+DKtYgaRo
zGxhHl2D0S9F7V1AFT1IBcI93UZ5XapRyMIHpGfZOQxkqcZshZYUG/X3RYpx1nDBwscKQg+UToHv
dPdsU5uSfZEUL+tAtukUo/LOZtAQR9A9Z3Qu0LTrmYEsztZ7hw7uniUSphrt7fLv0NaZXQCyZyYs
shVK2rR3eZYCg2ztHfAUj026ceQu7cHdZZrJNgd8QJZq78Ym2oWr2D2nWPEVQavCk8PiYgNkaX7O
Zjw9rOTqqcZXfC2gQzmNGwBVO1wQ+oa6/oc/XcMAsgSymfLNdLuRRg9BVnsiaWjXO/qeO4u5I9t1
kK29gtUO5Y26jJPwuqCtG8RZC5C1nR0tBrJd5FCSrQ6XH/EWv8Y5F3jrne6eky6MdpAiyVbS5EGJ
GrPYLq1ejoMUCWQ5R/eXdSINF7RS04myldAMK1e+CbLl47mre6gXZCvNN9MdMZJu96lE48h5O/XO
SAZZkCUCWZAVlNV36olAFmQzxWW6KVy0mKjrUr0JcDIC1ZhTTAhZW19nd06XFWZMdEBW6Jz7cEbE
D+cyziBbIB0B2XrrOMvmm2Xe/nPOtY9a+ZV11U6VA9l6CZslp9ABX8CgQd7JYTJZ0nEjarrJAVmQ
rToP4lzAOdHJr8U4O32toVttVZKLsEHRzznaOd2hhF3CPclAtjl8J9ooj/Nczm32zGwQQ7U/SIDV
2SCmFGQTNTkgC7LTpwCc8zp31a/4SnfYOMjiLAkMEwdBlmLaf8VCnYmDIIuGyoTyQjbjMeYgq0dP
FNu014/vkoc/ml0Asktr+UmOPCNkzS7A2RqD0n4rqZ1BFmSb7rjlPV57wt0UOQc5F9srK4JfZQ4G
BVlpbI0t/1TTLTmXcaaDDQ/IguycLT9ggSyBLM4Wbfyn7SBznsuZQFZXhSiwL1JnrlDgibCfLJ0S
lPBN5SGb+sSzqUrDw0YhCTjndM6Tp4rZTzwD2VaAVXO2krdjyHkMsxwaD7I6bjM/QoC1DGcKTXRA
dvmQLfCIYhbOFu6ZdTaIodogW+wpmjZH5lzAuXM0EcjqqtT8INHymvaMPbMJZ0RY8UVnBaVlQgSy
MlkKh2zNLT/nYs5lOJtrTNbsglZGCeJGxxwxQmPCTyEYLmii7xa0gZtKpxQd7WWUBsjWXsEJ5qbE
dJA5l+/lUOBjoiBAtvLsm3MxZzJc0FYF1/+IZnyDzPlgpizRkckSrHDO0cv5Cpmg2QXRSQPI0vyP
aMalk5xLRl3cQYoRs2Wc8dXWcEEKFNLCoq5lyJrC1Vy+SZS3l5M0kzVcALLtZt+cMx4XbxcukG2F
sxlXZHKexblxJkz7Sg1ka08JM771Bqx0vRzj9XEDEcq03QRZMss5XVZYwBlkqcZM1gbYqZ0TZYUZ
nUE2wYiBLiGVbIMbn8LVOeOrkVi3tTYto5eTEbIhaZM4W3z3Ku5ubYCd1zkasp1Nu0G2BchGb5RH
ywg8gWHT7hY5q2poYQMRDTqDLNWYI3NeTF/EhDaQhUKizoS2uNLwsNUY6Bmba9KpVxogm6Zqt98m
hwJ92oYhKFXhHOoMsiDbKGSDKiVu6s+0s9k5l3EOJUvevNum3a1kskFsDXoyASsvZOPm9gYxKxS4
pnCB7LnNMshyXkw8ZzrlDONksoAFsiALsguHbIGJVgWm0ZjNypkzyJLlZEQyWSIikCUiIpAlIgJZ
IiKQJSIikK24rIloiQLZKiDLmTPn1pxBFmQ5c+YMsiDLmTNnkCVByZkzZ5AFWc6cOYMsyHLmzBlk
adoKfv7x+erhan2/fvOnNxd/uLi8vVzdrd599+7p4xPnxp1/fH5+uLq6X6//9ObNHy4ubi8v71ar
7969+/iknGt3BtlaIHvz/ubtn99u6nX3s6nvb//5Ledmnd/f3Pz57ds+44sNc//5rXKu2hlkq4Ds
pqnsrdrtz+Z3ODfovElXDxlfbH5HOVfrDLLzQ3bTfh6s3ZfPUFvKeanOmxx2nPHFUD6rnOd1Lg3Z
3S8a+dVffy36VntXyJ15cf8f+/zj81APpbfP8uE/Hzg34vzj8/PQKEHvuMF/Pijnupznh+z47y0D
2d6zg868ePDvvXq4Glm7ezosnBfp/HB1dYxx/6CBcp7ReWbIHswBv576t3sI4JgUcs/PY/7kMyE7
PpNd3697KvJFfRW8ultxbsT5fr0+CrJ3K+Vcl/OckN2T0m7/zu7vD12cKtk8H7LHDhe8zBQZX8GX
t5ecG3F+ma01/nN7qZzrcp4NspPT7bR/fkLGfdB8/xf1X+yt2m3t1DHnRpx3H/C3B4yVc13O80B2
iLO72zIeBdmR/3zkcMHJkD1hTFbLz1kmK5MNH5ONeON0GvLGD2VM9Y3GsDgbkzUmGz674GCPe+TF
8cO44zlodgFnswvUYMrZBUMoHGLW7jjDmF8YujgEwd7DJMyT5TyLs3my2Z1ngGzjskKGsxVfVnzR
DJDtrPXmbO+C5TqDbBWQfWlL+99yfumhXD9ec27WeZPPDs002Fx/vFbOVTuDbC2Q7Yb3suwdA+Lc
lPPQfrK947DKuSpnkK0Ispw5c+6cjEBChzNnziALspw5cwZZkOXMmTPIktDhzJkzyIIsZ86cQbZ5
yBLRUgWyMlnOnDnLZEGWM2fOIEtChzNnziALspw5cwZZkOXMmTPIktDhzJkzyKaH7NAOQE8fn850
HtrD6eMT59ad46IuYzxH3DPI1gLZm/c3Q2dgbOp7aD/2Mc7vb26GTjHZxOjQjvqcW3COi7qM8Rx0
zyBbBWQz7qvPObuzcyLK3DPIzg/ZjCdEcc7u7MSzMvc8FrKFKTxysVroVx+82A0cvlvPabVxZ51y
zu7s7N4y91w1ZGf59t7zxg8eQr7/nx/8Q+LOfH+4ujrGuL+TxXmRznFRlzGe4+55Asi+StyGIPXq
K06A0S7ddk1GZqAjE+SDf9TBYh15cX2/7qnIF/VV8OpuNdL5fr0+KijvVpxbcY6LuozxHHfP50K2
F3MHr5wJ2T0cHw/HMQnymH8yCWT7T8ccruDL28uRzkPnmw59bi85t+IcF3UZ4znunqccLhiT4oVC
9oSLx44bjITssWOy/VW7rZ06Hum8Gx5vDxhzbsU5LuoyxnPcPU85XLAHskO/s9vT34PC3cGH8cMU
u2MLB//kcyArk+Usk5XJRg0X7EI2dLhg/AurY1uOka+zjMlyNiZrTLYEZMe81xoaNh0DozHm51w8
6p3baTg2u4Cz2QVmFxyA7FA/fc8Lrv2/s3/0ds882fHTFY6dXXDsCIN5spw782Tzx3MV82RpElnx
xdmKLyu+aAbIdvYu4GzvguWWBshWAdmXtrT/LeeXHsr14/XJzpv2f+jN7Ob64zXndp3joi5jPAfd
M8jWAtlueC/L3jGgo5yH9t/sHbfi3JRzXNRljOeIewbZiiDLmTPnzskIJHQ4c+YMsiDLmTNnkAVZ
zpw5gywJHc6cOYMsyHLmzBlkm4csES1VICuT5cyZs0wWZDlz5gyyJHQ4c+YMsiDLmTNnkAVZzpw5
gywJHc6cOYNsesgO7QD09PHpTOehXYs+PnGe0jmuBjPGhngG2boge/P+ZugMjE2MDu3HPsb5/c3N
0Lkdm0ga2kOecz01mDE2xDPI1gVZJyNkd3bKgHgG2Xoh64yv7M7OyxLP9UJ2zBGwhZE38gzaY4/C
7ZxWu1BnJ7+K59oh23tU+FyQ7eXm7s/jLx78xozn1HMuU4MZY0M8J4PsbmL48vPQxaNyzKEkehLI
jsf6+n7dU40v6qvh1d1qpPP9en1U6NytOJ/iHFeDGWNDPFc6XLD73z0g2/2F3osnM/FMyB47XNB/
OuZwUF7eXo50HjrRc+hze8n5FOe4GswYG+J5CZAd30/f32c/FrJj+L7fvP9ibzhua6eSRzrvBsfb
A8acT3GOq8GMsSGem4Bs7w6PuxePffHV+0Xnj8lq+WWyMlmZbNZMdnyXf3xhjUyNx0PWGJYxWWOy
xmRLvOLf88P5wwXje/RTvfgyu8DsArMLxHPtkD04JWAIl3tmF5yWyZony3mWGjRPNntsVAHZpmSF
zFKdrfgSzyBbNWQ7a73zO9u7QDyDbNWQfWn/+9/MfulVXT9en+y8aaWH3p9urj9ec57GOa4GM8aG
eAbZ6iDbDe+/2TtudZTz0C6ZvaNLnCuswYyxIZ5BtjrIcubMuXMyAgkdzpw5gyzIcubMGWRBljNn
ziBLQoczZ84gC7KcOXMG2eYhS0RLFcjKZDlz5iyTBVnOnDmDLAkdzpw5gyzIcubMGWRBljNnziBL
QoczZ84gmx6yQ7sWPX18OtP506fnH364+vBh/fj45h//uHh4uPz++9Xz87tPn56qvWfO2xraHerj
k3KuvZxBthbI3ry/GTq3YxNJQ3vIj3H+979vHh/fbti6+9kw91//+rbCe+a8rfc3N0Pno2xYMLRX
v3KupJxBtgrIxu0kv0lXe/G6/dn8TlX3zHlbTnPIXs4gOz9k485E2uSwBwn78hnKZ5d0qpWTuJSz
M75G3Xro3Z55MO3+NXaFT/f89Ol5e5Tgj3+8+MUvLn72s8+fX//64i9/eT1u8N//Lvl8VmfKKufO
abWzQ/bgeeP7Lx68t8Ln1P/ww9U2Rr/55nNF//73F7/73ecffv7zUYMGhe+Z87Yerq6OMe7vzCrn
Gcs5zXDBHqK9uvmXn7dRODID3fOlp5F3PGTX9+ueanxRXw2v7lYjnT98WPeODPztb5+9f/rT19e/
/341+z1z3tb9en3Uw3+3Us51lXNuyA5dPC0DnQqy+wnee73/RM/h0Lm8vRzp/DJb69Xnr3+9+OUv
P3v/9rev/9fDw+Xs98x5W0Mnpw59bi+Vc13lvEzI7v+bR0L24GjA+d/+/4u9QbOtnUoe6dybxv7q
V58tf/Ob/tdfs98z523tPt5vDxgr57rKOQ1kd8cBup29WXv/zqHxhCDIHo6SCjLZn/zks/Hf/95D
WJmsTFY5N5rJDkF2/N951HDBLqlDIVt+THboY0zWmKxybnRM9nz2nQPH6OGCYrMLXj4vGr8kwbtp
swuU8/JnF+zB357RgBNmFwwdJnHm5Nn91VBsnux+yJona56scm50nuySZMUXZyu+rPiiGSDb2buA
s70LllvOIFsFZF9a6f73p1/6PteP1yc7f9mF683wLlzXFd4z51d51tAb8M31x2vlXHU5g2wtkO2G
d8nsHV06ynloP9necdhK7pnzq3HD3n1Oe8cHlXNV5QyyFUGWM2fOnZMRSOhw5swZZEGWM2fOIAuy
nDlzBlkSOpw5cwZZkOXMmTPINg9ZIlqqQJaIaL7sSkEQEYEsERHIEhERyBIRgSwREcgSERHIEhHN
BlkiIgrS/wAtQVoaycuRxwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="H, asymp DVT.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - heparin versus no heparin: review authors' judgements about each methodological quality item for each included study that evaluated asymptomatic deep venous thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAHNCAIAAAAc5dx0AAAedUlEQVR42u3dvW4jRxaGYQIGDAcK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</FILE>
</FIGURE>
<FIGURE FILENAME="V, death.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - vitamin K antagonist (VKA) versus no VKA: review authors' judgements about each methodological quality item for each included study that evaluated mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAGvCAIAAABZ2XIlAAAbDElEQVR42u3dsW4kx9WGYQICBAUM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</FILE>
</FIGURE>
<FIGURE FILENAME="V, sympt DVT.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - vitamin K antagonist (VKA) versus no VKA: review authors' judgements about each methodological quality item for each included study that evaluated symptomatic deep venous thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAGvCAIAAABZ2XIlAAAbDElEQVR42u3dsW4kx9WGYQICBAUM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</FILE>
</FIGURE>
<FIGURE FILENAME="V, bleed maj min.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - vitamin K antagonist (VKA) versus no VKA: review authors' judgements about each methodological quality item for each included study that evaluated major bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbQAAAFVCAIAAAAITo02AAATaklEQVR42u3dsW4cydWGYQIGDAcM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</FILE>
</FIGURE>
<FIGURE FILENAME="V, asymp.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - vitamin K antagonist (VKA) versus no VKA: review authors' judgements about each methodological quality item for each included study that evaluated asymptomatic deep venous thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAFzCAIAAAA8Ja5xAAAWyklEQVR42u3dsW4cRxLG8QUMGA4Y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</FILE>
</FIGURE>
<FIGURE FILENAME="V, bleed maj min.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="12" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - vitamin K antagonist (VKA) versus no VKA: review authors' judgements about each methodological quality item for each included study that evaluated minor bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbQAAAFVCAIAAAAITo02AAATaklEQVR42u3dsW4cydWGYQIGDAcM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</FILE>
</FIGURE>
<FIGURE FILENAME="L vs V, death, sympt, asympt.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="13" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - low-molecular-weight heparin versus vitamin K antagonist: review authors' judgements about each methodological quality item for each included study that evaluated mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAFzCAIAAAA8Ja5xAAAWR0lEQVR42u3dv25kSRXHcUtIiMDB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</FILE>
</FIGURE>
<FIGURE FILENAME="L vs V, death, sympt, asympt.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="14" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - low-molecular-weight heparin versus vitamin K antagonist: review authors' judgements about each methodological quality item for each included study that evaluated symptomatic deep venous thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAFzCAIAAAA8Ja5xAAAWR0lEQVR42u3dv25kSRXHcUtIiMDB
BPMEPIMj1CKCiHdiQgeW2NBvgXgExEA4TLQZYtdGsxM48ELGLKNLz1paWe57b9/uvqe6TtXnJ2s1
6rV/vq469a1TdevPxQUREYVqICKiAIEsERHIEhGBLBERgSwREcgSEYEsERGBLBERyBIRgSwREYFs
E1ViMx4RyFJEZSz5kIhAlg6uiaP/LxGBLBERyFJNKa2qIQJZCiSsiQIikCWQJSKQBVkiAll6XiUI
SwSyREQEskREIEsvq8TOWiKQpYj6eP4PVUMEshQIWZwlAlkCWSIC2ZycVTVEIEtERCBLRASyZgku
xqRwiECWiIhAlogIZFWJuQIikKWo+tj7CRGBLIEsEYFs9ZxVNUQgS6vWhCVcRCBLREQgS0QEskRE
IEtERCBLRASytLBKrC4gAlmKqA+FQASyBLJEBLI4S0QgSyP1YU6WCGSJiAhkiYhAlqZnDBQIEcjS
mvWx9xMiAlkCWSIC2c4gayKCCGQpBIWjVqqeCGQpJDsOypSJCGSJiEC243wzdMfXT1YqnQhkKWrS
YPcfRASy3aFw5hOQpfURIBhAtp9YD5ouAFma79TFA8h2msmuXtlaFE3F208RIjxAlohq79QJZI3g
iCw1AdnuM4u4bbXqnQhkQTZqdYFKJwLZvqskcifC6jkytRFsRjkgSyBL4UMogQGytAJnVTrNUFV4
gGwXIzixTiALsmRQT0117YAAsiB7pKeXG0QgSzJZIpAlAzdqN+r06yBL8E3GTyBLFTekmU8IZMUG
yPaSZsadJwuyBLIgS+HJrEqnmT5egYAsVZQjExHIpmSifJMIZClqRG92jM4VeEIOZEGWEoxCRB2B
rHCnkLpLV2uiDmQ7zYZUTV7IDqlufgVZkKUQfKv3UMhmjA2EBVnqFAEZUUUEsgnGbhF3fBERyCJs
yOyYiqbCXTuBbEeQteMLsM7StZPGJtyp9xoUdSDbY5WIdZD1zCBLOSvbXAFg6dpBtufGecT/Pc5f
vQMWgWy/jXP+Q5AlAlmqa1APsjWMSOqPOoEBslQdvik7Z734AlmirD1ZivYFsiBLRCALslR3E7Lj
i5Yn4AoEZIkAi0CW1miiK55dsPcT6rOcRQLIdt1EI6gtyQJZnAVZTVQrAtmzDZ5EC8jiLKVhlgIR
D+Kgl5wi73WqRCBLhrGUr5zN14MsgWzuUUi6yxEEBsh211ZTOFNqQumAQVa+SSTqQJaEO03MG/Q8
fiJl2hFknRlasgaVM4FsXzmFk5bOAlnlTCCr8VO/5WwJF8gSyOYu6iyFbAkXyPbSMqN3fElVaJ6w
OAuyRASyIEvCXSWmqj6jHJDtpiYCpgu83NBNEsiSBgmyBLJE1OjQ2ygHZLueN1jdufP0Ckemcu11
Y0M5g2xH4T5YJzs2eBf5cbGhnEG2o3AH2anGPzzbL7AWVjK+YIyG7LrlDLIEspkgS7tRsUoRKWeQ
7SjcX1Z29zNlYl45gyxR2rZkPXITlQiyBrOUoxJVqIoD2Y44m/F0qALlHHfv+ooVmjQpzpXaB72s
A9kEQbk6UyRZBV4wrgjZ1Knx6MPX+VcEPRXIworSiBkertdHFlgOFd21v/ik5mR29WcDWVhRGrWX
RvSzFdgCkwWyMtm+ZgxWj8Xnda3Sc5VGaDstn9eDLMmwaLVxd587vppphqudNaptNBzu8w72fbXx
i6rCijYIst3lFKO1bN9Xul+U9IrGzvN6kK09KFM4G9QXgGyuZWd5x0kgS9Rp4hY0lRS6XyApW9Z9
RweyRJ1mWGVQCC8g21EqRDPl3GGGdZZgdp4s1ZKtUOFyDj20O8s63M679qBj10G2F8i6RfW8pRGx
FC/olRogyGRxdoUhm/VbibqcYq+nVl+dLepANkdzMhFRoKgToTCuy7Hja7ccrC4gqjpN7nzHV8ZJ
Kutkac1UCwdXb/yhWEm04yvvJBXIdoTCIfjQOT1NyRNU+xzU2/EFsu1XMMiWLw07vrJHnR1fIIuz
YiMwNlY/MUPFgWwvmaw52TJYyZJhlZniSLovA2Q76Pe8m4osgejXU0lf9Ug/I8IPZKnHNDPj7qno
8xh17UG0Vaadhkv9C4BG+VLznbKjkB1iLmpL1GaT4nv3gY9+eJCtOiIjrpV2P2uZJ48u5xTYSroZ
wZxsjyPlFY8XybLKMm9khm4ZWDHDAtmimRO0VR6UHULW5EkDvY6DeEC2I8gOXm7ociogV78lIBQq
D8pq66jYLYS5Xk+lyLBS5/UgS93l3aELreI2GctklcaSXg1k6QyhM8QvtIreSGryRDnvLQ1nF9CR
QKzWs4EMK27onehmhCkfRx0SyB4TQNHAykXYMlMcofiOizqQJZztbs4kXVaYtNcZer0nAmQNNvUK
KTPZIc/uqc5PgAPZ7ppo/T1/A5wNokloOXsTCLIgWymtcp2BK7dqoycrnICDLMiesy1ZZQmyS4AV
0fumKA2Q7WWwmfFVjzyopHOWDrj8WcMgS7VgJSJGi70GrD8rLHn5Y80dcJmzhkGWTJ6s3IoSzX1n
dI6DbIH+xpxss2QZYg7fKnDtc+c7kdLRMN0F6SkvWYC2Cglbpt9Oge90kI0jS7pZDgJZkO0uDwp1
bmBhb+goJ2mBgGyL/V48VtR7ui5HgUwNdOLOGratls4WOvB9Fqyk2xjtjAhNolPIDnW/Ty9zF0DE
n1AMKykmT1LHM8j2Ml2Q8SVSUFboCL5iNdhzaQxO4TLSrCR0Cjx2ydWsIJurNIY8Zw2DbEeQLZZ6
Z1xolWLoHf2qJ3Ucgiy1zNliBM9YfbmuzAEEkO2LKa59bqCPtNai80PoQba7xh96IymmgGyZqItb
a7F6DYKscK/R+aeWk3EFbsahd/QqjixRF7FwEGR7GV65e4rKZ98Zo855svLN6jKs6OtnyuSbGXNk
qzgKxAnIgmz7A+To9jkEvJApMPTufMdXos5MmYJsstBPN9h0JXjqNmjHV/u9aP0ZVrECSdGZOcI8
ugajX4o6u4AqakgFwj3dQXlDqlnIwhekZzk5DGSpxmyFWoqN+scixThruqDxuYLQC6VT4DvdMzvU
puRYJMXLOpDtOsWofLAZNMUR9MwZnQt07UZmIIuz9T6hi7vPEglrzfYO+U9oG6wuANkTExbZCiXt
2oc8W4FBtvYBeIpmk24eeUh7cXeZbrLPCR+QpdqHsYlO4Sr2zCl2fEXQqvDisLjYAFk6P2cz3h5W
cvdU5zu+GhhQruMGQNVOF4S+oa6/8afrGECWQDZTvpnuNNLoKchqbyQNHXpHP/NgM3dkvw6ytVew
2qG8UZdxEd4QdHSDOOsBso6zo2YgO0ROJTnqsP2It/k1zrnAW+90z5x0Y7SLFEm2kiYPStSZxQ5p
jXJcpEggyzl6vGwQabqgl5pOlK2EZli58k2QLR/PQ91TvSBbab6Z7oqRdKdPJZpHzjuod0cyyIIs
EciCrKCsflBPBLIgmyku0y3homaibkj1JsDNCFRjTrEiZB19nd05XVaYMdEBWaFzauOMiB/OZZxB
tkA6ArL11nGWwzfLvP3nnOsctfI766pdKgey9RI2S05hAN7ApEHexWEyWTJwI+q6ywFZkK06D+Jc
wDnRza/FOLt+raFbbVWSi7BB0c852jndpYRDwjPJQLY7fCc6KI/zuZz7HJk5IIZqb0iANTggphRk
E3U5IAuy66cAnPM6D9Xv+Ep32TjI4iwJDAsHQZZi+n/FQoOFgyCLhsqE8kI24zXmIGtETxTbtdeP
75KXP1pdALKt9fwkRz4jZK0uwNkag9J5K6mdQRZkux645b1ee8XTFDkHORc7KyuCX2UuBgVZaWyN
Pf9ayy05l3GmvR0PyILsOXt+wAJZAlmcLdr5rztA5nwuZwJZQxWiwLFInblCgRbhPFk6Jijhm8pD
NvWNZ2uVhsZGIQk453TOq6eK2W88A9legFVztpJ3YMh5CbNcGg+yBm5nbkKA1YYzhSY6INs+ZAs0
UczC2cIjs8EBMVQbZIu1onVzZM4FnAdXE4GsoUrNDYna69ozjsxWXBFhxxedFJS2CRHIymQpHLI1
9/ycizmX4WyuOVmrC3qZJYibHXPFCC0JP4VguqCLsVvQAW4qnVIMtNsoDZCtvYITrE2JGSBzLj/K
ocBmoiBAtvLsm3MxZzJd0FcF199EM75B5rw3U5boyGQJVjjnGOX8BJmg1QXRSQPI0vmbaMatk5xL
Rl3cRYoRq2Xc8dXXdEEKFFJjUdczZC3h6i7fJMo7ykmayZouANl+s2/OGa+LdwoXyPbC2Yw7Mjmf
xblzJqz7Sg1ka08JM771Bqx0oxzz9XETEcq03wRZMss5XVZYwBlkqcZM1gHYqZ0TZYUZnUE2wYyB
ISGV7IM7X8I1uOOrk1h3tDa1McrJCNmQtEmcNT+8intaB2DndY6G7ODQbpDtAbLRB+VRG4EnMBza
3SNnVQ01NhHRoTPIUo05MudmxiIWtIEsFBINFrTFlYbGVmOgZ+yuyaBeaYBsmqp9/jY5FOjrdgxB
qQrnUGeQBdlOIRtUKXFLf9Zdzc65jHMoWfLm3Q7t7iWTDWJrUMsErLyQjVvbG8SsUOBawgWyp3bL
IMu5mXjOdMsZxslkAQtkQRZkG4dsgYVWBZbRWM3KmTPIku1kRDJZIiKQJSIikCUiAlkiIpAlIiKQ
rbisiahFgWwVkOXMmXNvziALspw5cwZZkOXMmTPIkqDkzJkzyIIsZ86cQRZkOXPmDLK0bgU//vB4
fXe9eb959ddXF3++uHx7efXu6s03bx4+PZzo/Pnz4/ffX3/8uLm/f/Xttxd3d5fffXf1+Pjm8+dT
nX94fLy7vn6/2fz11as/X1y8vbx8d3X1zZs3nx56dI6rQeWct5xBthbI3n64ff2319uI2f3aRtJX
//rqaOf//Of2/v71lq27X1vm/vvfxzt/uL392+vXY498sY3Rf33Vl3NcDSrn1OUMslVAdtsJjwbN
86/t9xzhvE1XR/H6/Gv7PUc4b7v3fY98sf2eTpzjalA5Zy9nkD0/ZLc98964efqa6qWnnLc57F7C
Pn1N5bNTzts+f9kjX0z1/y05x9Wgcs5ezqUhe+Jh46M/WODigBM/nH/Uxx8ep8Y+o6Ohj//9uND5
8+fH57MEf/nLxa9/ffGLX3z5+t3vLv7+95fzBv/731LnHx4fp0ZVo+Os/35s2TmuBpVz9nI+D2SP
5mOBi31Gf8WJH+79e6/vrhfGzcxQaNT5+++vn2P0l7/8UtF/+tPFH//45R+/+tWiSYNR57vr60Me
eXyQ1YxzXA0q5+zlfH7I7oJp6mFmfnDXYffPW55slofs5v1mpBqfNFbDV++uFjp//LgZnRn4xz++
eP/85y8//+67pc7vN5uDgvLdVcvOcTWonLOXc12QnSfU/B9wxD/2psPFIPu0BmV56Fy+vVzo/LRa
68XX119f/OY3X7z/8IeX/+vubqnz0+qW5V9vL1t2jqtB5Zy9nJuF7PLE+dCpiYWQXZ6Pf/lwNGie
a6eSFzqPprG//e0Xy9//fvz110Ln3bB7veeRW3aOq0HlnL2cq4PszDuxFJB9jtdqM9mf/eyL8T//
OUJYmaxMVjn3kske94NrQXbm7dyJMwOVzMlOfZmTNSernFubk92bMB6XXZ4yJ7uQyxlXFzx9PWn5
lgRvva0uUM7JVhfMzwksusVhltSnrC6Yerw21snOQ9Y6WetklXML62Q7lx1frTrb8aWcQbZqyA7O
Lsjv7OwC5QyyVUP2qZcef3/649jn5v7maOcfT+F6NX0K1/HO2/5/6s3s9vP7m76c42pQOacuZ5Ct
BbLD9CmZo7NLBzlPnSc7Og97kPPU+Zuj81bNO8fVoHLOW84gWxFkOXPmPLgZgYQOZ86cQRZkOXPm
DLIgy5kzZ5AlocOZM2eQBVnOnDmDbPeQJaJWBbIyWc6cOctkQZYzZ84gS0KHM2fOIAuynDlzBlmQ
5cyZM8iS0OHMmTPIpofs1NlCD58eTnSeOlvo0wPn3p3joi5jPEc8M8jWAtnbD7dTt2ts63vqpPcl
zh9ub6du19jG6NRJ75x7cI6LuozxHPTMIFsFZJ2rz7m8c1zUZYznuGcG2fND1g1RnFu6LytjPMc9
81LIFqbwws1qob9674fDxP3h9dxW665TzuWjLmM8xz1z1ZA9y29/cQ34zIfDxGXj88/czG3ynLM7
x0VdxniOe+YVIPsicZuC1ItfcQSMdum2a7IwA12YIO/9o/YW68IPN+83IxX5pLEKvnp3tdD5/WZz
UFC+u+Lci3Nc1GWM57hnPhWyo5jb+8mJkJ3h+HI4LkmQl/zIKpAdv3dzuoIv314udJ66d3Pq6+0l
516c46IuYzzHPfOa0wVLUrxQyB7x4aHzBgshe+ic7HjVPtdOHS903g2P13uMOffiHBd1GeM57pnX
nC6YgezU9+yO9GdQuDv5sHyaYnduYe+ffApkZbKcZbIy2ajpgl3Ihk4XLH9hdWjPsfB1ljlZzuZk
zcmWgOyS91pT06ZLYLTE/JQPD3rndhyOrS7gbHWB1QV7IDs1Tp95wTX/PfOztzPrZJcvVzh0dcGh
MwzWyXIerJPNH89VrJOlVWTHF2c7vuz4ojNAdnB2AWdnF7RbGiBbBWSf+tLxt5w/jlBu7m+Odt72
/1NvZref399w7tc5LuoyxnPQM4NsLZAdps+yHJ0DOsh56vzN0Xkrzl05x0VdxniOeGaQrQiynDlz
HtyMQEKHM2fOIAuynDlzBlmQ5cyZM8iS0OHMmTPIgixnzpxBtnvIElGrAlmZLGfOnGWyIMuZM2eQ
JaHDmTNnkAVZzpw5gyzIcubMGWRJ6HDmzBlk00N26gSgh08P1TpPnYf06aFH54zlnDHqcjmDbC2Q
vf1wO3UHxra+p85jP6/zh9vbqRtBtiyYOp2+VeeM5Zwx6tI5g2wVkHVGfXZndwFwBtl6Ieu2pezO
brXiXCNkZy5/jXie0QvJJ4tjwQW3h16FO7g3tFFn97Nyrheyo5eERzN9vizmv/+ID/dWQ9yd73HO
d9fXhxiPD2abcc5YzhmjLqNzvZDd/XyXXy++fz6jHD3KYf6vjuDp6Ieb95uRinzSWAVfvbs6u/P7
zeagxv/uqmXnjOWcMeoyOlcxXbD73yWAm/r3EiwunJQoBtnx2zGnK/jy7eXZnafuCp36envZsnPG
cs4YdRmdk0F2flC/LmSP+xV75z3G/5zRqn2unTo+u/Nu4L3eY9yyc8Zyzhh1GZ0TQHZmumBvqrs7
Y1AGsjJZmaxMlnMmyC4H3KE/vjDfNCdrTtacrDnZxHOyy0f0x0H20Ex2ZmGZ1QVWF1hdwDnZ6oKF
bD10umDqp14sSxjl6ehlEtbJvpB1stnL2WrWMs5nhmyHsuOrVWc7vjiDbNWQHZxdkN/Z2QWcQbZq
yD71peNvOX8codzc31TovM2zpt6Abz+/v+nLOWM5Z4y6dM4gWwtkh+mzLEfngCpxnjrndHR+sHnn
jOWcMepyOYNsRZDlzJnz4GYEEjqcOXMGWZDlzJkzyIIsZ86cQZaEDmfOnEEWZDlz5gyy3UOWiFoV
yBIRnS+7UhBERCBLRASyREQEskREIEtEBLJERASyRERngywREQXp/3KvJB6dQGkyAAAAAElFTkSu
QmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="L vs V, maj bleed.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="15" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - low-molecular-weight heparin versus vitamin K antagonist: review authors' judgements about each methodological quality item for each included study that evaluated major bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbQAAAFVCAIAAAAITo02AAAThUlEQVR42u3dsY4dSdmH8ZGQEMEE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</FILE>
</FIGURE>
<FIGURE FILENAME="L vs V thrombocytopenia, pulm embol.png" FILE_TYPE="PNG" ID="FIG-16" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="16" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - low-molecular-weight heparin versus vitamin K antagonist: review authors' judgements about each methodological quality item for each included study that evaluated thrombocytopenia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAFVCAIAAADt0EhaAAATCElEQVR42u3dsW7cRheGYV2AihS+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</FILE>
</FIGURE>
<FIGURE FILENAME="L vs V, death, sympt, asympt.png" FILE_TYPE="PNG" ID="FIG-17" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="17" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - low-molecular-weight heparin versus vitamin K antagonist: review authors' judgements about each methodological quality item for each included study that evaluated asymptomatic deep venous thrombosis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAFzCAIAAAA8Ja5xAAAWR0lEQVR42u3dv25kSRXHcUtIiMDB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</FILE>
</FIGURE>
<FIGURE FILENAME="L vs V, min bleed.png" FILE_TYPE="PNG" ID="FIG-18" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="18" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - low-molecular-weight heparin versus vitamin K antagonist: review authors' judgements about each methodological quality item for each included study that evaluated minor bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAbQAAAE3CAIAAABNciNnAAARKElEQVR42u3dsW5cRRuH8ZWQEIWL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</FILE>
</FIGURE>
<FIGURE FILENAME="L vs V thrombocytopenia, pulm embol.png" FILE_TYPE="PNG" ID="FIG-19" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="19" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of bias summary - low-molecular-weight heparin versus vitamin K antagonist: review authors' judgements about each methodological quality item for each included study that evaluated pulmonary embolism.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcwAAAFVCAIAAADt0EhaAAATCElEQVR42u3dsW7cRheGYV2AihS+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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<APPENDIX ID="APP-01" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Search strategies for the electronic databases - update 2010</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Strategy</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL)</P>
</TD>
<TD>
<P>#1 heparin OR low molecular weight heparin OR LMWH OR low-molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran<BR/>#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA<BR/>#3 fondaparinux OR Arixtra<BR/>#4 ximelagatran OR Exanta<BR/>#5 Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban</P>
<P>#6 1 OR 2 OR 3 OR 4 OR 5<BR/>#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumor OR tumor<BR/>#8 6 AND 7<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<P>#1 Heparin/<BR/>#2 Heparin.tw<BR/>#3 Heparin, Low-Molecular-Weight/<BR/>#4 (LMWH OR low molecular weight heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran).tw<BR/>#5 1 OR 2 OR 3 OR 4<BR/>#6 Coumarins/<BR/>#7 Warfarin/<BR/>#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA).tw<BR/>#9 6 OR 7 OR 8<BR/>#10 (fondaparinux OR Arixtra).tw<BR/>#11 (ximelagatran OR Exanta).tw</P>
<P>#12 (Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban).tw.<BR/>#13 5 OR 9 OR 10 OR 11 OR 12<BR/>#14 Neoplasms/<BR/>#15 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumor OR tumor).tw<BR/>#16 14 OR 15<BR/>#17 clinical trial.pt. OR random:.tw. OR tu.xs.<BR/>#18 animals/ NOT human/<BR/>#19 17 NOT 18<BR/>#20 13 AND 16 AND 19<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<P>#1 Heparin/<BR/>#2 heparin.tw<BR/>#3 Low Molecular Weight Heparin/<BR/>#4 (LMWH OR low molecular weight heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran).tw<BR/>#5 1 OR 2 OR 3 OR 4<BR/>#6 Coumarin derivative/<BR/>#7 Warfarin/<BR/>#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA).tw<BR/>#9 6 OR 7 OR 8<BR/>#10 fondaparinux/<BR/>#11 (fondaparinux OR Arixtra).tw<BR/>#12 ximelagatran/<BR/>#13 (ximelagatran OR Exanta).tw</P>
<P>#14 (Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apixaban).tw.<BR/>#15 5 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14<BR/>#16 Neoplasm/<BR/>#17 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumor OR tumor).tw<BR/>#18 16 OR 17<BR/>#19 Random:.tw. OR clinical trial:.mp. OR exp health care quality<BR/>#20 animals/ NOT human/<BR/>#21 19 NOT 20<BR/>#22 15 AND 18 AND 21<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ISI (International Scientific Information) the Web of Science</P>
</TD>
<TD>
<P>#1 heparin OR low molecular weight heparin OR LMWH OR low-molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran<BR/>#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA<BR/>#3 fondaparinux OR Arixtra<BR/>#4 ximelagatran OR Exanta</P>
<P># 5 Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apixaban<BR/>#6 1 OR 2 OR 3 OR 4 OR 5<BR/>#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumor OR tumor<BR/>#8 random$ OR placebo$ OR versus OR vs OR double blind OR double-blind OR compar$ OR controlled<BR/>#9 6 AND 7 AND 8<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Search strategies for the electronic databases - update 2013</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Strategy</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL)</P>
</TD>
<TD>
<P>#1 MeSH descriptor: [Heparin] explode all trees</P>
<P>#2 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum)</P>
<P>#3 MeSH descriptor: [Coumarins] explode all trees</P>
<P>#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA)</P>
<P>#5 (fondaparinux or arixtra)</P>
<P>#6 (ximelagatran or exanta)</P>
<P>#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban)</P>
<P>#8 #1 or #2 or #3 or #4 or #5 or #6 or #7</P>
<P>#9 MeSH descriptor: [Neoplasms] explode all trees</P>
<P>#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*)</P>
<P>#11 #9 or #10</P>
<P>#12 #8 and #10<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<P>#1 exp Heparin/</P>
<P>#2 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum).tw.</P>
<P>#3 exp Coumarins/</P>
<P>#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA).tw.</P>
<P>#5 (fondaparinux or arixtra).tw.</P>
<P>#6 (ximelagatran or exanta).tw.</P>
<P>#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban).tw.</P>
<P>#8 1 or 2 or 3 or 4 or 5 or 6 or 7</P>
<P>#9 exp Neoplasms/</P>
<P>#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).tw.</P>
<P>#11 9 or 10</P>
<P>#12 8 and 11</P>
<P>#13 randomised controlled trial.pt.</P>
<P>#14 controlled clinical trial.pt.</P>
<P>#15 randomized.ab.</P>
<P>#16 placebo.ab.</P>
<P>#17 drug therapy.fs.</P>
<P>#18 randomly.ab.</P>
<P>#19 trial.ab.</P>
<P>#20 groups.ab.</P>
<P>#21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20</P>
<P>#22 12 and 21</P>
<P>#23 exp animals/ not humans.sh.</P>
<P>#24 22 not 23</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<P>#1 heparin/</P>
<P>#2 exp low molecular weight heparin/</P>
<P>#3 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum).tw.</P>
<P>#4 exp coumarin derivative/</P>
<P>#5 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA).tw.</P>
<P>#6 (fondaparinux or arixtra).tw.</P>
<P>#7 (ximelagatran or exanta).tw.</P>
<P>#8 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban).tw.</P>
<P>#9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P>
<P>#10 exp neoplasm/</P>
<P>#11 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).tw.</P>
<P>#12 10 or 11</P>
<P>#13 9 and 12</P>
<P>#14 crossover procedure/</P>
<P>#15 double-blind procedure/</P>
<P>#16 randomised controlled trial/</P>
<P>#17 single-blind procedure/</P>
<P>#18 random*.mp.</P>
<P>#19 factorial*.mp.</P>
<P>#20 (crossover* or cross over* or cross-over*).mp.</P>
<P>#21 placebo*.mp.</P>
<P>#22 (double* adj blind*).mp.</P>
<P>#23 (singl* adj blind*).mp.</P>
<P>#24 assign*.mp.</P>
<P>#25 allocat*.mp.</P>
<P>#26 volunteer*.mp.</P>
<P>#27 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26</P>
<P>#28 13 and 27</P>
<P>#29 (exp animal/ or nonhuman/ or exp animal experiment/) not human/</P>
<P>#30 28 not 29</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="3">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Detailed statistical data abstraction</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<P>
<B>Comparison: low-molecular-weight heparin (LMWH) versus no LMWH</B>
</P>
<TABLE COLS="13" ROWS="9">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: mortality</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No LMWH</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>68 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>294 - (9 + 26) = 259</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>145 - (5 + 12) = 128</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>140</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>140 - 5 = 135</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 - 0 = 17</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>15 - 0 = 15</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>13 [5]</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>191 - 31 - 5 = 155</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>194 - 33 - 6 = 155</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[4] Table 2: reasons for early withdrawal.</P>
<P>[5] "Overall, 13 enoxaparin patients and 20 placebo patients died during the study period." (Applies to both arms.)</P>
<TABLE COLS="13" ROWS="10">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: symptomatic deep venous thrombosis</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No LMWH</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>3 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>68 [5]</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>294 - (9 + 26) = 259</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>145 - (5 + 12) = 128</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>140</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>140 - 5 = 135</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 - 0 = 17</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>15 - 0 = 15</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4 + 15 = 19 [6]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>56 - 19 = 37</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2 + 11 = 13</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>57 - 13 = 44</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>191 - 31 - 5 = 155</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>194 - 33 - 6 = 155</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The rate of symptomatic CVCrT [central venous catheter-related thrombosis] was 2.0% without any difference between the groups: 0.9% group A, 2.5% group D and 2.6% group NT".</P>
<P>[4] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[5] Table 2: reasons for early withdrawal.</P>
<P>[6] "15 (27%) in the nadroparin group and 11 (19%) in the placebo group did not undergo venography, because of prior catheter removal because of suspected serious infections (five patients in each group), logistic problems, including catheter removal during weekends (six patients in the nadroparin group and four patients in the placebo group), or withdrawal of informed consent (four patients in the nadroparin group and two patients in the placebo group)" (applies to both arms).</P>
<TABLE COLS="13" ROWS="8">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: major bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No LMWH</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>68 [5]</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>294 - (9 + 26) = 259</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>145 - (5 + 12) = 128</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4 + 15 = 19 [6]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>56 - 19 = 37</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2 + 11 = 13</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>57 - 13 = 44</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>191 - 31 - 5 = 155</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>194 - 33 - 6 = 155</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "One patient refused randomization and three patients were excluded after randomization because of catheter insertion failure" (applies to both).</P>
<P>[4] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[5] Table 2: reasons for early withdrawal).</P>
<P>[6] "15 (27%) in the nadroparin group and 11 (19%) in the placebo group did not undergo venography, because of prior catheter removal because of suspected serious infections (five patients in each group), logistic problems, including catheter removal during weekends (six patients in the nadroparin group and four patients in the placebo group), or withdrawal of informed consent (four patients in the nadroparin group and two patients in the placebo group)" (applies to both arms).</P>
<TABLE COLS="13" ROWS="6">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: minor bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No LMWH</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120 </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>191 - 31 - 5 = 155</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>194 - 33 - 6 = 155</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<TABLE COLS="13" ROWS="6">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: infection</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No LMWH</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>68 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>294 - (9 + 26) = 259</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>145 - (5 + 12) = 128</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4 + 15 = 19 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>56 - 19 = 37</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2 + 11 = 13</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>57 - 13 = 44</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] Table 2: reasons for early withdrawal).</P>
<P>[4] "15 (27%) in the nadroparin group and 11 (19%) in the placebo group did not undergo venography, because of prior catheter removal because of suspected serious infections (five patients in each group), logistic problems, including catheter removal during weekends (six patients in the nadroparin group and four patients in the placebo group), or withdrawal of informed consent (four patients in the nadroparin group and two patients in the placebo group)" (applies to both arms).</P>
<TABLE COLS="13" ROWS="8">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: thrombocytopenia</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No LMWH</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>68 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>294 - (9 + 26) = 259</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>145 - (5 + 12) = 128</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>140</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>140 - 5 = 135</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 - 0 = 17</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>15 - 0 = 15</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>191 - 31 - 5 = 155</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>194 - 33 - 6 = 155</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] Table 2: reasons for early withdrawal.</P>
<TABLE COLS="13" ROWS="10">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: asymptomatic deep venous thrombosis</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No LMWH</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Karthaus-2006" TYPE="STUDY">Karthaus 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>68 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>294 - (9 + 26) = 259</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>145 - (5 + 12) = 128</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>140</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>140 - 5 = 135</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 - 0 = 17</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>15 - 0 = 15</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Niers-2007" TYPE="STUDY">Niers 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4 + 15 = 19 [5]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>56 - 19 = 37</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2 + 11 = 13</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>57 - 13 = 44</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Verso-2005" TYPE="STUDY">Verso 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>191 - 31 - 5 = 155</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>194 - 33 - 6 = 155</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[4] Table 2: reasons for early withdrawal.</P>
<P>[5] "15 (27%) in the nadroparin group and 11 (19%) in the placebo group did not undergo venography, because of prior catheter removal because of suspected serious infections (five patients in each group), logistic problems, including catheter removal during weekends (six patients in the nadroparin group and four patients in the placebo group), or withdrawal of informed consent (four patients in the nadroparin group and two patients in the placebo group)" (applies to both arms).</P>
<P>
<B>Comparison: vitamin K antagonist (VKA) versus no VKA</B>
</P>
<TABLE COLS="13" ROWS="10">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: mortality</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>
</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>
<B>60 - 1 = 59</B>
</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>
<B>61 - 5 = 56</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>
</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>
<B>45 - 0 = 45</B>
</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>
<B>43 - 0 = 43</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>138 - 4 = 134</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>140</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>140 - 5 = 135</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>152 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>408</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>408 - 13 - 35 = 360</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>158</P>
</TD>
<TD VALIGN="TOP">
<P>404</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>404 - 1 - 12 = 391</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] From web figure WARP CONSORT diagram.</P>
<TABLE COLS="13" ROWS="9">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: symptomatic deep venous thrombosis</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>
</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>
<B>60 - 1 = 59</B>
</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>
<B>61 - 5 = 56</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Heaton-2002" TYPE="STUDY">Heaton 2002</LINK>
</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>
<B>45</B>
</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>
<B>43</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>138 - 4 = 134</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>140</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>140 - 5 = 135</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>30 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>408</P>
</TD>
<TD VALIGN="TOP">
<P>13 [5]</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>408 - 13 - 35 = 360</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>404</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>404 - 1 - 12 = 391</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The rate of symptomatic CVCrT [central venous catheter-related thrombosis] was 2.0% without any difference between the groups: 0.9% group A, 2.5% group D and 2.6% group NT".</P>
<P>[4] From table 2, all VTE are considered DVT.</P>
<P>[5] From web figure WARP CONSORT diagram.</P>
<TABLE COLS="13" ROWS="6">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: major bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>408</P>
</TD>
<TD VALIGN="TOP">
<P>13 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>408 - 13 - 35 = 360</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>404</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>404 - 1 - 12 = 391</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] From web figure WARP CONSORT diagram.</P>
<TABLE COLS="13" ROWS="6">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: minor bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Young-2009" TYPE="STUDY">Young 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>408</P>
</TD>
<TD VALIGN="TOP">
<P>13 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>408 - 13 - 35 = 360</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>404</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>404 - 1 - 12 = 391</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] From web figure WARP CONSORT diagram.</P>
<TABLE COLS="13" ROWS="7">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: asymptomatic deep venous thrombosis</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>No VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD>
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bern-1990" TYPE="STUDY">Bern 1990</LINK>
</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>
<B>60 - 1 = 59</B>
</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>
<B>61 - 5 = 56</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>138 - 4 = 134</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>140</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>140 - 5 = 135</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>
<B>Comparison: low-molecular-weight heparin (LMWH) versus vitamin K antagonists (VKA)</B>
</P>
<TABLE COLS="13" ROWS="7">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: mortality</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>138 - 4 = 134</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 1 - 8 = 21</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 6 = 24</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[4] "Missing data were equally distributed between the two treatment groups. Overall, ten patients died before completing the study, six in the nadroparin group and four in the warfarin group. Due to technical difficulties or patients' refusal, venograms of the upper extremities could not be performed in four patients, two in each treatment group. None of these patients had clinical evidence of thrombosis".</P>
<TABLE COLS="13" ROWS="7">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: symptomatic deep venous thrombosis</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>3 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>138 - 4 = 134</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1 [5]</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 1 - 8 = 21</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 6 = 24</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The rate of symptomatic CVCrT [central venous catheter-related thrombosis] was 2.0% without any difference between the groups: 0.9% group A, 2.5% group D and 2.6% group NT".</P>
<P>[4] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[5] "Missing data were equally distributed between the two treatment groups. Overall, ten patients died before completing the study, six in the nadroparin group and four in the warfarin group. Due to technical difficulties or patients' refusal, venograms of the upper extremities could not be performed in four patients, two in each treatment group. None of these patients had clinical evidence of thrombosis".</P>
<TABLE COLS="13" ROWS="6">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: major bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120 </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 1 - 8 = 21</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 6 = 24</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[4] "Missing data were equally distributed between the two treatment groups. Overall, ten patients died before completing the study, six in the nadroparin group and four in the warfarin group. Due to technical difficulties or patients' refusal, venograms of the upper extremities could not be performed in four patients, two in each treatment group. None of these patients had clinical evidence of thrombosis".</P>
<TABLE COLS="13" ROWS="5">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: minor bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<TABLE COLS="13" ROWS="7">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: thrombocytopenia</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>138 - 4 = 134</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 1 - 8 = 21</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 6 = 24</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Monreal-1996" TYPE="STUDY">Monreal 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 - 0 = 17</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>15 - 0 = 15</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] "Missing data were equally distributed between the two treatment groups. Overall, ten patients died before completing the study, six in the nadroparin group and four in the warfarin group. Due to technical difficulties or patients' refusal, venograms of the upper extremities could not be performed in four patients, two in each treatment group. None of these patients had clinical evidence of thrombosis".</P>
<TABLE COLS="13" ROWS="7">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: asymptomatic deep venous thrombosis</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Study name</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>LMWH</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>VKA</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Events</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No.</P>
<P>rand.</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. most likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>No. less likely to have MPD</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. with available outcome data (for CCA)</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pre-trt [1]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [2]</P>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-De-Cicco-2009" TYPE="STUDY">De Cicco 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>45 [3]</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>21 [4]</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 30 = 120</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 - 36 = 114</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lavau_x002d_Denes-2013" TYPE="STUDY">Lavau-Denes 2013</LINK>
</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>142</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>
<B>142 - 4 = 138</B>
</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>138</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>
<B>138 - 4 = 134</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mismetti-2003" TYPE="STUDY">Mismetti 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1 [5]</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 1 - 8 = 21</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 - 6 = 24</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; MPD: missing participant data; No: number; Post-trt: post-treatment; Pre-trt: pre-treatment; rand: randomized.</P>
<P>[1] Participants categorized as 'ineligible' and did not receive first dose.</P>
<P>[2] Participants categorized as 'lost to follow-up' and 'withdrew consent'.</P>
<P>[3] We calculated total number of deep venous thrombosis (symptomatic + asymptomatic) by: total number of participants - never central venous catheter-related thrombosis at day 30 (from table 4) this value - symptomatic = asymptomatic.</P>
<P>[4] "The overall dropout rate was 22.7% (Figure 2). The causes and number of dropouts in the three study groups are reported in Table 1".</P>
<P>[5] "Missing data were equally distributed between the two treatment groups. Overall, ten patients died before completing the study, six in the nadroparin group and four in the warfarin group. Due to technical difficulties or patients' refusal, venograms of the upper extremities could not be performed in four patients, two in each treatment group. None of these patients had clinical evidence of thrombosis".</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn" NO="4">
<TITLE MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">Detailed results of sensitivity analysis</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-29 11:58:06 +0100" MODIFIED_BY="Gail Quinn">
<TABLE COLS="2" ROWS="14">
<TR>
<TD VALIGN="TOP">
<P>
<B>Systematic review</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>CVC</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comparison</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>LMWH vs. no LMWH</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Symptomatic DVT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CCA effect estimate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.48; 95% CI 0.27 to 0.86</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Sensitivity analysis</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.80; 95% CI 0.54 to 1.20</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>None of participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.48; 95% CI 0.26 to 0.86</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Best-case scenario (intervention: none; control: all)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.20; 95% CI 0.12 to 0.32</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Worst-case scenario (intervention: all; control: none)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.91; 95% CI 0.57 to 6.38</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.47; 95% CI 0.26 to 0.84</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1.5 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.48; 95% CI 0.26 to 0.89</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 2 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.48; 95% CI 0.26 to 0.89</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 3 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.50; 95% CI 0.25 to 1.00</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 5 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.53; 95% CI 0.25 to 1.15</B>
</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="2" ROWS="14">
<TR>
<TD VALIGN="TOP">
<P>
<B>Systematic review</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>CVC</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comparison</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>VKA vs. no VKA</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Asymptomatic DVT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CCA effect estimate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.43; 95% CI 0.30 to 0.62</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Sensitivity analysis</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.55; 95% CI 0.42 to 0.72</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>None of participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.45; 95% CI</B> <B>0.31 to 0.65</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Best-case scenario (intervention: none; control: all)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.3; 95% CI .22 to 0.53</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Worst-case scenario (intervention: all; control: none)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.76; 95% CI 0.57 to 1.02</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.38; 95% CI 0.24 to 0.61</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1.5 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.38; 95% CI 0.27 to 0.54</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 2 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.40; 95% CI 0.29 to 0.55</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 3 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.45; 95% CI 0.34 to 0.61</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 5 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.54; 95% CI 0.41 to 0.70</B>
</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="2" ROWS="14">
<TR>
<TD VALIGN="TOP">
<P>
<B>Systematic review</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>CVC</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comparison</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>LMWH vs. VKA</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Thrombocytopenia</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CCA effect estimate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 3.73; 95% CI 2.26 to 6.16</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Sensitivity analysis</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>2.43; 95% CI 1.22 to 4.85</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>None of participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>3.71; 95% CI 2.24 to 6.14</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Best-case scenario (intervention: none; control: all)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>4.34; 95% CI 2.64 to 7.13</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Worst-case scenario (intervention: all; control: none)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.04; 95% CI 0.10 to 10.46</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>3.75; 95% CI 2.27 to 6.17</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>1.5 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>3.53; 95% CI 2.17 to 5.73</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>2 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>2.85; 95% CI 1.18 to 6.87</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>3 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>2.85; 95% CI 1.18 to 6.87</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>5 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>2.82; 95% CI 1.30 to 6.12</B>
</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="2" ROWS="14">
<TR>
<TD VALIGN="TOP">
<P>
<B>Systematic review</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>CVC</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comparison</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>LMWH vs. VKA</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Asymptomatic DVT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CCA effect estimate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.74; 95% CI 1.20 to 2.52</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Sensitivity analysis</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.32; 95% CI 1.03 to 1.68</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>None of participants with MPD had the event</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.80; 95% CI 1.23 to 2.63</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Best-case scenario (intervention: none; control: all)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>2.69; 95% CI 1.62 to 4.46</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Worst-case scenario (intervention: all; control: none)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.86; 95% CI 0.65 to 1.15</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>1 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.44; 95% CI 1.03 to 2.01</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>1.5 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.33; 95% CI 0.97 to 1.84</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>2 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.27; 95% CI 0.93 to 1.74</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>3 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>1.08; 95% CI 0.81 to 1.45</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>RI 1 <SUB>intervention </SUB>5 <SUB>control</SUB>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR </B>
<B>0.89; 95% CI 0.68 to 1.16</B>
</P>
</TD>
</TR>
</TABLE>
<P>CCA: complete case analysis; CI: confidence interval; CVC: central venous catheter; DVT: deep venous thrombosis; LMWH: low-molecular-weight heparin; MPD: missing participant data; RR: risk ratio; VKA: vitamin K antagonist.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;44 full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;9559 records screened&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;9559 records after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;10,033 records identified through database searching&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;56 additional records identified through other sources&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9515 records excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;32 full-text articles excluded, with reasons:&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;13 study not an RCT&lt;/p&gt;&lt;p&gt;4 review&lt;/p&gt;&lt;p&gt;3 no obtainable needed data from authors&lt;/p&gt;&lt;p&gt;2 different drug/agent studied&lt;/p&gt;&lt;p&gt;2 editorial or letter to the editor&lt;/p&gt;&lt;p&gt;2 intervention not relevant&lt;/p&gt;&lt;p&gt;2 intervention compared to urokinase&lt;/p&gt;&lt;p&gt;2 not population of interest/no CVC&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;1 differential follow-up time&lt;/p&gt;&lt;p&gt;1 concerns about accuracy and validity of study&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>